[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fwA1UmmHsaMp1Qrf3rdiK1Y53T0EwGyxXqD01RKxa-jA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of Texas Southwestern Medical Center",[4],981,false,230,43,915453,105,589,[14,17,19,22,25,28,31,34],{"name":15,"count":16},"Depression",25,{"name":18,"count":16},"Hypertension",{"name":20,"count":21},"Breast Cancer",22,{"name":23,"count":24},"Obesity",19,{"name":26,"count":27},"Bipolar Disorder",17,{"name":29,"count":30},"Major Depressive Disorder",16,{"name":32,"count":33},"Prostate Cancer",13,{"name":35,"count":33},"Heart Failure",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03747120","Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]","2024-11-08","Paclitaxel",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05326464","Tofacitinib in Recurrent GBM Patients","2025-06-16","Tofacitinib 10mg",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03565913","Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V","2025-12-31","EffCaMgCit",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03621553","Vitamin D Homeostasis in Sarcoidosis","2026-02","Ergocalciferol",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06745128","Tirzepatide for Obesity and Meth Use Disorder","2026-03-31","Tirzepatide",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04614194","Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib","2026-04-15","Letrozole",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05029999","CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","2026-04-20","PLD Chemotherapy",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05489523","Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation","2026-05-01","Tafamidis 61 MG",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT03546686","Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","2026-06","Pembrolizumab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT03502967","Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate","2026-06-30","Hyperpolarized [1-13C] Pyruvate",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,139,175,199,217,244,268,296,314,334,359,403,455,480,505,537,555,576,602,648,722,782,822,861,918,940,989,1040,1084,1132,1162,1184,1206,1235,1253,1281,1299,1320,1338,1356,1374,1400,1426,1444,1468,1493,1520,1538,1562,1587,1613,1631,1649,1673,1698,1722,1740,1758,1776,1798,1816,1839,1861,1885,1903,1933,1951,1969,1987,2005,2029,2057,2075,2093,2111,2129,2147,2191,2214,2238,2261,2279,2297,2323,2348,2366,2384,2402,2431,2455,2475,2493,2516,2534,2555,2573,2591,2624,2642,2667,2693,2717,2740,2758,2785,2809,2867,2922,2965,3006,3057,3099,3143,3179,3215,3237,3269,3301,3341,3369,3401,3423,3459,3491,3524,3546,3579,3604,3630,3653,3680,3707,3725,3751,3769,3787,3810,3833,3857,3880,3898,3921,3947,3965,3990,4008,4026,4053,4071,4089,4107,4130,4154,4179,4207,4225,4243,4261,4279,4302,4320,4344,4362,4388,4413,4431,4449,4475,4501,4519,4537,4560,4585,4609,4633,4657,4675,4693,4711,4735,4753,4771,4789,4816,4834,4852,4877,4900,4927,4945,4963,4981,5008,5026,5050,5075,5093,5115,5141,5159,5177,5195,5213,5237,5265,5290,5308,5332,5350,5382,5400,5424,5442,5465,5490,5513,5538,5556,5579,5603,5646,5685,5724,5758,5790,5820,5842,5867,5885,5903,5927,5951,5978,5996,6019,6047,6065,6091,6109,6134,6157,6181,6204,6232,6256,6280,6325,6355,6400,6433,6459,6487,6520,6555,6593,6628,6650,6682,6704,6726,6748,6770,6808,6840,6868,6890,6914,6932,6958,6976,6998,7021,7039,7062,7088,7110,7134,7157,7180,7198,7224,7242,7264,7288,7314,7332,7354,7382,7404,7422,7447,7465,7491,7509,7527,7545,7568,7592,7610,7636,7659,7677,7695,7719,7740,7763,7781,7805,7826,7849,7874,7892,7916,7939,7962,7985,8008,8026,8044,8062,8088,8112,8139,8157,8181,8199,8217,8235,8253,8271,8294,8312,8340,8358,8382,8400,8418,8441,8466,8484,8502,8525,8543,8564,8587,8611,8635,8653,8671,8696,8714,8737,8755,8777,8809,8827,8849,8871,8889,8910,8928,8946,8964,8990,9008,9026,9050,9068,9086,9110,9128,9152,9176,9199,9224,9242,9263,9286,9310,9334,9352,9373,9402,9420,9438,9456,9478,9502,9520,9538,9561,9586,9611,9636,9672,9698,9716,9742,9760,9785,9807,9833,9851,9874,9898,9919,9941,9964,9987,10005,10027,10050,10068,10092,10118,10136,10185,10243,10287,10332,10367,10398,10424,10446,10474,10500,10522,10551,10578,10611,10633,10651,10669,10687,10708,10731,10749,10775,10793,10817,10843,10861,10879,10902,10920,10941,10963,10987,11010,11031,11059,11081,11107,11125,11143,11166,11184,11202,11226,11248,11271,11293,11314,11337,11362,11386,11408,11430,11464,11491,11509,11527,11550,11574],{"intervention":96,"totalTrials":97,"cells":98},"Potassium Citrate",2,{"EARLY_PHASE1":99,"PHASE1":117,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":137},{"trials":100,"activeCount":116,"soonestReadout":106},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT04651088","Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet","NOT_YET_RECRUITING",[88],"2026-12","2027-07","2026-07-01",15,[111],"Kidney Stone",[113,114,115],"Potassium citrate","Sodium bicarbonate","Potassium Bicarbonate",1,{"trials":118,"activeCount":119},[],0,{"trials":121,"activeCount":119},[],{"trials":123,"activeCount":119},[],{"trials":125,"activeCount":116,"soonestReadout":131},[126],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":132,"start":133,"enrollment":16,"conditions":134,"interventions":136},"NCT06003348","Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones","RECRUITING",[92],"2028-05-31","2028-08-31","2023-12-13",[135],"Calcium Phosphate Kidney Stones",[96],{"trials":138,"activeCount":119},[],{"intervention":56,"totalTrials":97,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":173},{"trials":142,"activeCount":119},[],{"trials":144,"activeCount":119},[],{"trials":146,"activeCount":119},[],{"trials":148,"activeCount":119},[],{"trials":150,"activeCount":116,"soonestReadout":55},[151,161],{"nctId":53,"briefTitle":54,"status":129,"phases":152,"primaryCompletion":55,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":159},[92],"2026-12-30","2010-07-01",90,[157,158],"Sarcoidosis","Vitamin D Insufficiency",[56,160],"Calcium Citrate with Vitamin D2",{"nctId":162,"briefTitle":163,"status":164,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":172},"NCT05084248","Vitamin D Deficiency in Adults Following a Major Burn Injury","COMPLETED",[92],"2025-08-18","2022-09-29",48,[170,171],"Vitamin D Deficiency","Burns",[56],{"trials":174,"activeCount":119},[],{"intervention":176,"totalTrials":116,"cells":177},"Deucravacitinib",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":197},{"trials":179,"activeCount":119},[],{"trials":181,"activeCount":119},[],{"trials":183,"activeCount":119},[],{"trials":185,"activeCount":119},[],{"trials":187,"activeCount":116,"soonestReadout":192},[188],{"nctId":189,"briefTitle":190,"status":104,"phases":191,"primaryCompletion":192,"completion":192,"start":65,"enrollment":193,"conditions":194,"interventions":196},"NCT07280702","Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease",[92],"2027-12-15",128,[195],"Psoriatic Arthritis (PsA)",[176],{"trials":198,"activeCount":119},[],{"intervention":160,"totalTrials":116,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":119},[],{"trials":204,"activeCount":119},[],{"trials":206,"activeCount":119},[],{"trials":208,"activeCount":119},[],{"trials":210,"activeCount":116,"soonestReadout":55},[211],{"nctId":53,"briefTitle":54,"status":129,"phases":212,"primaryCompletion":55,"completion":153,"start":154,"enrollment":155,"conditions":213,"interventions":214},[92],[157,158],[56,160],{"trials":216,"activeCount":119},[],{"intervention":218,"totalTrials":116,"cells":219},"Semaglutide",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":242},{"trials":221,"activeCount":119},[],{"trials":223,"activeCount":119},[],{"trials":225,"activeCount":119},[],{"trials":227,"activeCount":119},[],{"trials":229,"activeCount":116,"soonestReadout":235},[230],{"nctId":231,"briefTitle":232,"status":233,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":9,"conditions":238,"interventions":241},"NCT06042153","DIALYSIS-TIR Study","ACTIVE_NOT_RECRUITING",[92],"2027-09","2028-09","2023-12-05",[239,240],"Type 2 Diabetes","End Stage Renal Disease on Dialysis",[218],{"trials":243,"activeCount":119},[],{"intervention":245,"totalTrials":116,"cells":246},"Denosumab",{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":266},{"trials":248,"activeCount":119},[],{"trials":250,"activeCount":119},[],{"trials":252,"activeCount":119},[],{"trials":254,"activeCount":119},[],{"trials":256,"activeCount":116,"soonestReadout":107},[257],{"nctId":258,"briefTitle":259,"status":129,"phases":260,"primaryCompletion":107,"completion":107,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT03921060","Markers of Osteoporosis in Cystic Fibrosis",[92],"2021-09-02",100,[264],"Cystic Fibrosis",[245],{"trials":267,"activeCount":119},[],{"intervention":269,"totalTrials":116,"cells":270},"clozapine",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":294},{"trials":272,"activeCount":119},[],{"trials":274,"activeCount":119},[],{"trials":276,"activeCount":119},[],{"trials":278,"activeCount":119},[],{"trials":280,"activeCount":116,"soonestReadout":285},[281],{"nctId":282,"briefTitle":283,"status":129,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":292},"NCT04580134","CLOZAPINE Response in Biotype-1",[92],"2027-04-30","2022-03-01",524,[289,290,291],"Schizophrenia","Schizoaffective Disorder","Bipolar 1 Disorder",[269,293],"risperidone",{"trials":295,"activeCount":119},[],{"intervention":293,"totalTrials":116,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":312},{"trials":299,"activeCount":119},[],{"trials":301,"activeCount":119},[],{"trials":303,"activeCount":119},[],{"trials":305,"activeCount":119},[],{"trials":307,"activeCount":116,"soonestReadout":285},[308],{"nctId":282,"briefTitle":283,"status":129,"phases":309,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":310,"interventions":311},[92],[289,290,291],[269,293],{"trials":313,"activeCount":119},[],{"intervention":76,"totalTrials":116,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":332},{"trials":317,"activeCount":119},[],{"trials":319,"activeCount":119},[],{"trials":321,"activeCount":119},[],{"trials":323,"activeCount":119},[],{"trials":325,"activeCount":116,"soonestReadout":75},[326],{"nctId":73,"briefTitle":74,"status":129,"phases":327,"primaryCompletion":75,"completion":75,"start":328,"enrollment":16,"conditions":329,"interventions":331},[92],"2023-05-01",[330],"Transthyretin Cardiac Amyloidosis",[76],{"trials":333,"activeCount":119},[],{"intervention":335,"totalTrials":116,"cells":336},"Cladribine",{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":357},{"trials":338,"activeCount":119},[],{"trials":340,"activeCount":119},[],{"trials":342,"activeCount":119},[],{"trials":344,"activeCount":119},[],{"trials":346,"activeCount":116,"soonestReadout":351},[347],{"nctId":348,"briefTitle":349,"status":233,"phases":350,"primaryCompletion":351,"completion":106,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT04178005","Cladribine Tablets After Treatment With Natalizumab (CLADRINA)",[92],"2026-08-30","2020-02-19",40,[355],"Multiple Sclerosis",[335],{"trials":358,"activeCount":119},[],{"intervention":51,"totalTrials":360,"cells":361},3,{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":399,"NA":401},{"trials":363,"activeCount":119},[],{"trials":365,"activeCount":119},[],{"trials":367,"activeCount":119},[],{"trials":369,"activeCount":97,"soonestReadout":50},[370,382,392],{"nctId":371,"briefTitle":372,"status":129,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":381},"NCT05998863","EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy",[91],"2026-09-30","2026-12-31","2024-04-19",56,[379,380],"Osteoporosis","Hypomagnesemia",[51],{"nctId":383,"briefTitle":384,"status":385,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":391},"NCT03812380","Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate","TERMINATED",[91],"2021-08-11","2019-01-01",62,[379,380],[51],{"nctId":48,"briefTitle":49,"status":233,"phases":393,"primaryCompletion":50,"completion":50,"start":394,"enrollment":395,"conditions":396,"interventions":398},[90,91],"2017-01-22",269,[397],"CKD Stage 5",[51],{"trials":400,"activeCount":119},[],{"trials":402,"activeCount":119},[],{"intervention":404,"totalTrials":360,"cells":405},"Gemcitabine",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":422,"PHASE3":437,"PHASE4":451,"NA":453},{"trials":407,"activeCount":119},[],{"trials":409,"activeCount":119},[410],{"nctId":411,"briefTitle":412,"status":385,"phases":413,"primaryCompletion":414,"completion":415,"start":416,"enrollment":27,"conditions":417,"interventions":419},"NCT02514031","ARQ-761 Treatment With Gemcitabine\u002FNab-Paclitaxel Chemotherapy In Pancreatic Cancer",[89],"2018-05-22","2022-05","2016-03-24",[418],"Pancreatic Cancer",[420,404,421],"ARQ-761","nab-paclitaxel",{"trials":423,"activeCount":119},[424],{"nctId":425,"briefTitle":426,"status":385,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":433},"NCT03649321","Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer",[89,90],"2022-06-27","2019-01-03",9,[432],"Cancer of Pancreas",[434,435,404,436],"Bemcentinib","Nab-paclitaxel","Cisplatin",{"trials":438,"activeCount":116,"soonestReadout":443},[439],{"nctId":440,"briefTitle":441,"status":129,"phases":442,"primaryCompletion":443,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":450},"NCT04865939","Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma",[91],"2029-11-01","2031-11-01","2021-11-29",132,[448,449],"Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma Ureter",[404],{"trials":452,"activeCount":119},[],{"trials":454,"activeCount":119},[],{"intervention":456,"totalTrials":116,"cells":457},"Curcumin",{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":476,"NA":478},{"trials":459,"activeCount":119},[],{"trials":461,"activeCount":119},[],{"trials":463,"activeCount":119},[],{"trials":465,"activeCount":116,"soonestReadout":470},[466],{"nctId":467,"briefTitle":468,"status":129,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT03769766","Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance",[91],"2029-11","2030-11","2019-03-11",291,[32],[456],{"trials":477,"activeCount":119},[],{"trials":479,"activeCount":119},[],{"intervention":481,"totalTrials":116,"cells":482},"Weight loss",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":501,"NA":503},{"trials":484,"activeCount":119},[],{"trials":486,"activeCount":119},[],{"trials":488,"activeCount":119},[],{"trials":490,"activeCount":116,"soonestReadout":153},[491],{"nctId":492,"briefTitle":493,"status":129,"phases":494,"primaryCompletion":153,"completion":153,"start":495,"enrollment":496,"conditions":497,"interventions":500},"NCT07223242","Tailored Exercise Training Study Among Adults With HFpEF",[90,91],"2025-02-18",120,[498,499],"HFpEF - Heart Failure With Preserved Ejection Fraction","Diabetic Cardiomyopathies",[481],{"trials":502,"activeCount":119},[],{"trials":504,"activeCount":119},[],{"intervention":506,"totalTrials":116,"cells":507},"Admixture of propofol and etomidate at a ratio by volume of 75%\u002F25%",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":533,"NA":535},{"trials":509,"activeCount":119},[],{"trials":511,"activeCount":119},[],{"trials":513,"activeCount":119},[],{"trials":515,"activeCount":116,"soonestReadout":520},[516],{"nctId":517,"briefTitle":518,"status":129,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":531},"NCT05358535","Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)",[91],"2027-01","2027-03","2022-09-19",200,[525,526,527,528,529,530],"Anesthesia","Propofol Adverse Reaction","Etomidate Adverse Reaction","Anesthesia Complication","Anesthesia; Adverse Effect","Anesthesia; Reaction",[506,532],"Admixture of propofol and etomidate at a ratio by volume of 25%\u002F75%",{"trials":534,"activeCount":119},[],{"trials":536,"activeCount":119},[],{"intervention":532,"totalTrials":116,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":551,"NA":553},{"trials":540,"activeCount":119},[],{"trials":542,"activeCount":119},[],{"trials":544,"activeCount":119},[],{"trials":546,"activeCount":116,"soonestReadout":520},[547],{"nctId":517,"briefTitle":518,"status":129,"phases":548,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":549,"interventions":550},[91],[525,526,527,528,529,530],[506,532],{"trials":552,"activeCount":119},[],{"trials":554,"activeCount":119},[],{"intervention":46,"totalTrials":116,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":572,"NA":574},{"trials":558,"activeCount":119},[],{"trials":560,"activeCount":119},[],{"trials":562,"activeCount":119},[],{"trials":564,"activeCount":116,"soonestReadout":45},[565],{"nctId":43,"briefTitle":44,"status":233,"phases":566,"primaryCompletion":45,"completion":567,"start":568,"enrollment":27,"conditions":569,"interventions":571},[91],"2027-06-01","2022-10-07",[570],"Glioblastoma",[46],{"trials":573,"activeCount":119},[],{"trials":575,"activeCount":119},[],{"intervention":577,"totalTrials":116,"cells":578},"Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor",{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":598,"NA":600},{"trials":580,"activeCount":119},[],{"trials":582,"activeCount":119},[],{"trials":584,"activeCount":119},[],{"trials":586,"activeCount":116,"soonestReadout":591},[587],{"nctId":588,"briefTitle":589,"status":104,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":597},"NCT07018297","Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure",[91],"2028-08-01","2028-09-01","2026-08",250,[35,596],"Acute Decompensated Heart Failure",[577],{"trials":599,"activeCount":119},[],{"trials":601,"activeCount":119},[],{"intervention":81,"totalTrials":360,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":605,"activeCount":119},[],{"trials":607,"activeCount":119},[],{"trials":609,"activeCount":360,"soonestReadout":40},[610,623,633],{"nctId":611,"briefTitle":612,"status":129,"phases":613,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":621},"NCT06266338","Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)",[90],"2026-10-31","2027-10-31","2024-03-11",30,[619,620],"Cervix Cancer","Cervical Cancer",[81,622],"Lenvatinib",{"nctId":38,"briefTitle":39,"status":233,"phases":624,"primaryCompletion":40,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},[90],"2029-12","2019-01-25",138,[629,20],"HER2-positive Breast Cancer",[41,631,632,81],"Trastuzumab","Pertuzumab",{"nctId":78,"briefTitle":79,"status":233,"phases":634,"primaryCompletion":80,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},[90],"2028-06","2019-11-12",51,[20],[81,640,641],"Ipilimumab","Nivolumab",{"trials":643,"activeCount":119},[],{"trials":645,"activeCount":119},[],{"trials":647,"activeCount":119},[],{"intervention":649,"totalTrials":650,"cells":651},"Ketamine Hydrochloride",5,{"EARLY_PHASE1":652,"PHASE1":665,"PHASE2":667,"PHASE3":693,"PHASE4":708,"NA":720},{"trials":653,"activeCount":116,"soonestReadout":106},[654],{"nctId":655,"briefTitle":656,"status":129,"phases":657,"primaryCompletion":106,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":664},"NCT06062628","Ketamine in Severe Traumatic Brain Injury",[88],"2027-06","2026-06-01",10,[662,663],"Traumatic Brain Injury","Traumatic Encephalopathy",[649],{"trials":666,"activeCount":119},[],{"trials":668,"activeCount":116,"soonestReadout":673},[669,682],{"nctId":670,"briefTitle":671,"status":129,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":496,"conditions":676,"interventions":680},"NCT06496750","Ketamine for Methamphetamine Use Disorder",[90],"2026-08-18","2026-10-15","2024-09-11",[677,678,679],"Substance Use Disorders","Substance Use","Methamphetamine Abuse",[649,681],"Midazolam Hydrochloride",{"nctId":683,"briefTitle":684,"status":164,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":691},"NCT05046184","Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets",[90],"2025-04-30","2022-05-05",165,[29,690],"Healthy Controls",[649,692],"Midazolam",{"trials":694,"activeCount":119},[695],{"nctId":696,"briefTitle":697,"status":164,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":707},"NCT04592809","Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents",[91],"2025-07-01","2025-08-31","2022-10-03",50,[704,705,706],"Suicide, Attempted","Suicide and Depression","Suicide Threat",[649,681],{"trials":709,"activeCount":119},[710],{"nctId":711,"briefTitle":712,"status":164,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":9,"conditions":716,"interventions":719},"NCT03621085","Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine",[92],"2021-06-30","2018-06-01",[717,718],"Hemorrhage","Healthy",[649],{"trials":721,"activeCount":119},[],{"intervention":723,"totalTrials":724,"cells":725},"Polypill",4,{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":727,"activeCount":119},[],{"trials":729,"activeCount":119},[],{"trials":731,"activeCount":97,"soonestReadout":759},[732,742,755,765],{"nctId":733,"briefTitle":734,"status":129,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":741},"NCT07032389","A Polypill for Acute Coronary Syndrome",[90],"2029-08-01","2025-12-05",1000,[740],"Acute Coronary Syndrome",[723],{"nctId":743,"briefTitle":744,"status":164,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":753},"NCT05514938","Polypill in Acute Coronary Syndrome",[90],"2025-05-30","2025-06-05","2022-11-30",140,[740,751,752],"Lipid Disorder","Coronary Artery Disease",[723,754],"Usual Care",{"nctId":756,"briefTitle":757,"status":129,"phases":758,"primaryCompletion":759,"completion":760,"start":616,"enrollment":523,"conditions":761,"interventions":763},"NCT06143566","Polypill for Prevention of Cardiomyopathy",[89,90],"2027-09-01","2027-12-01",[239,762],"High Blood Pressure",[723,764],"Combined prescription of the individual medications",{"nctId":766,"briefTitle":767,"status":164,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":774},"NCT04633005","Polypill Strategy for Heart Failure With Reduced Ejection Fraction",[90],"2025-10-15","2025-10-31","2021-11-15",212,[35],[723,775],"Control Rx",{"trials":777,"activeCount":119},[],{"trials":779,"activeCount":119},[],{"trials":781,"activeCount":119},[],{"intervention":783,"totalTrials":97,"cells":784},"Atezolizumab",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":786,"activeCount":119},[],{"trials":788,"activeCount":119},[],{"trials":790,"activeCount":97,"soonestReadout":808},[791,804],{"nctId":792,"briefTitle":793,"status":129,"phases":794,"primaryCompletion":520,"completion":520,"start":795,"enrollment":796,"conditions":797,"interventions":800},"NCT04796012","VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed\u002FRefractory Solid Tumors",[89,90],"2023-04-18",23,[798,799],"Solid Tumor","Rhabdomyosarcoma",[783,801,802,803],"Vincristine","Irinotecan","Temozolomide",{"nctId":805,"briefTitle":806,"status":233,"phases":807,"primaryCompletion":808,"completion":809,"start":810,"enrollment":21,"conditions":811,"interventions":813},"NCT05999812","Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer",[90],"2026-10-01","2028-10-01","2023-12-19",[812],"Colorectal Cancer",[814,783,815],"all trans Retinoic Acid","Bevacizumab",{"trials":817,"activeCount":119},[],{"trials":819,"activeCount":119},[],{"trials":821,"activeCount":119},[],{"intervention":823,"totalTrials":97,"cells":824},"Cadonilimab",{"EARLY_PHASE1":825,"PHASE1":838,"PHASE2":840,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":826,"activeCount":116,"soonestReadout":831},[827],{"nctId":828,"briefTitle":829,"status":104,"phases":830,"primaryCompletion":831,"completion":832,"start":75,"enrollment":833,"conditions":834,"interventions":836},"NCT07446257","THIO and Cadonilimab in Resectable Hepatocellular Carcinoma",[88],"2030-05-01","2031-05-01",60,[835],"Resectable Hepatocellular Carcinoma",[837,823],"ateganosine",{"trials":839,"activeCount":119},[],{"trials":841,"activeCount":116,"soonestReadout":846},[842],{"nctId":843,"briefTitle":844,"status":129,"phases":845,"primaryCompletion":846,"completion":847,"start":495,"enrollment":848,"conditions":849,"interventions":853},"NCT06789848","Ligufalimab and Cadonilimab in Advanced Liver Cancers",[90],"2029-05-31","2030-05-31",64,[850,851,852],"Advanced Hepatocellular Carcinoma","Refractory Hepatocellular Carcinoma","Biliary Tract Cancer",[854,823],"Ligufalimab",{"trials":856,"activeCount":119},[],{"trials":858,"activeCount":119},[],{"trials":860,"activeCount":119},[],{"intervention":862,"totalTrials":724,"cells":863},"Escitalopram",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":880,"PHASE4":893,"NA":916},{"trials":865,"activeCount":119},[],{"trials":867,"activeCount":119},[],{"trials":869,"activeCount":116,"soonestReadout":874},[870],{"nctId":871,"briefTitle":872,"status":129,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":11,"conditions":877,"interventions":879},"NCT06216535","Escitalopram in Asthma Patients With Frequent Exacerbation",[90],"2028-12-01","2029-06-01","2025-05-19",[878],"Asthma",[862],{"trials":881,"activeCount":119},[882],{"nctId":883,"briefTitle":884,"status":385,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT00642694","Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon",[91],"2010-05","2007-05",29,[29,890],"Insomnia",[862,892],"Ramelteon",{"trials":894,"activeCount":119},[895,905],{"nctId":896,"briefTitle":897,"status":385,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":903},"NCT03993457","Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression",[92],"2022-03-25","2019-07-23",18,[15],[862,904],"Bupropion",{"nctId":906,"briefTitle":907,"status":164,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":915},"NCT00621946","Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder",[92],"2010-03","2008-03",26,[913,914],"Severe Asthma","Moderate or Severe Major Depressive Disorder",[862],{"trials":917,"activeCount":119},[],{"intervention":681,"totalTrials":97,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":930,"PHASE4":936,"NA":938},{"trials":921,"activeCount":119},[],{"trials":923,"activeCount":119},[],{"trials":925,"activeCount":116,"soonestReadout":673},[926],{"nctId":670,"briefTitle":671,"status":129,"phases":927,"primaryCompletion":673,"completion":674,"start":675,"enrollment":496,"conditions":928,"interventions":929},[90],[677,678,679],[649,681],{"trials":931,"activeCount":119},[932],{"nctId":696,"briefTitle":697,"status":164,"phases":933,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":934,"interventions":935},[91],[704,705,706],[649,681],{"trials":937,"activeCount":119},[],{"trials":939,"activeCount":119},[],{"intervention":641,"totalTrials":724,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":943,"activeCount":119},[],{"trials":945,"activeCount":119},[],{"trials":947,"activeCount":116,"soonestReadout":80},[948,959,969,979],{"nctId":949,"briefTitle":950,"status":951,"phases":952,"primaryCompletion":953,"completion":953,"start":954,"enrollment":119,"conditions":955,"interventions":958},"NCT03126461","SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients","WITHDRAWN",[90],"2022-12-31","2018-03-01",[956,957],"Melanoma","Metastatic Melanoma",[640,641],{"nctId":960,"briefTitle":961,"status":951,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":119,"conditions":966,"interventions":968},"NCT03808168","Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia",[90],"2019-06-01","2020-06-01","2019-01-15",[967],"Cervix Uteri--Diseases",[641],{"nctId":970,"briefTitle":971,"status":385,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":978},"NCT02781506","Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma",[90],"2021-05-24","2016-06-20",7,[977],"Metastatic Clear Cell Renal Cell Carcinoma",[641],{"nctId":78,"briefTitle":79,"status":233,"phases":980,"primaryCompletion":80,"completion":635,"start":636,"enrollment":637,"conditions":981,"interventions":982},[90],[20],[81,640,641],{"trials":984,"activeCount":119},[],{"trials":986,"activeCount":119},[],{"trials":988,"activeCount":119},[],{"intervention":990,"totalTrials":724,"cells":991},"paclitaxel",{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":993,"activeCount":119},[],{"trials":995,"activeCount":119},[],{"trials":997,"activeCount":116,"soonestReadout":40},[998,1010,1014,1024],{"nctId":999,"briefTitle":1000,"status":164,"phases":1001,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":1004,"conditions":1005,"interventions":1007},"NCT01757288","Phase I\u002FII NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA\u002FB NSCLC",[89,90],"2019-06-03","2013-03-25",98,[1006],"STAGE IIIA\u002FB NSCLC \u002F INOPERABLE LUNG CANCER",[1008,1009,1008],"NAB-PACLITAXEL","PACLITAXEL",{"nctId":38,"briefTitle":39,"status":233,"phases":1011,"primaryCompletion":40,"completion":625,"start":626,"enrollment":627,"conditions":1012,"interventions":1013},[90],[629,20],[41,631,632,81],{"nctId":1015,"briefTitle":1016,"status":385,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1022},"NCT00622466","Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer",[90],"2016-10","2008-04-23",20,[20],[990,1023],"sorafenib tosylate",{"nctId":1025,"briefTitle":1026,"status":951,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":119,"conditions":1030,"interventions":1032},"NCT00547443","Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",[89,90],"2009-07","2007-07",[1031],"Lung Cancer",[1033,990,1023],"carboplatin",{"trials":1035,"activeCount":119},[],{"trials":1037,"activeCount":119},[],{"trials":1039,"activeCount":119},[],{"intervention":815,"totalTrials":360,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1056,"PHASE2":1058,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1043,"activeCount":119},[1044],{"nctId":1045,"briefTitle":1046,"status":385,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":660,"conditions":1050,"interventions":1054},"NCT04074785","Abemaciclib w\u002FBevacizumab in Recurrent GBM Pts w\u002FLoss of CDKN2A\u002FB or Gain or Amplification of CDK4\u002F6",[88],"2023-10-16","2019-12-13",[1051,570,1052,1053],"GBM","Brain Tumor","Brain Tumor, Recurrent",[1055,815],"Abemaciclib",{"trials":1057,"activeCount":119},[],{"trials":1059,"activeCount":116,"soonestReadout":808},[1060,1074],{"nctId":1061,"briefTitle":1062,"status":164,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1070},"NCT00295503","Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma",[90],"2010-06","2010-08","2006-02",53,[1069],"Mesothelioma",[1071,1072,1073],"bevacizumab","cisplatin","pemetrexed",{"nctId":805,"briefTitle":806,"status":233,"phases":1075,"primaryCompletion":808,"completion":809,"start":810,"enrollment":21,"conditions":1076,"interventions":1077},[90],[812],[814,783,815],{"trials":1079,"activeCount":119},[],{"trials":1081,"activeCount":119},[],{"trials":1083,"activeCount":119},[],{"intervention":1085,"totalTrials":360,"cells":1086},"Orlistat",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1088,"activeCount":119},[],{"trials":1090,"activeCount":119},[],{"trials":1092,"activeCount":116,"soonestReadout":1097},[1093,1104,1116],{"nctId":1094,"briefTitle":1095,"status":129,"phases":1096,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1103},"NCT05816343","Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia",[90],"2027-08-01","2029-05-30","2024-01-26",28,[1102],"Type 1 Hyperlipoprotenemia",[1085],{"nctId":1105,"briefTitle":1106,"status":385,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":650,"conditions":1110,"interventions":1112},"NCT01675154","Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia",[90],"2020-06-30","2015-11",[1111],"Type 1 Hyperlipoproteinemia",[1113,1114,1085,1115],"SLx-4090 placebo","Orlistat Placebo","Slx-4090",{"nctId":1117,"briefTitle":1118,"status":164,"phases":1119,"primaryCompletion":1120,"completion":953,"start":1121,"enrollment":97,"conditions":1122,"interventions":1125},"NCT02767531","Orlistat for the Treatment of Type I Hyperlipoproteinemia",[90],"2018-05-31","2015-12",[1123,1124],"Hyperlipoproteinemia Type I","Hypertriglyceridemia",[1085],{"trials":1127,"activeCount":119},[],{"trials":1129,"activeCount":119},[],{"trials":1131,"activeCount":119},[],{"intervention":66,"totalTrials":97,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1135,"activeCount":119},[],{"trials":1137,"activeCount":119},[],{"trials":1139,"activeCount":116,"soonestReadout":65},[1140,1146],{"nctId":63,"briefTitle":64,"status":129,"phases":1141,"primaryCompletion":65,"completion":1142,"start":1143,"enrollment":833,"conditions":1144,"interventions":1145},[90],"2028-04-15","2021-04-15",[20],[66,1055],{"nctId":1147,"briefTitle":1148,"status":164,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1155},"NCT03747042","Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer",[90],"2025-02-24","2018-11-27",61,[1154],"Breast Cancer Female",[66],{"trials":1157,"activeCount":119},[],{"trials":1159,"activeCount":119},[],{"trials":1161,"activeCount":119},[],{"intervention":1055,"totalTrials":97,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1170,"PHASE2":1172,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1165,"activeCount":119},[1166],{"nctId":1045,"briefTitle":1046,"status":385,"phases":1167,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":660,"conditions":1168,"interventions":1169},[88],[1051,570,1052,1053],[1055,815],{"trials":1171,"activeCount":119},[],{"trials":1173,"activeCount":116,"soonestReadout":65},[1174],{"nctId":63,"briefTitle":64,"status":129,"phases":1175,"primaryCompletion":65,"completion":1142,"start":1143,"enrollment":833,"conditions":1176,"interventions":1177},[90],[20],[66,1055],{"trials":1179,"activeCount":119},[],{"trials":1181,"activeCount":119},[],{"trials":1183,"activeCount":119},[],{"intervention":640,"totalTrials":97,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1200,"PHASE4":1202,"NA":1204},{"trials":1187,"activeCount":119},[],{"trials":1189,"activeCount":119},[],{"trials":1191,"activeCount":116,"soonestReadout":80},[1192,1196],{"nctId":949,"briefTitle":950,"status":951,"phases":1193,"primaryCompletion":953,"completion":953,"start":954,"enrollment":119,"conditions":1194,"interventions":1195},[90],[956,957],[640,641],{"nctId":78,"briefTitle":79,"status":233,"phases":1197,"primaryCompletion":80,"completion":635,"start":636,"enrollment":637,"conditions":1198,"interventions":1199},[90],[20],[81,640,641],{"trials":1201,"activeCount":119},[],{"trials":1203,"activeCount":119},[],{"trials":1205,"activeCount":119},[],{"intervention":1207,"totalTrials":116,"cells":1208},"intra-nasal ketorolac",{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1210,"activeCount":119},[],{"trials":1212,"activeCount":119},[],{"trials":1214,"activeCount":116,"soonestReadout":1219},[1215],{"nctId":1216,"briefTitle":1217,"status":129,"phases":1218,"primaryCompletion":1219,"completion":760,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1227},"NCT06158620","Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease",[89,90],"2027-04-01","2025-03-01",80,[1223,1224,1225,1226],"Post Operative Pain","Urolithiasis","Ureter Calculi","Stent Complication",[1207,1228],"oral diclofenac",{"trials":1230,"activeCount":119},[],{"trials":1232,"activeCount":119},[],{"trials":1234,"activeCount":119},[],{"intervention":1228,"totalTrials":116,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":119},[],{"trials":1240,"activeCount":119},[],{"trials":1242,"activeCount":116,"soonestReadout":1219},[1243],{"nctId":1216,"briefTitle":1217,"status":129,"phases":1244,"primaryCompletion":1219,"completion":760,"start":1220,"enrollment":1221,"conditions":1245,"interventions":1246},[89,90],[1223,1224,1225,1226],[1207,1228],{"trials":1248,"activeCount":119},[],{"trials":1250,"activeCount":119},[],{"trials":1252,"activeCount":119},[],{"intervention":1254,"totalTrials":116,"cells":1255},"Zimberelimab",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1257,"activeCount":119},[],{"trials":1259,"activeCount":119},[],{"trials":1261,"activeCount":116,"soonestReadout":108},[1262],{"nctId":1263,"briefTitle":1264,"status":233,"phases":1265,"primaryCompletion":108,"completion":567,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1273},"NCT05724563","Domvanalimab and Zimberelimab in Advanced Liver Cancers",[90],"2023-06-01",58,[1269,1270,1271,1272],"Hepatobiliary Cancer","Liver Cancer","Cholangiocarcinoma","Hepatocellular Carcinoma",[1254,1274],"Domvanalimab",{"trials":1276,"activeCount":119},[],{"trials":1278,"activeCount":119},[],{"trials":1280,"activeCount":119},[],{"intervention":1274,"totalTrials":116,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":119},[],{"trials":1286,"activeCount":119},[],{"trials":1288,"activeCount":116,"soonestReadout":108},[1289],{"nctId":1263,"briefTitle":1264,"status":233,"phases":1290,"primaryCompletion":108,"completion":567,"start":1266,"enrollment":1267,"conditions":1291,"interventions":1292},[90],[1269,1270,1271,1272],[1254,1274],{"trials":1294,"activeCount":119},[],{"trials":1296,"activeCount":119},[],{"trials":1298,"activeCount":119},[],{"intervention":61,"totalTrials":116,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1302,"activeCount":119},[],{"trials":1304,"activeCount":119},[],{"trials":1306,"activeCount":116,"soonestReadout":60},[1307],{"nctId":58,"briefTitle":59,"status":233,"phases":1308,"primaryCompletion":60,"completion":60,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1313},[90],"2025-02-03",45,[23,1312],"Methamphetamine Use Disorder",[61],{"trials":1315,"activeCount":119},[],{"trials":1317,"activeCount":119},[],{"trials":1319,"activeCount":119},[],{"intervention":801,"totalTrials":116,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1323,"activeCount":119},[],{"trials":1325,"activeCount":119},[],{"trials":1327,"activeCount":116,"soonestReadout":520},[1328],{"nctId":792,"briefTitle":793,"status":129,"phases":1329,"primaryCompletion":520,"completion":520,"start":795,"enrollment":796,"conditions":1330,"interventions":1331},[89,90],[798,799],[783,801,802,803],{"trials":1333,"activeCount":119},[],{"trials":1335,"activeCount":119},[],{"trials":1337,"activeCount":119},[],{"intervention":802,"totalTrials":116,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1341,"activeCount":119},[],{"trials":1343,"activeCount":119},[],{"trials":1345,"activeCount":116,"soonestReadout":520},[1346],{"nctId":792,"briefTitle":793,"status":129,"phases":1347,"primaryCompletion":520,"completion":520,"start":795,"enrollment":796,"conditions":1348,"interventions":1349},[89,90],[798,799],[783,801,802,803],{"trials":1351,"activeCount":119},[],{"trials":1353,"activeCount":119},[],{"trials":1355,"activeCount":119},[],{"intervention":803,"totalTrials":116,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1359,"activeCount":119},[],{"trials":1361,"activeCount":119},[],{"trials":1363,"activeCount":116,"soonestReadout":520},[1364],{"nctId":792,"briefTitle":793,"status":129,"phases":1365,"primaryCompletion":520,"completion":520,"start":795,"enrollment":796,"conditions":1366,"interventions":1367},[89,90],[798,799],[783,801,802,803],{"trials":1369,"activeCount":119},[],{"trials":1371,"activeCount":119},[],{"trials":1373,"activeCount":119},[],{"intervention":1375,"totalTrials":116,"cells":1376},"Mitoquinone\u002Fmitoquinol mesylate",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1378,"activeCount":119},[],{"trials":1380,"activeCount":119},[],{"trials":1382,"activeCount":116,"soonestReadout":1387},[1383],{"nctId":1384,"briefTitle":1385,"status":129,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":1389,"conditions":1390,"interventions":1393},"NCT05886816","Mitoquinone\u002FMitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19",[90],"2026-07-31","2024-03-01",112,[1391,1392],"SARS-CoV Infection","COVID-19",[1375],{"trials":1395,"activeCount":119},[],{"trials":1397,"activeCount":119},[],{"trials":1399,"activeCount":119},[],{"intervention":1401,"totalTrials":116,"cells":1402},"IMSA101",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1420,"PHASE4":1422,"NA":1424},{"trials":1404,"activeCount":119},[],{"trials":1406,"activeCount":119},[],{"trials":1408,"activeCount":116,"soonestReadout":1413},[1409],{"nctId":1410,"briefTitle":1411,"status":129,"phases":1412,"primaryCompletion":1413,"completion":1414,"start":1415,"enrollment":109,"conditions":1416,"interventions":1419},"NCT06601296","Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer",[90],"2027-10","2028-10","2025-04-01",[1417,1418],"Metastatic Renal Cell Carcinoma ( mRCC)","OligoProgressive Metastatic Disease",[1401],{"trials":1421,"activeCount":119},[],{"trials":1423,"activeCount":119},[],{"trials":1425,"activeCount":119},[],{"intervention":622,"totalTrials":116,"cells":1427},{"EARLY_PHASE1":1428,"PHASE1":1430,"PHASE2":1432,"PHASE3":1438,"PHASE4":1440,"NA":1442},{"trials":1429,"activeCount":119},[],{"trials":1431,"activeCount":119},[],{"trials":1433,"activeCount":116,"soonestReadout":614},[1434],{"nctId":611,"briefTitle":612,"status":129,"phases":1435,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":1436,"interventions":1437},[90],[619,620],[81,622],{"trials":1439,"activeCount":119},[],{"trials":1441,"activeCount":119},[],{"trials":1443,"activeCount":119},[],{"intervention":1445,"totalTrials":116,"cells":1446},"erlotinib hydrochloride",{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1448,"activeCount":119},[],{"trials":1450,"activeCount":119},[],{"trials":1452,"activeCount":116,"soonestReadout":1457},[1453],{"nctId":1454,"briefTitle":1455,"status":104,"phases":1456,"primaryCompletion":1457,"completion":1457,"start":593,"enrollment":833,"conditions":1458,"interventions":1461},"NCT04172779","Erlotinib for Hepatocellular Carcinoma Chemoprevention",[90],"2030-12",[1459,1460],"Cirrhosis, Liver","Advanced Liver Fibrosis",[1445],{"trials":1463,"activeCount":119},[],{"trials":1465,"activeCount":119},[],{"trials":1467,"activeCount":119},[],{"intervention":1469,"totalTrials":116,"cells":1470},"Osimertinib",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1472,"activeCount":119},[],{"trials":1474,"activeCount":119},[],{"trials":1476,"activeCount":116,"soonestReadout":1481},[1477],{"nctId":1478,"briefTitle":1479,"status":233,"phases":1480,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1486},"NCT03667820","Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC",[90],"2027-09-30","2018-09-26",41,[1485],"Non-small Cell Lung Cancer (NSCLC)",[1469],{"trials":1488,"activeCount":119},[],{"trials":1490,"activeCount":119},[],{"trials":1492,"activeCount":119},[],{"intervention":1494,"totalTrials":116,"cells":1495},"Iomab-B",{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1497,"activeCount":119},[],{"trials":1499,"activeCount":119},[],{"trials":1501,"activeCount":116,"soonestReadout":1506},[1502],{"nctId":1503,"briefTitle":1504,"status":129,"phases":1505,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":617,"conditions":1509,"interventions":1512},"NCT06768905","IOMAB-CAR-T Followed by CAR-T Cell Therapy in R\u002FR DLBCL",[89,90],"2029-05","2030-05","2025-04-25",[1510,1511],"Non Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma",[1494,1513],"CAR-T cell",{"trials":1515,"activeCount":119},[],{"trials":1517,"activeCount":119},[],{"trials":1519,"activeCount":119},[],{"intervention":1513,"totalTrials":116,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1523,"activeCount":119},[],{"trials":1525,"activeCount":119},[],{"trials":1527,"activeCount":116,"soonestReadout":1506},[1528],{"nctId":1503,"briefTitle":1504,"status":129,"phases":1529,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":617,"conditions":1530,"interventions":1531},[89,90],[1510,1511],[1494,1513],{"trials":1533,"activeCount":119},[],{"trials":1535,"activeCount":119},[],{"trials":1537,"activeCount":119},[],{"intervention":1539,"totalTrials":116,"cells":1540},"microbubble CEUS Contrast Enhanced Ultrasound",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1542,"activeCount":119},[],{"trials":1544,"activeCount":119},[],{"trials":1546,"activeCount":116,"soonestReadout":1551},[1547],{"nctId":1548,"briefTitle":1549,"status":129,"phases":1550,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1067,"conditions":1554,"interventions":1555},"NCT06444269","Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial",[90],"2027-07-01","2028-07-01","2024-10-11",[20],[1539],{"trials":1557,"activeCount":119},[],{"trials":1559,"activeCount":119},[],{"trials":1561,"activeCount":119},[],{"intervention":1563,"totalTrials":116,"cells":1564},"Afatinib + Prednisone",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1566,"activeCount":119},[],{"trials":1568,"activeCount":119},[],{"trials":1570,"activeCount":116,"soonestReadout":1575},[1571],{"nctId":1572,"briefTitle":1573,"status":233,"phases":1574,"primaryCompletion":1575,"completion":759,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1580},"NCT04497584","Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC",[90],"2026-09-01","2021-08-04",12,[1579],"Advanced Squamous Non Small Cell Lung Cancer",[1563],{"trials":1582,"activeCount":119},[],{"trials":1584,"activeCount":119},[],{"trials":1586,"activeCount":119},[],{"intervention":1588,"totalTrials":116,"cells":1589},"Neoadjuvant Lenvatinib",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1591,"activeCount":119},[],{"trials":1593,"activeCount":119},[],{"trials":1595,"activeCount":116,"soonestReadout":1600},[1596],{"nctId":1597,"briefTitle":1598,"status":129,"phases":1599,"primaryCompletion":1600,"completion":593,"start":1601,"enrollment":617,"conditions":1602,"interventions":1604},"NCT05319015","Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",[90],"2026-07","2023-01-06",[1603],"Renal Cell Carcinoma",[1588,1605,1606],"Neoadjuvant Pembrolizumab","Adjuvant Pembrolizumab",{"trials":1608,"activeCount":119},[],{"trials":1610,"activeCount":119},[],{"trials":1612,"activeCount":119},[],{"intervention":1605,"totalTrials":116,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1616,"activeCount":119},[],{"trials":1618,"activeCount":119},[],{"trials":1620,"activeCount":116,"soonestReadout":1600},[1621],{"nctId":1597,"briefTitle":1598,"status":129,"phases":1622,"primaryCompletion":1600,"completion":593,"start":1601,"enrollment":617,"conditions":1623,"interventions":1624},[90],[1603],[1588,1605,1606],{"trials":1626,"activeCount":119},[],{"trials":1628,"activeCount":119},[],{"trials":1630,"activeCount":119},[],{"intervention":1606,"totalTrials":116,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1634,"activeCount":119},[],{"trials":1636,"activeCount":119},[],{"trials":1638,"activeCount":116,"soonestReadout":1600},[1639],{"nctId":1597,"briefTitle":1598,"status":129,"phases":1640,"primaryCompletion":1600,"completion":593,"start":1601,"enrollment":617,"conditions":1641,"interventions":1642},[90],[1603],[1588,1605,1606],{"trials":1644,"activeCount":119},[],{"trials":1646,"activeCount":119},[],{"trials":1648,"activeCount":119},[],{"intervention":1650,"totalTrials":116,"cells":1651},"Low Dose Colchicine",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1653,"activeCount":119},[],{"trials":1655,"activeCount":119},[],{"trials":1657,"activeCount":116,"soonestReadout":1387},[1658],{"nctId":1659,"briefTitle":1660,"status":129,"phases":1661,"primaryCompletion":1387,"completion":1662,"start":1663,"enrollment":833,"conditions":1664,"interventions":1666},"NCT06130059","Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation",[90],"2027-12-31","2024-04-24",[35,1665],"Inflammation",[1650],{"trials":1668,"activeCount":119},[],{"trials":1670,"activeCount":119},[],{"trials":1672,"activeCount":119},[],{"intervention":1674,"totalTrials":116,"cells":1675},"Pegsitacianine",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1677,"activeCount":119},[],{"trials":1679,"activeCount":119},[],{"trials":1681,"activeCount":116,"soonestReadout":1662},[1682],{"nctId":1683,"briefTitle":1684,"status":129,"phases":1685,"primaryCompletion":1662,"completion":1662,"start":1686,"enrollment":496,"conditions":1687,"interventions":1691},"NCT05576974","A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)",[90],"2024-04-17",[1688,1689,1690],"Head and Neck Cancer","Unknown Primary Cancer","Head and Neck Squamous Cell Carcinoma",[1674],{"trials":1693,"activeCount":119},[],{"trials":1695,"activeCount":119},[],{"trials":1697,"activeCount":119},[],{"intervention":1699,"totalTrials":116,"cells":1700},"KMgCit",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1702,"activeCount":119},[],{"trials":1704,"activeCount":119},[],{"trials":1706,"activeCount":116,"soonestReadout":1711},[1707],{"nctId":1708,"briefTitle":1709,"status":104,"phases":1710,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1310,"conditions":1714,"interventions":1715},"NCT05145309","Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans",[90],"2031-12-01","2032-12-01","2026-11-15",[18],[1699],{"trials":1717,"activeCount":119},[],{"trials":1719,"activeCount":119},[],{"trials":1721,"activeCount":119},[],{"intervention":814,"totalTrials":116,"cells":1723},{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1725,"activeCount":119},[],{"trials":1727,"activeCount":119},[],{"trials":1729,"activeCount":116,"soonestReadout":808},[1730],{"nctId":805,"briefTitle":806,"status":233,"phases":1731,"primaryCompletion":808,"completion":809,"start":810,"enrollment":21,"conditions":1732,"interventions":1733},[90],[812],[814,783,815],{"trials":1735,"activeCount":119},[],{"trials":1737,"activeCount":119},[],{"trials":1739,"activeCount":119},[],{"intervention":631,"totalTrials":116,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":119},[],{"trials":1745,"activeCount":119},[],{"trials":1747,"activeCount":116,"soonestReadout":40},[1748],{"nctId":38,"briefTitle":39,"status":233,"phases":1749,"primaryCompletion":40,"completion":625,"start":626,"enrollment":627,"conditions":1750,"interventions":1751},[90],[629,20],[41,631,632,81],{"trials":1753,"activeCount":119},[],{"trials":1755,"activeCount":119},[],{"trials":1757,"activeCount":119},[],{"intervention":632,"totalTrials":116,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":119},[],{"trials":1763,"activeCount":119},[],{"trials":1765,"activeCount":116,"soonestReadout":40},[1766],{"nctId":38,"briefTitle":39,"status":233,"phases":1767,"primaryCompletion":40,"completion":625,"start":626,"enrollment":627,"conditions":1768,"interventions":1769},[90],[629,20],[41,631,632,81],{"trials":1771,"activeCount":119},[],{"trials":1773,"activeCount":119},[],{"trials":1775,"activeCount":119},[],{"intervention":1777,"totalTrials":116,"cells":1778},"Epigallocatechin gallate",{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1780,"activeCount":119},[],{"trials":1782,"activeCount":119},[],{"trials":1784,"activeCount":116,"soonestReadout":132},[1785],{"nctId":1786,"briefTitle":1787,"status":129,"phases":1788,"primaryCompletion":132,"completion":132,"start":1789,"enrollment":833,"conditions":1790,"interventions":1791},"NCT06015022","EGCG for Hepatocellular Carcinoma Chemoprevention",[90],"2024-09-01",[1459],[1777],{"trials":1793,"activeCount":119},[],{"trials":1795,"activeCount":119},[],{"trials":1797,"activeCount":119},[],{"intervention":764,"totalTrials":116,"cells":1799},{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1810,"PHASE4":1812,"NA":1814},{"trials":1801,"activeCount":119},[],{"trials":1803,"activeCount":119},[],{"trials":1805,"activeCount":116,"soonestReadout":759},[1806],{"nctId":756,"briefTitle":757,"status":129,"phases":1807,"primaryCompletion":759,"completion":760,"start":616,"enrollment":523,"conditions":1808,"interventions":1809},[89,90],[239,762],[723,764],{"trials":1811,"activeCount":119},[],{"trials":1813,"activeCount":119},[],{"trials":1815,"activeCount":119},[],{"intervention":1817,"totalTrials":116,"cells":1818},"Enfortumab vedotin",{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1820,"activeCount":119},[],{"trials":1822,"activeCount":119},[],{"trials":1824,"activeCount":116,"soonestReadout":108},[1825],{"nctId":1826,"briefTitle":1827,"status":129,"phases":1828,"primaryCompletion":108,"completion":1551,"start":1829,"enrollment":24,"conditions":1830,"interventions":1832},"NCT06394570","Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer",[89,90],"2024-09-10",[1831],"Bladder Cancer",[1817],{"trials":1834,"activeCount":119},[],{"trials":1836,"activeCount":119},[],{"trials":1838,"activeCount":119},[],{"intervention":1840,"totalTrials":116,"cells":1841},"ENI using IMRT with or without chemotherapy",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1843,"activeCount":119},[],{"trials":1845,"activeCount":119},[],{"trials":1847,"activeCount":116,"soonestReadout":1552},[1848],{"nctId":1849,"briefTitle":1850,"status":129,"phases":1851,"primaryCompletion":1552,"completion":1552,"start":1852,"enrollment":1221,"conditions":1853,"interventions":1854},"NCT06477692","Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy",[90],"2024-11-14",[1688],[1840],{"trials":1856,"activeCount":119},[],{"trials":1858,"activeCount":119},[],{"trials":1860,"activeCount":119},[],{"intervention":1862,"totalTrials":116,"cells":1863},"Cabozantinib 80 MG",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1865,"activeCount":119},[],{"trials":1867,"activeCount":119},[],{"trials":1869,"activeCount":116,"soonestReadout":1575},[1870],{"nctId":1871,"briefTitle":1872,"status":129,"phases":1873,"primaryCompletion":1575,"completion":1874,"start":1875,"enrollment":901,"conditions":1876,"interventions":1878},"NCT05931393","Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)",[90],"2028-12-31","2023-12-20",[1877,1603],"RCC",[1862],{"trials":1880,"activeCount":119},[],{"trials":1882,"activeCount":119},[],{"trials":1884,"activeCount":119},[],{"intervention":854,"totalTrials":116,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1888,"activeCount":119},[],{"trials":1890,"activeCount":119},[],{"trials":1892,"activeCount":116,"soonestReadout":846},[1893],{"nctId":843,"briefTitle":844,"status":129,"phases":1894,"primaryCompletion":846,"completion":847,"start":495,"enrollment":848,"conditions":1895,"interventions":1896},[90],[850,851,852],[854,823],{"trials":1898,"activeCount":119},[],{"trials":1900,"activeCount":119},[],{"trials":1902,"activeCount":119},[],{"intervention":1904,"totalTrials":116,"cells":1905},"Belantamab mafodotin 2.5 mg\u002Fkg",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1907,"activeCount":119},[],{"trials":1909,"activeCount":119},[],{"trials":1911,"activeCount":116,"soonestReadout":1916},[1912],{"nctId":1913,"briefTitle":1914,"status":129,"phases":1915,"primaryCompletion":1916,"completion":759,"start":1917,"enrollment":1918,"conditions":1919,"interventions":1922},"NCT05145816","Phase 1\u002F2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis",[89,90],"2027-03-01","2024-02-15",37,[1920,1921],"AL Amyloidosis","Amyloidosis",[1904,1923,1924,1923,1925,1926],"Belantamab mafodotin 1.9 mg\u002Fkg","Belantamab mafodotin 1.4 mg\u002Fkg","Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages","Belantamab mafodotin 1.0 mg\u002Fkg",{"trials":1928,"activeCount":119},[],{"trials":1930,"activeCount":119},[],{"trials":1932,"activeCount":119},[],{"intervention":1923,"totalTrials":116,"cells":1934},{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1945,"PHASE4":1947,"NA":1949},{"trials":1936,"activeCount":119},[],{"trials":1938,"activeCount":119},[],{"trials":1940,"activeCount":116,"soonestReadout":1916},[1941],{"nctId":1913,"briefTitle":1914,"status":129,"phases":1942,"primaryCompletion":1916,"completion":759,"start":1917,"enrollment":1918,"conditions":1943,"interventions":1944},[89,90],[1920,1921],[1904,1923,1924,1923,1925,1926],{"trials":1946,"activeCount":119},[],{"trials":1948,"activeCount":119},[],{"trials":1950,"activeCount":119},[],{"intervention":1924,"totalTrials":116,"cells":1952},{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1954,"activeCount":119},[],{"trials":1956,"activeCount":119},[],{"trials":1958,"activeCount":116,"soonestReadout":1916},[1959],{"nctId":1913,"briefTitle":1914,"status":129,"phases":1960,"primaryCompletion":1916,"completion":759,"start":1917,"enrollment":1918,"conditions":1961,"interventions":1962},[89,90],[1920,1921],[1904,1923,1924,1923,1925,1926],{"trials":1964,"activeCount":119},[],{"trials":1966,"activeCount":119},[],{"trials":1968,"activeCount":119},[],{"intervention":1925,"totalTrials":116,"cells":1970},{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1972,"activeCount":119},[],{"trials":1974,"activeCount":119},[],{"trials":1976,"activeCount":116,"soonestReadout":1916},[1977],{"nctId":1913,"briefTitle":1914,"status":129,"phases":1978,"primaryCompletion":1916,"completion":759,"start":1917,"enrollment":1918,"conditions":1979,"interventions":1980},[89,90],[1920,1921],[1904,1923,1924,1923,1925,1926],{"trials":1982,"activeCount":119},[],{"trials":1984,"activeCount":119},[],{"trials":1986,"activeCount":119},[],{"intervention":1926,"totalTrials":116,"cells":1988},{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1990,"activeCount":119},[],{"trials":1992,"activeCount":119},[],{"trials":1994,"activeCount":116,"soonestReadout":1916},[1995],{"nctId":1913,"briefTitle":1914,"status":129,"phases":1996,"primaryCompletion":1916,"completion":759,"start":1917,"enrollment":1918,"conditions":1997,"interventions":1998},[89,90],[1920,1921],[1904,1923,1924,1923,1925,1926],{"trials":2000,"activeCount":119},[],{"trials":2002,"activeCount":119},[],{"trials":2004,"activeCount":119},[],{"intervention":2006,"totalTrials":116,"cells":2007},"Androgen Deprivation Therapy",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2009,"activeCount":119},[],{"trials":2011,"activeCount":119},[],{"trials":2013,"activeCount":116,"soonestReadout":2018},[2014],{"nctId":2015,"briefTitle":2016,"status":129,"phases":2017,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2022},"NCT07313241","Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)",[90],"2030-11-14","2025-11-14",68,[32],[2006],{"trials":2024,"activeCount":119},[],{"trials":2026,"activeCount":119},[],{"trials":2028,"activeCount":119},[],{"intervention":2030,"totalTrials":116,"cells":2031},"Sirolimus 0.5 Mg Oral",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":2033,"activeCount":119},[],{"trials":2035,"activeCount":119},[],{"trials":2037,"activeCount":116,"soonestReadout":759},[2038],{"nctId":2039,"briefTitle":2040,"status":129,"phases":2041,"primaryCompletion":759,"completion":2042,"start":55,"enrollment":833,"conditions":2043,"interventions":2045},"NCT06727305","MTOR Inhibitors in Older Adults",[89,90],"2027-11-13",[2044],"Aging",[2030,2046,2047,2048,2049,2050],"Sirolimus 1Mg Oral","Sirolimus 2 MG Oral","Everolimus 0.5 MG Oral","Everolimus 1 MG Oral","Everolimus 2 MG Oral",{"trials":2052,"activeCount":119},[],{"trials":2054,"activeCount":119},[],{"trials":2056,"activeCount":119},[],{"intervention":2046,"totalTrials":116,"cells":2058},{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2060,"activeCount":119},[],{"trials":2062,"activeCount":119},[],{"trials":2064,"activeCount":116,"soonestReadout":759},[2065],{"nctId":2039,"briefTitle":2040,"status":129,"phases":2066,"primaryCompletion":759,"completion":2042,"start":55,"enrollment":833,"conditions":2067,"interventions":2068},[89,90],[2044],[2030,2046,2047,2048,2049,2050],{"trials":2070,"activeCount":119},[],{"trials":2072,"activeCount":119},[],{"trials":2074,"activeCount":119},[],{"intervention":2047,"totalTrials":116,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2078,"activeCount":119},[],{"trials":2080,"activeCount":119},[],{"trials":2082,"activeCount":116,"soonestReadout":759},[2083],{"nctId":2039,"briefTitle":2040,"status":129,"phases":2084,"primaryCompletion":759,"completion":2042,"start":55,"enrollment":833,"conditions":2085,"interventions":2086},[89,90],[2044],[2030,2046,2047,2048,2049,2050],{"trials":2088,"activeCount":119},[],{"trials":2090,"activeCount":119},[],{"trials":2092,"activeCount":119},[],{"intervention":2048,"totalTrials":116,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":119},[],{"trials":2098,"activeCount":119},[],{"trials":2100,"activeCount":116,"soonestReadout":759},[2101],{"nctId":2039,"briefTitle":2040,"status":129,"phases":2102,"primaryCompletion":759,"completion":2042,"start":55,"enrollment":833,"conditions":2103,"interventions":2104},[89,90],[2044],[2030,2046,2047,2048,2049,2050],{"trials":2106,"activeCount":119},[],{"trials":2108,"activeCount":119},[],{"trials":2110,"activeCount":119},[],{"intervention":2049,"totalTrials":116,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2114,"activeCount":119},[],{"trials":2116,"activeCount":119},[],{"trials":2118,"activeCount":116,"soonestReadout":759},[2119],{"nctId":2039,"briefTitle":2040,"status":129,"phases":2120,"primaryCompletion":759,"completion":2042,"start":55,"enrollment":833,"conditions":2121,"interventions":2122},[89,90],[2044],[2030,2046,2047,2048,2049,2050],{"trials":2124,"activeCount":119},[],{"trials":2126,"activeCount":119},[],{"trials":2128,"activeCount":119},[],{"intervention":2050,"totalTrials":116,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":119},[],{"trials":2134,"activeCount":119},[],{"trials":2136,"activeCount":116,"soonestReadout":759},[2137],{"nctId":2039,"briefTitle":2040,"status":129,"phases":2138,"primaryCompletion":759,"completion":2042,"start":55,"enrollment":833,"conditions":2139,"interventions":2140},[89,90],[2044],[2030,2046,2047,2048,2049,2050],{"trials":2142,"activeCount":119},[],{"trials":2144,"activeCount":119},[],{"trials":2146,"activeCount":119},[],{"intervention":2148,"totalTrials":97,"cells":2149},"cyclophosphamide",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2167,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2151,"activeCount":119},[],{"trials":2153,"activeCount":116,"soonestReadout":2158},[2154],{"nctId":2155,"briefTitle":2156,"status":104,"phases":2157,"primaryCompletion":2158,"completion":2159,"start":659,"enrollment":650,"conditions":2160,"interventions":2162},"NCT07573332","A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients",[89],"2030-08-01","2031-08-01",[2161],"AQP4+ NMOSD",[2163,2164,2165,2166],"CC-97540","Fludarabine","Cyclophosphamide","Tocilizumab",{"trials":2168,"activeCount":119},[2169],{"nctId":2170,"briefTitle":2171,"status":385,"phases":2172,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":2175,"interventions":2178},"NCT00041288","Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL",[90],"2003-01","2001-10",[2176,2177],"Leukemia","Lymphoma",[2179,2148,2180,2181,2182,2183,2184],"therapeutic allogeneic lymphocytes","cyclosporine","fludarabine phosphate","methotrexate","mycophenolate mofetil","tacrolimus",{"trials":2186,"activeCount":119},[],{"trials":2188,"activeCount":119},[],{"trials":2190,"activeCount":119},[],{"intervention":2192,"totalTrials":116,"cells":2193},"Potassium Citrate Extended Release Oral",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2195,"activeCount":119},[],{"trials":2197,"activeCount":116,"soonestReadout":2202},[2198],{"nctId":2199,"briefTitle":2200,"status":104,"phases":2201,"primaryCompletion":2202,"completion":615,"start":108,"enrollment":1020,"conditions":2203,"interventions":2205},"NCT06819111","Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention",[89],"2027-07-31",[2204],"Kidney Calculi",[2192],{"trials":2207,"activeCount":119},[],{"trials":2209,"activeCount":119},[],{"trials":2211,"activeCount":119},[],{"trials":2213,"activeCount":119},[],{"intervention":2215,"totalTrials":116,"cells":2216},"68-Ga PSMA11",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2218,"activeCount":119},[],{"trials":2220,"activeCount":116,"soonestReadout":2225},[2221],{"nctId":2222,"briefTitle":2223,"status":129,"phases":2224,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":1020,"conditions":2227,"interventions":2229},"NCT06044857","PSMA PET Response Guided SabR in High Risk Pca",[89],"2026-11","2024-03-07",[2228],"Prostate Adenocarcinoma",[2215],{"trials":2231,"activeCount":119},[],{"trials":2233,"activeCount":119},[],{"trials":2235,"activeCount":119},[],{"trials":2237,"activeCount":119},[],{"intervention":71,"totalTrials":116,"cells":2239},{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2241,"activeCount":119},[],{"trials":2243,"activeCount":116,"soonestReadout":70},[2244],{"nctId":68,"briefTitle":69,"status":129,"phases":2245,"primaryCompletion":70,"completion":70,"start":2246,"enrollment":617,"conditions":2247,"interventions":2250},[89],"2022-04-20",[2248,2249],"HER2-negative Breast Cancer","Metastatic Breast Cancer",[71,2251,2252],"CDX-1140","CDX-301",{"trials":2254,"activeCount":119},[],{"trials":2256,"activeCount":119},[],{"trials":2258,"activeCount":119},[],{"trials":2260,"activeCount":119},[],{"intervention":2251,"totalTrials":116,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2277},{"trials":2264,"activeCount":119},[],{"trials":2266,"activeCount":116,"soonestReadout":70},[2267],{"nctId":68,"briefTitle":69,"status":129,"phases":2268,"primaryCompletion":70,"completion":70,"start":2246,"enrollment":617,"conditions":2269,"interventions":2270},[89],[2248,2249],[71,2251,2252],{"trials":2272,"activeCount":119},[],{"trials":2274,"activeCount":119},[],{"trials":2276,"activeCount":119},[],{"trials":2278,"activeCount":119},[],{"intervention":2252,"totalTrials":116,"cells":2280},{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2289,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2282,"activeCount":119},[],{"trials":2284,"activeCount":116,"soonestReadout":70},[2285],{"nctId":68,"briefTitle":69,"status":129,"phases":2286,"primaryCompletion":70,"completion":70,"start":2246,"enrollment":617,"conditions":2287,"interventions":2288},[89],[2248,2249],[71,2251,2252],{"trials":2290,"activeCount":119},[],{"trials":2292,"activeCount":119},[],{"trials":2294,"activeCount":119},[],{"trials":2296,"activeCount":119},[],{"intervention":2298,"totalTrials":116,"cells":2299},"Nitrofurantoin",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2315,"PHASE3":2317,"PHASE4":2319,"NA":2321},{"trials":2301,"activeCount":119},[],{"trials":2303,"activeCount":116,"soonestReadout":1552},[2304],{"nctId":2305,"briefTitle":2306,"status":129,"phases":2307,"primaryCompletion":1552,"completion":2308,"start":2309,"enrollment":2310,"conditions":2311,"interventions":2314},"NCT06907199","Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections",[89],"2029-01-30","2026-04-06",104,[2312,2313],"Recurrent UTIs","Cystitis Recurrent",[2298],{"trials":2316,"activeCount":119},[],{"trials":2318,"activeCount":119},[],{"trials":2320,"activeCount":119},[],{"trials":2322,"activeCount":119},[],{"intervention":2324,"totalTrials":116,"cells":2325},"scAAV9\u002FJeT-GAN",{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2327,"activeCount":119},[],{"trials":2329,"activeCount":116,"soonestReadout":2334},[2330],{"nctId":2331,"briefTitle":2332,"status":129,"phases":2333,"primaryCompletion":2334,"completion":2335,"start":2336,"enrollment":724,"conditions":2337,"interventions":2339},"NCT07543991","Intraneural Administration of scAAV9\u002FJeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)",[89],"2031-12-31","2032-06-30","2026-03-01",[2338],"Giant Axonal Neuropathy (GAN)",[2324],{"trials":2341,"activeCount":119},[],{"trials":2343,"activeCount":119},[],{"trials":2345,"activeCount":119},[],{"trials":2347,"activeCount":119},[],{"intervention":2163,"totalTrials":116,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2358,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":119},[],{"trials":2353,"activeCount":116,"soonestReadout":2158},[2354],{"nctId":2155,"briefTitle":2156,"status":104,"phases":2355,"primaryCompletion":2158,"completion":2159,"start":659,"enrollment":650,"conditions":2356,"interventions":2357},[89],[2161],[2163,2164,2165,2166],{"trials":2359,"activeCount":119},[],{"trials":2361,"activeCount":119},[],{"trials":2363,"activeCount":119},[],{"trials":2365,"activeCount":119},[],{"intervention":2164,"totalTrials":116,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":119},[],{"trials":2371,"activeCount":116,"soonestReadout":2158},[2372],{"nctId":2155,"briefTitle":2156,"status":104,"phases":2373,"primaryCompletion":2158,"completion":2159,"start":659,"enrollment":650,"conditions":2374,"interventions":2375},[89],[2161],[2163,2164,2165,2166],{"trials":2377,"activeCount":119},[],{"trials":2379,"activeCount":119},[],{"trials":2381,"activeCount":119},[],{"trials":2383,"activeCount":119},[],{"intervention":2166,"totalTrials":116,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2387,"activeCount":119},[],{"trials":2389,"activeCount":116,"soonestReadout":2158},[2390],{"nctId":2155,"briefTitle":2156,"status":104,"phases":2391,"primaryCompletion":2158,"completion":2159,"start":659,"enrollment":650,"conditions":2392,"interventions":2393},[89],[2161],[2163,2164,2165,2166],{"trials":2395,"activeCount":119},[],{"trials":2397,"activeCount":119},[],{"trials":2399,"activeCount":119},[],{"trials":2401,"activeCount":119},[],{"intervention":2403,"totalTrials":116,"cells":2404},"Scopolamine",{"EARLY_PHASE1":2405,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2406,"activeCount":116,"soonestReadout":2411},[2407],{"nctId":2408,"briefTitle":2409,"status":129,"phases":2410,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":833,"conditions":2414,"interventions":2420},"NCT05594017","Pharmacological Modulation of Brain Oscillations in Memory Processing",[88],"2026-11-30","2027-05-31","2019-08-01",[2415,2416,2417,2418,2419],"Epilepsy","Seizures","Cognitive Impairment, Mild","Memory Disorders","Memory Loss",[2403],{"trials":2422,"activeCount":119},[],{"trials":2424,"activeCount":119},[],{"trials":2426,"activeCount":119},[],{"trials":2428,"activeCount":119},[],{"trials":2430,"activeCount":119},[],{"intervention":2432,"totalTrials":116,"cells":2433},"COBENFY KarXT",{"EARLY_PHASE1":2434,"PHASE1":2445,"PHASE2":2447,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2435,"activeCount":116,"soonestReadout":2440},[2436],{"nctId":2437,"briefTitle":2438,"status":104,"phases":2439,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":702,"conditions":2442,"interventions":2444},"NCT07228338","Cholinergic Enhancement of Theta",[88],"2031-10","2026-10",[2415,2416,2417,2443,2419],"Memory Disorder",[2432],{"trials":2446,"activeCount":119},[],{"trials":2448,"activeCount":119},[],{"trials":2450,"activeCount":119},[],{"trials":2452,"activeCount":119},[],{"trials":2454,"activeCount":119},[],{"intervention":86,"totalTrials":116,"cells":2456},{"EARLY_PHASE1":2457,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2458,"activeCount":116,"soonestReadout":85},[2459],{"nctId":83,"briefTitle":84,"status":2460,"phases":2461,"primaryCompletion":85,"completion":85,"start":715,"enrollment":833,"conditions":2462,"interventions":2463},"ENROLLING_BY_INVITATION",[88],[662],[86,2464],"Hyperpolarized [2-13C] Pyruvate",{"trials":2466,"activeCount":119},[],{"trials":2468,"activeCount":119},[],{"trials":2470,"activeCount":119},[],{"trials":2472,"activeCount":119},[],{"trials":2474,"activeCount":119},[],{"intervention":2464,"totalTrials":116,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2483,"PHASE2":2485,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":116,"soonestReadout":85},[2479],{"nctId":83,"briefTitle":84,"status":2460,"phases":2480,"primaryCompletion":85,"completion":85,"start":715,"enrollment":833,"conditions":2481,"interventions":2482},[88],[662],[86,2464],{"trials":2484,"activeCount":119},[],{"trials":2486,"activeCount":119},[],{"trials":2488,"activeCount":119},[],{"trials":2490,"activeCount":119},[],{"trials":2492,"activeCount":119},[],{"intervention":2494,"totalTrials":116,"cells":2495},"Neuropeptide Y",{"EARLY_PHASE1":2496,"PHASE1":2506,"PHASE2":2508,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2497,"activeCount":116,"soonestReadout":2502},[2498],{"nctId":2499,"briefTitle":2500,"status":129,"phases":2501,"primaryCompletion":2502,"completion":2502,"start":2503,"enrollment":262,"conditions":2504,"interventions":2505},"NCT04838678","Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)",[88],"2026-08-31","2021-07-18",[18,23],[2494],{"trials":2507,"activeCount":119},[],{"trials":2509,"activeCount":119},[],{"trials":2511,"activeCount":119},[],{"trials":2513,"activeCount":119},[],{"trials":2515,"activeCount":119},[],{"intervention":837,"totalTrials":116,"cells":2517},{"EARLY_PHASE1":2518,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2519,"activeCount":116,"soonestReadout":831},[2520],{"nctId":828,"briefTitle":829,"status":104,"phases":2521,"primaryCompletion":831,"completion":832,"start":75,"enrollment":833,"conditions":2522,"interventions":2523},[88],[835],[837,823],{"trials":2525,"activeCount":119},[],{"trials":2527,"activeCount":119},[],{"trials":2529,"activeCount":119},[],{"trials":2531,"activeCount":119},[],{"trials":2533,"activeCount":119},[],{"intervention":2535,"totalTrials":116,"cells":2536},"Acetadote",{"EARLY_PHASE1":2537,"PHASE1":2545,"PHASE2":2547,"PHASE3":2549,"PHASE4":2551,"NA":2553},{"trials":2538,"activeCount":116,"soonestReadout":1551},[2539],{"nctId":2540,"briefTitle":2541,"status":104,"phases":2542,"primaryCompletion":1551,"completion":1552,"start":108,"enrollment":660,"conditions":2543,"interventions":2544},"NCT07387666","Imaging Acetadote Metabolism in Glioblastoma",[88],[570,1051],[2535],{"trials":2546,"activeCount":119},[],{"trials":2548,"activeCount":119},[],{"trials":2550,"activeCount":119},[],{"trials":2552,"activeCount":119},[],{"trials":2554,"activeCount":119},[],{"intervention":114,"totalTrials":116,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":116,"soonestReadout":106},[2559],{"nctId":102,"briefTitle":103,"status":104,"phases":2560,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":2561,"interventions":2562},[88],[111],[113,114,115],{"trials":2564,"activeCount":119},[],{"trials":2566,"activeCount":119},[],{"trials":2568,"activeCount":119},[],{"trials":2570,"activeCount":119},[],{"trials":2572,"activeCount":119},[],{"intervention":115,"totalTrials":116,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":116,"soonestReadout":106},[2577],{"nctId":102,"briefTitle":103,"status":104,"phases":2578,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":2579,"interventions":2580},[88],[111],[113,114,115],{"trials":2582,"activeCount":119},[],{"trials":2584,"activeCount":119},[],{"trials":2586,"activeCount":119},[],{"trials":2588,"activeCount":119},[],{"trials":2590,"activeCount":119},[],{"intervention":2592,"totalTrials":97,"cells":2593},"Hyperpolarized 13C-Pyruvate",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2595,"activeCount":119},[],{"trials":2597,"activeCount":119},[],{"trials":2599,"activeCount":119},[],{"trials":2601,"activeCount":119},[],{"trials":2603,"activeCount":119},[],{"trials":2605,"activeCount":116,"soonestReadout":375},[2606,2614],{"nctId":2607,"briefTitle":2608,"status":129,"phases":2609,"primaryCompletion":375,"completion":375,"start":963,"enrollment":16,"conditions":2610,"interventions":2612},"NCT03067467","Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)",[],[2611],"Brain Tumor Adult",[2592,2613],"Gadolinium",{"nctId":2615,"briefTitle":2616,"status":164,"phases":2617,"primaryCompletion":2618,"completion":2618,"start":2619,"enrollment":360,"conditions":2620,"interventions":2622},"NCT04968210","Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)",[],"2024-12-17","2022-05-27",[2621],"Pulmonary Arterial Hypertension",[2623],"Hyperpolarized 13C-pyruvate",{"intervention":2613,"totalTrials":116,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2627,"activeCount":119},[],{"trials":2629,"activeCount":119},[],{"trials":2631,"activeCount":119},[],{"trials":2633,"activeCount":119},[],{"trials":2635,"activeCount":119},[],{"trials":2637,"activeCount":116,"soonestReadout":375},[2638],{"nctId":2607,"briefTitle":2608,"status":129,"phases":2639,"primaryCompletion":375,"completion":375,"start":963,"enrollment":16,"conditions":2640,"interventions":2641},[],[2611],[2592,2613],{"intervention":2643,"totalTrials":116,"cells":2644},"Ravulizumab",{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2651,"PHASE4":2653,"NA":2655},{"trials":2646,"activeCount":119},[],{"trials":2648,"activeCount":119},[],{"trials":2650,"activeCount":119},[],{"trials":2652,"activeCount":119},[],{"trials":2654,"activeCount":119},[],{"trials":2656,"activeCount":116,"soonestReadout":375},[2657],{"nctId":2658,"briefTitle":2659,"status":129,"phases":2660,"primaryCompletion":375,"completion":2661,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2666},"NCT06398158","Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder",[],"2027-06-30","2024-07-10",35,[2665],"Neuromyelitis Optica",[2643],{"intervention":2668,"totalTrials":116,"cells":2669},"Weight loss SOC Treatment with second generation anti-diabetic medications",{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2671,"activeCount":119},[],{"trials":2673,"activeCount":119},[],{"trials":2675,"activeCount":119},[],{"trials":2677,"activeCount":119},[],{"trials":2679,"activeCount":119},[],{"trials":2681,"activeCount":116,"soonestReadout":2686},[2682],{"nctId":2683,"briefTitle":2684,"status":2460,"phases":2685,"primaryCompletion":2686,"completion":2687,"start":2688,"enrollment":2689,"conditions":2690,"interventions":2692},"NCT06930495","The Effect of Adiposity on Muscle and Microvascular Function in HFpEF",[],"2028-03-01","2028-06-01","2024-12-10",95,[2691],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[2668],{"intervention":2694,"totalTrials":116,"cells":2695},"Apomorphine Injectable Solution",{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2704,"NA":2706},{"trials":2697,"activeCount":119},[],{"trials":2699,"activeCount":119},[],{"trials":2701,"activeCount":119},[],{"trials":2703,"activeCount":119},[],{"trials":2705,"activeCount":119},[],{"trials":2707,"activeCount":116,"soonestReadout":760},[2708],{"nctId":2709,"briefTitle":2710,"status":129,"phases":2711,"primaryCompletion":760,"completion":874,"start":2712,"enrollment":496,"conditions":2713,"interventions":2716},"NCT04957095","Motor Network Physiology",[93],"2022-02-18",[2714,2715],"Parkinson Disease","Essential Tremor",[2694],{"intervention":2718,"totalTrials":116,"cells":2719},"Anti-resorptive agents",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2721,"activeCount":119},[],{"trials":2723,"activeCount":119},[],{"trials":2725,"activeCount":119},[],{"trials":2727,"activeCount":119},[],{"trials":2729,"activeCount":119},[],{"trials":2731,"activeCount":116,"soonestReadout":521},[2732],{"nctId":2733,"briefTitle":2734,"status":2460,"phases":2735,"primaryCompletion":521,"completion":521,"start":2736,"enrollment":16,"conditions":2737,"interventions":2738},"NCT06811363","Contribution of Bone to Urine Citrate",[],"2026-02-28",[379],[2718,2739],"Anabolic Agents",{"intervention":2739,"totalTrials":116,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2750,"NA":2752},{"trials":2743,"activeCount":119},[],{"trials":2745,"activeCount":119},[],{"trials":2747,"activeCount":119},[],{"trials":2749,"activeCount":119},[],{"trials":2751,"activeCount":119},[],{"trials":2753,"activeCount":116,"soonestReadout":521},[2754],{"nctId":2733,"briefTitle":2734,"status":2460,"phases":2755,"primaryCompletion":521,"completion":521,"start":2736,"enrollment":16,"conditions":2756,"interventions":2757},[],[379],[2718,2739],{"intervention":2759,"totalTrials":116,"cells":2760},"Intervention 2: Semaglutide",{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2762,"activeCount":119},[],{"trials":2764,"activeCount":119},[],{"trials":2766,"activeCount":119},[],{"trials":2768,"activeCount":119},[],{"trials":2770,"activeCount":119},[],{"trials":2772,"activeCount":116,"soonestReadout":847},[2773],{"nctId":2774,"briefTitle":2775,"status":129,"phases":2776,"primaryCompletion":847,"completion":847,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2784},"NCT07361874","IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion",[93],"2026-03-05",75,[2780,2781,2782,2783],"Mild Autonomous Cortisol Secretion (MACS)","Autonomous Cortisol Secretion (ACS)","Subclinical Cushing's","Mild Autonomous Cortisol Excess",[2759],{"intervention":2786,"totalTrials":116,"cells":2787},"Q-Cells®",{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2794,"PHASE4":2796,"NA":2798},{"trials":2789,"activeCount":119},[],{"trials":2791,"activeCount":119},[],{"trials":2793,"activeCount":119},[],{"trials":2795,"activeCount":119},[],{"trials":2797,"activeCount":119},[],{"trials":2799,"activeCount":116,"soonestReadout":2804},[2800],{"nctId":2801,"briefTitle":2802,"status":2460,"phases":2803,"primaryCompletion":2804,"completion":2804,"start":2805,"enrollment":430,"conditions":2806,"interventions":2808},"NCT06163508","A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells",[],"2035-12","2023-12-12",[2807],"Transverse Myelitis",[2786],{"intervention":2810,"totalTrials":724,"cells":2811},"Ketamine",{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2836,"PHASE3":2838,"PHASE4":2851,"NA":2865},{"trials":2813,"activeCount":119},[],{"trials":2815,"activeCount":119},[2816,2826],{"nctId":2817,"briefTitle":2818,"status":385,"phases":2819,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":650,"conditions":2822,"interventions":2825},"NCT00618397","Pharmacokinetics of Low Dose Ketamine Infusion",[89],"2015-06","2006-06",[2823,2824],"Sedation","Opioid Tolerance",[2810],{"nctId":2827,"briefTitle":2828,"status":385,"phases":2829,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2833,"interventions":2834},"NCT04429685","The Effects of Low Dose Ketamine on Cardiovascular Function",[89],"2021-05-28","2020-11-01",6,[718],[2810,2835],"Saline",{"trials":2837,"activeCount":119},[],{"trials":2839,"activeCount":119},[2840],{"nctId":2841,"briefTitle":2842,"status":951,"phases":2843,"primaryCompletion":2844,"completion":2845,"start":2846,"enrollment":119,"conditions":2847,"interventions":2849},"NCT02311777","Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain",[91],"2016-09-20","2017-09-20","2015-05-15",[2848],"Phantom Pain",[2850,2810],"Pregabalin",{"trials":2852,"activeCount":119},[2853],{"nctId":2854,"briefTitle":2855,"status":164,"phases":2856,"primaryCompletion":2857,"completion":2857,"start":2858,"enrollment":2859,"conditions":2860,"interventions":2863},"NCT02643381","Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial",[92],"2020-12-01","2016-06-06",801,[2861,2862],"Cardiopulmonary Arrest","Respiratory Arrest",[2864,2810],"Etomidate",{"trials":2866,"activeCount":119},[],{"intervention":2868,"totalTrials":724,"cells":2869},"Hydrocortisone",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2898,"PHASE4":2908,"NA":2920},{"trials":2871,"activeCount":119},[],{"trials":2873,"activeCount":119},[],{"trials":2875,"activeCount":119},[2876,2887],{"nctId":2877,"briefTitle":2878,"status":951,"phases":2879,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":119,"conditions":2882,"interventions":2884},"NCT03548246","Androgen Reduction in Congenital Adrenal Hyperplasia",[90],"2026-01","2023-01",[2883],"Congenital Adrenal Hyperplasia",[2885,2868,2886],"Abiraterone acetate","Fludrocortisone",{"nctId":2888,"briefTitle":2889,"status":164,"phases":2890,"primaryCompletion":2891,"completion":2891,"start":2892,"enrollment":2893,"conditions":2894,"interventions":2896},"NCT01828515","Vilazodone for Corticosteroid-Induced Memory Impairment",[90],"2014-04","2012-12",24,[2895],"Memory Impairment",[2897,2868],"Vilazodone",{"trials":2899,"activeCount":119},[2900],{"nctId":2901,"briefTitle":2902,"status":164,"phases":2903,"primaryCompletion":1028,"completion":1028,"start":2904,"enrollment":27,"conditions":2905,"interventions":2906},"NCT00591006","Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes",[91],"2008-01",[718],[2907,2868],"Phenytoin",{"trials":2909,"activeCount":119},[2910],{"nctId":2911,"briefTitle":2912,"status":164,"phases":2913,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":2916,"conditions":2917,"interventions":2919},"NCT03896659","Exploring the Effects of Corticosteroids on the Human Hippocampus",[92],"2024-09-16","2019-10-01",66,[2868,15,2918],"Healthy Volunteers",[2868],{"trials":2921,"activeCount":119},[],{"intervention":2923,"totalTrials":360,"cells":2924},"Quetiapine",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2933,"NA":2963},{"trials":2926,"activeCount":119},[],{"trials":2928,"activeCount":119},[],{"trials":2930,"activeCount":119},[],{"trials":2932,"activeCount":119},[],{"trials":2934,"activeCount":119},[2935,2944,2954],{"nctId":2936,"briefTitle":2937,"status":164,"phases":2938,"primaryCompletion":2939,"completion":2939,"start":2940,"enrollment":262,"conditions":2941,"interventions":2943},"NCT00223210","An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence",[92],"2007-12","2005-11",[26,2942],"Cocaine Dependence",[2923],{"nctId":2945,"briefTitle":2946,"status":164,"phases":2947,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":2950,"conditions":2951,"interventions":2953},"NCT00223249","Quetiapine in Patients With Bipolar and Alcohol Abuse\u002FDependence",[92],"2004-08","2002-11",115,[26,2952],"Alcohol Abuse\u002FDependence",[2923],{"nctId":2955,"briefTitle":2956,"status":164,"phases":2957,"primaryCompletion":2958,"completion":2958,"start":2959,"enrollment":155,"conditions":2960,"interventions":2962},"NCT00457197","Quetiapine for Bipolar Disorder and Alcohol Dependence",[92],"2011-07","2007-03",[26,2961],"Alcohol Dependence",[2923],{"trials":2964,"activeCount":119},[],{"intervention":2966,"totalTrials":360,"cells":2967},"Lamotrigine",{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2974,"PHASE4":2976,"NA":3004},{"trials":2969,"activeCount":119},[],{"trials":2971,"activeCount":119},[],{"trials":2973,"activeCount":119},[],{"trials":2975,"activeCount":119},[],{"trials":2977,"activeCount":119},[2978,2986,2993],{"nctId":2979,"briefTitle":2980,"status":164,"phases":2981,"primaryCompletion":2982,"completion":2982,"start":2983,"enrollment":1389,"conditions":2984,"interventions":2985},"NCT00280293","Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency",[92],"2010-01","2006-03",[26,2942],[2966],{"nctId":2987,"briefTitle":2988,"status":164,"phases":2989,"primaryCompletion":2820,"completion":2820,"start":1064,"enrollment":2990,"conditions":2991,"interventions":2992},"NCT01142310","Reversing Corticosteroid Induced Memory Impairment",[92],54,[2895],[2966],{"nctId":2994,"briefTitle":2995,"status":164,"phases":2996,"primaryCompletion":2997,"completion":2997,"start":2998,"enrollment":1100,"conditions":2999,"interventions":3003},"NCT00223262","Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients",[92],"2005-09","2002-08",[3000,3001,3002],"Memory Impairment Due to Corticosteroid Use","Hypomania Due to Corticosteroid Use","Hippocampal Atrophy Due to Corticosteroid",[2966],{"trials":3005,"activeCount":119},[],{"intervention":3007,"totalTrials":360,"cells":3008},"Sugammadex",{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3055},{"trials":3010,"activeCount":119},[],{"trials":3012,"activeCount":119},[],{"trials":3014,"activeCount":119},[],{"trials":3016,"activeCount":119},[],{"trials":3018,"activeCount":119},[3019,3030,3045],{"nctId":3020,"briefTitle":3021,"status":164,"phases":3022,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":3025,"conditions":3026,"interventions":3028},"NCT06225466","Muscle Relaxation for Pediatric Adenotonsillectomy",[92],"2024-09-27","2024-04-10",172,[3027],"Tonsillectomy",[3029,3007],"Rocuronium",{"nctId":3031,"briefTitle":3032,"status":164,"phases":3033,"primaryCompletion":3034,"completion":3034,"start":3035,"enrollment":3036,"conditions":3037,"interventions":3044},"NCT05794503","Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex",[92],"2024-06-30","2023-09-11",235,[3038,3039,3040,3007,3041,3042,3043],"Urinary Retention Postoperative","Laparoscopic Cholecystectomy","Neuromuscular Blockade","Neostigmine","Neuromuscular Blocking Agents","Physiological Effects of Drugs",[3041,3007],{"nctId":3046,"briefTitle":3047,"status":164,"phases":3048,"primaryCompletion":3049,"completion":3049,"start":3050,"enrollment":3051,"conditions":3052,"interventions":3053},"NCT03168308","Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients",[92],"2019-09-30","2017-09-26",92,[3040],[3007,3054],"Neostigmine w\u002F Glycopyrrolate",{"trials":3056,"activeCount":119},[],{"intervention":3058,"totalTrials":360,"cells":3059},"Pregnenolone",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3077,"PHASE4":3079,"NA":3097},{"trials":3061,"activeCount":119},[],{"trials":3063,"activeCount":119},[],{"trials":3065,"activeCount":119},[3066],{"nctId":3067,"briefTitle":3068,"status":164,"phases":3069,"primaryCompletion":3070,"completion":3070,"start":3071,"enrollment":3072,"conditions":3073,"interventions":3076},"NCT03505905","A Neurosteroid Intervention for Menopausal and Perimenopausal Depression",[89,90],"2024-12-03","2018-09-01",73,[29,3074,3075],"Menopause","Perimenopause",[3058],{"trials":3078,"activeCount":119},[],{"trials":3080,"activeCount":119},[3081,3088],{"nctId":3082,"briefTitle":3083,"status":164,"phases":3084,"primaryCompletion":3085,"completion":3085,"start":909,"enrollment":1221,"conditions":3086,"interventions":3087},"NCT01409096","Study Using Pregnenolone to Treat Bipolar Depression",[92],"2011-11",[26,29],[3058],{"nctId":3089,"briefTitle":3090,"status":164,"phases":3091,"completion":3092,"start":3093,"enrollment":2778,"conditions":3094,"interventions":3096},"NCT00223197","Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse",[92],"2006-04","2004-02",[26,29,3095],"Substance Abuse",[3058],{"trials":3098,"activeCount":119},[],{"intervention":3100,"totalTrials":360,"cells":3101},"Fentanyl",{"EARLY_PHASE1":3102,"PHASE1":3104,"PHASE2":3106,"PHASE3":3115,"PHASE4":3117,"NA":3141},{"trials":3103,"activeCount":119},[],{"trials":3105,"activeCount":119},[],{"trials":3107,"activeCount":119},[3108],{"nctId":3109,"briefTitle":3110,"status":164,"phases":3111,"primaryCompletion":3112,"completion":3112,"start":963,"enrollment":1483,"conditions":3113,"interventions":3114},"NCT04136548","Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Fentanyl",[89,90],"2020-11-18",[718],[3100],{"trials":3116,"activeCount":119},[],{"trials":3118,"activeCount":119},[3119,3132],{"nctId":3120,"briefTitle":3121,"status":385,"phases":3122,"primaryCompletion":3123,"completion":3124,"start":3125,"enrollment":3126,"conditions":3127,"interventions":3129},"NCT03115151","Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery",[92],"2022-08-18","2023-04-04","2017-05-08",46,[3128],"Pain",[3130,3131,3100],"Bupivacaine","Hydromorphone",{"nctId":3133,"briefTitle":3134,"status":164,"phases":3135,"primaryCompletion":3136,"completion":3136,"start":3137,"enrollment":262,"conditions":3138,"interventions":3140},"NCT01277861","Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment",[92],"2011-06","2011-01",[3139],"Administration Site Reaction",[3100],{"trials":3142,"activeCount":119},[],{"intervention":3144,"totalTrials":97,"cells":3145},"Carvedilol",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3152,"PHASE4":3154,"NA":3177},{"trials":3147,"activeCount":119},[],{"trials":3149,"activeCount":119},[],{"trials":3151,"activeCount":119},[],{"trials":3153,"activeCount":119},[],{"trials":3155,"activeCount":119},[3156,3166],{"nctId":3157,"briefTitle":3158,"status":164,"phases":3159,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":3162,"conditions":3163,"interventions":3165},"NCT00827775","Mechanisms and Treatment of Intradialytic Hypertension",[92],"2010-09","2009-06",55,[3164],"Intradialytic Hypertension",[3144],{"nctId":3167,"briefTitle":3168,"status":164,"phases":3169,"primaryCompletion":3170,"completion":3171,"start":3172,"enrollment":911,"conditions":3173,"interventions":3176},"NCT02946892","Effect of Carvedilol on Exercise Performance in Fontan Patients",[92],"2019-12","2020-01","2016-11",[3174,3175],"Single Ventricle","Fontan",[3144],{"trials":3178,"activeCount":119},[],{"intervention":3180,"totalTrials":97,"cells":3181},"Liposomal bupivacaine",{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3196,"PHASE3":3198,"PHASE4":3200,"NA":3213},{"trials":3183,"activeCount":119},[],{"trials":3185,"activeCount":119},[3186],{"nctId":3187,"briefTitle":3188,"status":951,"phases":3189,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":119,"conditions":3193,"interventions":3195},"NCT04479371","Liposomal Bupivacaine vs Standard Penile Block for Hypospadias Repair",[89],"2022-07-30","2023-07-30","2021-07",[3194],"Hypospadias",[3180,3130],{"trials":3197,"activeCount":119},[],{"trials":3199,"activeCount":119},[],{"trials":3201,"activeCount":119},[3202],{"nctId":3203,"briefTitle":3204,"status":164,"phases":3205,"primaryCompletion":3206,"completion":3207,"start":3208,"enrollment":833,"conditions":3209,"interventions":3211},"NCT02074709","TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management",[92],"2014-09","2015-02","2014-01",[3210],"Postoperative Pain",[3212,3180],"Plain bupivacaine",{"trials":3214,"activeCount":119},[],{"intervention":3130,"totalTrials":97,"cells":3216},{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3225,"PHASE3":3227,"PHASE4":3229,"NA":3235},{"trials":3218,"activeCount":119},[],{"trials":3220,"activeCount":119},[3221],{"nctId":3187,"briefTitle":3188,"status":951,"phases":3222,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":119,"conditions":3223,"interventions":3224},[89],[3194],[3180,3130],{"trials":3226,"activeCount":119},[],{"trials":3228,"activeCount":119},[],{"trials":3230,"activeCount":119},[3231],{"nctId":3120,"briefTitle":3121,"status":385,"phases":3232,"primaryCompletion":3123,"completion":3124,"start":3125,"enrollment":3126,"conditions":3233,"interventions":3234},[92],[3128],[3130,3131,3100],{"trials":3236,"activeCount":119},[],{"intervention":3238,"totalTrials":97,"cells":3239},"Aripiprazole",{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3244,"PHASE3":3246,"PHASE4":3257,"NA":3267},{"trials":3241,"activeCount":119},[],{"trials":3243,"activeCount":119},[],{"trials":3245,"activeCount":119},[],{"trials":3247,"activeCount":119},[3248],{"nctId":3249,"briefTitle":3250,"status":164,"phases":3251,"primaryCompletion":3252,"completion":3252,"start":3172,"enrollment":2778,"conditions":3253,"interventions":3256},"NCT02918370","Aripiprazole for Bipolar Disorder and Alcohol Use Disorder",[91],"2023-06-30",[26,3254,3255],"Alcoholism","Alcohol Abuse",[3238],{"trials":3258,"activeCount":119},[3259],{"nctId":3260,"briefTitle":3261,"status":164,"phases":3262,"primaryCompletion":3263,"completion":3263,"start":3264,"enrollment":27,"conditions":3265,"interventions":3266},"NCT00608543","Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression",[92],"2009-01","2005-10",[29],[3238],{"trials":3268,"activeCount":119},[],{"intervention":3270,"totalTrials":97,"cells":3271},"Memantine",{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3278,"PHASE4":3280,"NA":3299},{"trials":3273,"activeCount":119},[],{"trials":3275,"activeCount":119},[],{"trials":3277,"activeCount":119},[],{"trials":3279,"activeCount":119},[],{"trials":3281,"activeCount":119},[3282,3289],{"nctId":3283,"briefTitle":3284,"status":164,"phases":3285,"completion":3286,"start":2983,"enrollment":1020,"conditions":3287,"interventions":3288},"NCT00280774","Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes",[92],"2007-02",[3043],[3270],{"nctId":3290,"briefTitle":3291,"status":385,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":2940,"enrollment":1020,"conditions":3294,"interventions":3297},"NCT00283309","Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes",[92],"2007-04",[3295,3296],"Mood","Memory Deficit",[3270,3298],"Riluzole",{"trials":3300,"activeCount":119},[],{"intervention":3302,"totalTrials":97,"cells":3303},"Liraglutide",{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3310,"PHASE4":3312,"NA":3339},{"trials":3305,"activeCount":119},[],{"trials":3307,"activeCount":119},[],{"trials":3309,"activeCount":119},[],{"trials":3311,"activeCount":119},[],{"trials":3313,"activeCount":119},[3314,3325],{"nctId":3315,"briefTitle":3316,"status":164,"phases":3317,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":3036,"conditions":3320,"interventions":3324},"NCT03038620","Impact of Liraglutide 3.0 on Body Fat Distribution",[92],"2020-10-13","2017-01",[3321,3322,3323],"Obesity, Visceral","Cardiovascular Diseases","Fat Disorder",[3302],{"nctId":3326,"briefTitle":3327,"status":164,"phases":3328,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":3332,"interventions":3335},"NCT01966978","The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study",[92],"2017-12","2014-11",157,[3333,3334],"Diabetes Mellitus, Type 2","Diabetes",[3336,3337,3302,3338],"Metformin","Detemir","Insulin Aspart",{"trials":3340,"activeCount":119},[],{"intervention":892,"totalTrials":97,"cells":3342},{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3349,"PHASE4":3355,"NA":3367},{"trials":3344,"activeCount":119},[],{"trials":3346,"activeCount":119},[],{"trials":3348,"activeCount":119},[],{"trials":3350,"activeCount":119},[3351],{"nctId":883,"briefTitle":884,"status":385,"phases":3352,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":3353,"interventions":3354},[91],[29,890],[862,892],{"trials":3356,"activeCount":119},[3357],{"nctId":3358,"briefTitle":3359,"status":951,"phases":3360,"primaryCompletion":3361,"completion":3361,"start":3362,"enrollment":119,"conditions":3363,"interventions":3365},"NCT02840591","Ramelteon and Citicoline for Delirium",[92],"2017-11","2016-07",[3364],"Delirium",[892,3366],"Citicoline",{"trials":3368,"activeCount":119},[],{"intervention":3370,"totalTrials":97,"cells":3371},"Metoprolol succinate",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3378,"PHASE4":3380,"NA":3399},{"trials":3373,"activeCount":119},[],{"trials":3375,"activeCount":119},[],{"trials":3377,"activeCount":119},[],{"trials":3379,"activeCount":119},[],{"trials":3381,"activeCount":119},[3382,3392],{"nctId":3383,"briefTitle":3384,"status":164,"phases":3385,"primaryCompletion":3386,"completion":3386,"start":3387,"enrollment":3126,"conditions":3388,"interventions":3389},"NCT01502787","Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients",[92],"2013-06","2009-04",[18],[3370,3390,3391],"Nebivolol","Angiotensin II",{"nctId":3393,"briefTitle":3394,"status":164,"phases":3395,"primaryCompletion":1121,"completion":1121,"start":1065,"enrollment":3396,"conditions":3397,"interventions":3398},"NCT01501929","Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients",[92],32,[18],[3370,3390],{"trials":3400,"activeCount":119},[],{"intervention":3390,"totalTrials":97,"cells":3402},{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3409,"PHASE4":3411,"NA":3421},{"trials":3404,"activeCount":119},[],{"trials":3406,"activeCount":119},[],{"trials":3408,"activeCount":119},[],{"trials":3410,"activeCount":119},[],{"trials":3412,"activeCount":119},[3413,3417],{"nctId":3383,"briefTitle":3384,"status":164,"phases":3414,"primaryCompletion":3386,"completion":3386,"start":3387,"enrollment":3126,"conditions":3415,"interventions":3416},[92],[18],[3370,3390,3391],{"nctId":3393,"briefTitle":3394,"status":164,"phases":3418,"primaryCompletion":1121,"completion":1121,"start":1065,"enrollment":3396,"conditions":3419,"interventions":3420},[92],[18],[3370,3390],{"trials":3422,"activeCount":119},[],{"intervention":3424,"totalTrials":97,"cells":3425},"Pramlintide",{"EARLY_PHASE1":3426,"PHASE1":3428,"PHASE2":3430,"PHASE3":3432,"PHASE4":3434,"NA":3457},{"trials":3427,"activeCount":119},[],{"trials":3429,"activeCount":119},[],{"trials":3431,"activeCount":119},[],{"trials":3433,"activeCount":119},[],{"trials":3435,"activeCount":119},[3436,3446],{"nctId":3437,"briefTitle":3438,"status":164,"phases":3439,"primaryCompletion":3440,"completion":3440,"start":3441,"enrollment":3442,"conditions":3443,"interventions":3445},"NCT00690235","Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia",[92],"2011-08","2007-11",33,[289,290,3334,3444],"Weight Gain",[3424],{"nctId":3447,"briefTitle":3448,"status":951,"phases":3449,"primaryCompletion":3450,"completion":3450,"start":1029,"enrollment":119,"conditions":3451,"interventions":3453},"NCT00505882","Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes",[92],"2008-12",[3452],"Type 1 Diabetes",[3424,3454,3455,3456],"Glargine","Lispro","Aspart",{"trials":3458,"activeCount":119},[],{"intervention":3460,"totalTrials":97,"cells":3461},"rosiglitazone",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3489},{"trials":3463,"activeCount":119},[],{"trials":3465,"activeCount":119},[],{"trials":3467,"activeCount":119},[],{"trials":3469,"activeCount":119},[],{"trials":3471,"activeCount":119},[3472,3480],{"nctId":3473,"briefTitle":3474,"status":164,"phases":3475,"primaryCompletion":3293,"completion":3293,"start":3476,"enrollment":3477,"conditions":3478,"interventions":3479},"NCT00424762","Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride",[92],"2005-02",150,[3333],[3460],{"nctId":3481,"briefTitle":3482,"status":164,"phases":3483,"primaryCompletion":2959,"completion":3484,"start":3093,"enrollment":2893,"conditions":3485,"interventions":3487},"NCT00746174","Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone",[92],"2008-02",[3486],"Insulin Sensitivity",[3488],"Rosiglitazone",{"trials":3490,"activeCount":119},[],{"intervention":3492,"totalTrials":97,"cells":3493},"Potassium chloride powder",{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3510,"PHASE4":3512,"NA":3522},{"trials":3495,"activeCount":119},[],{"trials":3497,"activeCount":119},[],{"trials":3499,"activeCount":119},[3500],{"nctId":3501,"briefTitle":3502,"status":164,"phases":3503,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":2663,"conditions":3506,"interventions":3507},"NCT01682837","Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension",[90],"2015-03","2012-10",[18],[3492,3508,3509],"Potassium citrate powder","Potassium magnesium citrate powder",{"trials":3511,"activeCount":119},[],{"trials":3513,"activeCount":119},[3514],{"nctId":3515,"briefTitle":3502,"status":164,"phases":3516,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":617,"conditions":3519,"interventions":3520},"NCT02653560",[92],"2015-01","2012-09",[18],[3492,3521,3508],"Potassium magnesium Citrate",{"trials":3523,"activeCount":119},[],{"intervention":3508,"totalTrials":97,"cells":3525},{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3536,"PHASE4":3538,"NA":3544},{"trials":3527,"activeCount":119},[],{"trials":3529,"activeCount":119},[],{"trials":3531,"activeCount":119},[3532],{"nctId":3501,"briefTitle":3502,"status":164,"phases":3533,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":2663,"conditions":3534,"interventions":3535},[90],[18],[3492,3508,3509],{"trials":3537,"activeCount":119},[],{"trials":3539,"activeCount":119},[3540],{"nctId":3515,"briefTitle":3502,"status":164,"phases":3541,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":617,"conditions":3542,"interventions":3543},[92],[18],[3492,3521,3508],{"trials":3545,"activeCount":119},[],{"intervention":3547,"totalTrials":97,"cells":3548},"Misoprostol",{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3577},{"trials":3550,"activeCount":119},[],{"trials":3552,"activeCount":119},[3553],{"nctId":3554,"briefTitle":3555,"status":164,"phases":3556,"primaryCompletion":3557,"completion":3558,"start":3293,"enrollment":3126,"conditions":3559,"interventions":3561},"NCT00906126","Oral Misoprostol for Labor Augmentation: A Pilot Study",[89],"2008-09","2009-05",[3560],"Arrest of Dilation in Labor",[3547],{"trials":3563,"activeCount":119},[],{"trials":3565,"activeCount":119},[],{"trials":3567,"activeCount":119},[3568],{"nctId":3569,"briefTitle":3570,"status":164,"phases":3571,"primaryCompletion":3137,"completion":3137,"start":3450,"enrollment":3572,"conditions":3573,"interventions":3575},"NCT00906347","A Trial of Oral Misoprostol for Labor Augmentation",[92],350,[3574],"Labor Augmentation",[3547,3576],"Oxytocin",{"trials":3578,"activeCount":119},[],{"intervention":3580,"totalTrials":116,"cells":3581},"Hiprex",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3590,"NA":3602},{"trials":3583,"activeCount":119},[],{"trials":3585,"activeCount":119},[],{"trials":3587,"activeCount":119},[],{"trials":3589,"activeCount":119},[],{"trials":3591,"activeCount":119},[3592],{"nctId":3593,"briefTitle":3594,"status":385,"phases":3595,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":3598,"conditions":3599,"interventions":3601},"NCT04709601","Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.",[92],"2024-12-31","2021-01-04",14,[3600],"Urinary Tract Infections",[3580],{"trials":3603,"activeCount":119},[],{"intervention":3605,"totalTrials":116,"cells":3606},"N-acetylcysteine",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3628},{"trials":3608,"activeCount":119},[],{"trials":3610,"activeCount":119},[],{"trials":3612,"activeCount":119},[],{"trials":3614,"activeCount":119},[],{"trials":3616,"activeCount":119},[3617],{"nctId":3618,"briefTitle":3619,"status":385,"phases":3620,"primaryCompletion":3621,"completion":3622,"start":3450,"enrollment":3623,"conditions":3624,"interventions":3627},"NCT00896025","Study of N-Acetylcysteine in Acute Liver Failure (ALF)",[92],"2015-10-15","2016-03",255,[3625,3626],"Acute Liver Failure","Fulminant Hepatic Failure",[3605],{"trials":3629,"activeCount":119},[],{"intervention":3631,"totalTrials":116,"cells":3632},"Levemir (Detemir) and Novolog (Aspart) Insulin",{"EARLY_PHASE1":3633,"PHASE1":3635,"PHASE2":3637,"PHASE3":3639,"PHASE4":3641,"NA":3651},{"trials":3634,"activeCount":119},[],{"trials":3636,"activeCount":119},[],{"trials":3638,"activeCount":119},[],{"trials":3640,"activeCount":119},[],{"trials":3642,"activeCount":119},[3643],{"nctId":3644,"briefTitle":3645,"status":951,"phases":3646,"primaryCompletion":3647,"completion":3648,"start":3558,"enrollment":119,"conditions":3649,"interventions":3650},"NCT00906529","Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin",[92],"2010-12","2011-03",[239],[3631],{"trials":3652,"activeCount":119},[],{"intervention":3654,"totalTrials":116,"cells":3655},"Simvastatin 40mg",{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3662,"PHASE4":3664,"NA":3678},{"trials":3657,"activeCount":119},[],{"trials":3659,"activeCount":119},[],{"trials":3661,"activeCount":119},[],{"trials":3663,"activeCount":119},[],{"trials":3665,"activeCount":119},[3666],{"nctId":3667,"briefTitle":3668,"status":385,"phases":3669,"primaryCompletion":3670,"completion":3670,"start":3671,"enrollment":360,"conditions":3672,"interventions":3677},"NCT04507373","7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events",[92],"2021-12-20","2018-08-17",[3673,3674,3675,3676],"Muscle Cramp","Ache","Weakness, Muscle","Statin Adverse Reaction",[3654],{"trials":3679,"activeCount":119},[],{"intervention":3681,"totalTrials":116,"cells":3682},"Bivalirudin",{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3705},{"trials":3684,"activeCount":119},[],{"trials":3686,"activeCount":119},[],{"trials":3688,"activeCount":119},[],{"trials":3690,"activeCount":119},[],{"trials":3692,"activeCount":119},[3693],{"nctId":3694,"briefTitle":3695,"status":164,"phases":3696,"primaryCompletion":3697,"completion":3697,"start":3698,"enrollment":617,"conditions":3699,"interventions":3703},"NCT03318393","Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO",[92],"2021-10-08","2018-03-25",[3700,3701,3702],"Extracorporeal Membrane Oxygenation Complication","Pediatric ALL","Anticoagulants",[3681,3704],"Unfractionated heparin",{"trials":3706,"activeCount":119},[],{"intervention":3704,"totalTrials":116,"cells":3708},{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3717,"NA":3723},{"trials":3710,"activeCount":119},[],{"trials":3712,"activeCount":119},[],{"trials":3714,"activeCount":119},[],{"trials":3716,"activeCount":119},[],{"trials":3718,"activeCount":119},[3719],{"nctId":3694,"briefTitle":3695,"status":164,"phases":3720,"primaryCompletion":3697,"completion":3697,"start":3698,"enrollment":617,"conditions":3721,"interventions":3722},[92],[3700,3701,3702],[3681,3704],{"trials":3724,"activeCount":119},[],{"intervention":3726,"totalTrials":116,"cells":3727},"Nelfinavir",{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3749},{"trials":3729,"activeCount":119},[],{"trials":3731,"activeCount":119},[],{"trials":3733,"activeCount":119},[],{"trials":3735,"activeCount":119},[],{"trials":3737,"activeCount":119},[3738],{"nctId":3739,"briefTitle":3740,"status":164,"phases":3741,"primaryCompletion":3742,"completion":3743,"start":3744,"enrollment":377,"conditions":3745,"interventions":3747},"NCT00457665","Mechanisms of Lipodystrophy in HIV-Infected Pateints",[92],"2007-10","2014-10","2002-02",[3746],"HIV Infections",[3726,3748],"Efavirenz",{"trials":3750,"activeCount":119},[],{"intervention":3748,"totalTrials":116,"cells":3752},{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3757,"PHASE3":3759,"PHASE4":3761,"NA":3767},{"trials":3754,"activeCount":119},[],{"trials":3756,"activeCount":119},[],{"trials":3758,"activeCount":119},[],{"trials":3760,"activeCount":119},[],{"trials":3762,"activeCount":119},[3763],{"nctId":3739,"briefTitle":3740,"status":164,"phases":3764,"primaryCompletion":3742,"completion":3743,"start":3744,"enrollment":377,"conditions":3765,"interventions":3766},[92],[3746],[3726,3748],{"trials":3768,"activeCount":119},[],{"intervention":3029,"totalTrials":116,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3775,"PHASE3":3777,"PHASE4":3779,"NA":3785},{"trials":3772,"activeCount":119},[],{"trials":3774,"activeCount":119},[],{"trials":3776,"activeCount":119},[],{"trials":3778,"activeCount":119},[],{"trials":3780,"activeCount":119},[3781],{"nctId":3020,"briefTitle":3021,"status":164,"phases":3782,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":3025,"conditions":3783,"interventions":3784},[92],[3027],[3029,3007],{"trials":3786,"activeCount":119},[],{"intervention":3788,"totalTrials":116,"cells":3789},"Levetiracetam, Keppra",{"EARLY_PHASE1":3790,"PHASE1":3792,"PHASE2":3794,"PHASE3":3796,"PHASE4":3798,"NA":3808},{"trials":3791,"activeCount":119},[],{"trials":3793,"activeCount":119},[],{"trials":3795,"activeCount":119},[],{"trials":3797,"activeCount":119},[],{"trials":3799,"activeCount":119},[3800],{"nctId":3801,"briefTitle":3802,"status":164,"phases":3803,"primaryCompletion":2940,"completion":2940,"start":3476,"enrollment":617,"conditions":3804,"interventions":3807},"NCT00223223","Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study",[92],[3805,3806],"Memory Loss Associated With Corticosteroid Use","Manic State Associated With Corticosteroid Use",[3788],{"trials":3809,"activeCount":119},[],{"intervention":3811,"totalTrials":116,"cells":3812},"QR-bromocriptine",{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3831},{"trials":3814,"activeCount":119},[],{"trials":3816,"activeCount":119},[],{"trials":3818,"activeCount":119},[],{"trials":3820,"activeCount":119},[],{"trials":3822,"activeCount":119},[3823],{"nctId":3824,"briefTitle":3825,"status":164,"phases":3826,"primaryCompletion":3827,"completion":3828,"start":3085,"enrollment":109,"conditions":3829,"interventions":3830},"NCT01474018","QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes",[92],"2012-05","2012-06",[3333],[3811],{"trials":3832,"activeCount":119},[],{"intervention":3834,"totalTrials":116,"cells":3835},"Ambrisentan",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3842,"PHASE4":3844,"NA":3855},{"trials":3837,"activeCount":119},[],{"trials":3839,"activeCount":119},[],{"trials":3841,"activeCount":119},[],{"trials":3843,"activeCount":119},[],{"trials":3845,"activeCount":119},[3846],{"nctId":3847,"briefTitle":3848,"status":385,"phases":3849,"primaryCompletion":3850,"completion":3208,"start":3263,"enrollment":724,"conditions":3851,"interventions":3854},"NCT00840463","Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan",[92],"2013-09",[3852,3853],"Pulmonary Hypertension","Heart Failure With Preserved Ejection Fraction",[3834],{"trials":3856,"activeCount":119},[],{"intervention":3858,"totalTrials":116,"cells":3859},"Bupivacain",{"EARLY_PHASE1":3860,"PHASE1":3862,"PHASE2":3864,"PHASE3":3866,"PHASE4":3868,"NA":3878},{"trials":3861,"activeCount":119},[],{"trials":3863,"activeCount":119},[],{"trials":3865,"activeCount":119},[],{"trials":3867,"activeCount":119},[],{"trials":3869,"activeCount":119},[3870],{"nctId":3871,"briefTitle":3872,"status":951,"phases":3873,"primaryCompletion":3596,"completion":1662,"start":3874,"enrollment":119,"conditions":3875,"interventions":3877},"NCT05178485","Treatment Efficacy of Local Anesthetic\u002FSteroid Mixture Injection for Patients With Odynophonia",[92],"2023-07-01",[3876],"Patients With a Diagnosis of Odynophonia",[3858],{"trials":3879,"activeCount":119},[],{"intervention":3041,"totalTrials":116,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3886,"PHASE3":3888,"PHASE4":3890,"NA":3896},{"trials":3883,"activeCount":119},[],{"trials":3885,"activeCount":119},[],{"trials":3887,"activeCount":119},[],{"trials":3889,"activeCount":119},[],{"trials":3891,"activeCount":119},[3892],{"nctId":3031,"briefTitle":3032,"status":164,"phases":3893,"primaryCompletion":3034,"completion":3034,"start":3035,"enrollment":3036,"conditions":3894,"interventions":3895},[92],[3038,3039,3040,3007,3041,3042,3043],[3041,3007],{"trials":3897,"activeCount":119},[],{"intervention":3899,"totalTrials":116,"cells":3900},"Nebulized magnesium sulfate",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3907,"PHASE4":3909,"NA":3919},{"trials":3902,"activeCount":119},[],{"trials":3904,"activeCount":119},[],{"trials":3906,"activeCount":119},[],{"trials":3908,"activeCount":119},[],{"trials":3910,"activeCount":119},[3911],{"nctId":3912,"briefTitle":3913,"status":164,"phases":3914,"primaryCompletion":3915,"completion":3915,"start":3916,"enrollment":702,"conditions":3917,"interventions":3918},"NCT01515995","Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation",[92],"2015-10","2012-01",[878],[3899],{"trials":3920,"activeCount":119},[],{"intervention":3922,"totalTrials":116,"cells":3923},"Oral Acetaminophen",{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3930,"PHASE4":3932,"NA":3945},{"trials":3925,"activeCount":119},[],{"trials":3927,"activeCount":119},[],{"trials":3929,"activeCount":119},[],{"trials":3931,"activeCount":119},[],{"trials":3933,"activeCount":119},[3934],{"nctId":3935,"briefTitle":3936,"status":164,"phases":3937,"primaryCompletion":3938,"completion":3939,"start":3940,"enrollment":3941,"conditions":3942,"interventions":3943},"NCT02643394","Efficacy of Oral vs. Intravenous Acetaminophen",[92],"2016-09-02","2018-01-15","2015-08-17",110,[3210],[3922,3944],"Intravenous acetaminophen",{"trials":3946,"activeCount":119},[],{"intervention":3944,"totalTrials":116,"cells":3948},{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3955,"PHASE4":3957,"NA":3963},{"trials":3950,"activeCount":119},[],{"trials":3952,"activeCount":119},[],{"trials":3954,"activeCount":119},[],{"trials":3956,"activeCount":119},[],{"trials":3958,"activeCount":119},[3959],{"nctId":3935,"briefTitle":3936,"status":164,"phases":3960,"primaryCompletion":3938,"completion":3939,"start":3940,"enrollment":3941,"conditions":3961,"interventions":3962},[92],[3210],[3922,3944],{"trials":3964,"activeCount":119},[],{"intervention":3966,"totalTrials":116,"cells":3967},"Eloctate",{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3974,"PHASE4":3976,"NA":3988},{"trials":3969,"activeCount":119},[],{"trials":3971,"activeCount":119},[],{"trials":3973,"activeCount":119},[],{"trials":3975,"activeCount":119},[],{"trials":3977,"activeCount":119},[3978],{"nctId":3979,"briefTitle":3980,"status":951,"phases":3981,"primaryCompletion":107,"completion":107,"start":1143,"enrollment":119,"conditions":3982,"interventions":3985},"NCT04690322","POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies",[92],[3983,3984],"Hemophilia A","Factor VIII",[3966,3986,3987],"Adynovate","Emicizumab",{"trials":3989,"activeCount":119},[],{"intervention":3986,"totalTrials":116,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4006},{"trials":3993,"activeCount":119},[],{"trials":3995,"activeCount":119},[],{"trials":3997,"activeCount":119},[],{"trials":3999,"activeCount":119},[],{"trials":4001,"activeCount":119},[4002],{"nctId":3979,"briefTitle":3980,"status":951,"phases":4003,"primaryCompletion":107,"completion":107,"start":1143,"enrollment":119,"conditions":4004,"interventions":4005},[92],[3983,3984],[3966,3986,3987],{"trials":4007,"activeCount":119},[],{"intervention":3987,"totalTrials":116,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4024},{"trials":4011,"activeCount":119},[],{"trials":4013,"activeCount":119},[],{"trials":4015,"activeCount":119},[],{"trials":4017,"activeCount":119},[],{"trials":4019,"activeCount":119},[4020],{"nctId":3979,"briefTitle":3980,"status":951,"phases":4021,"primaryCompletion":107,"completion":107,"start":1143,"enrollment":119,"conditions":4022,"interventions":4023},[92],[3983,3984],[3966,3986,3987],{"trials":4025,"activeCount":119},[],{"intervention":4027,"totalTrials":116,"cells":4028},"High severity group: Escitalopram",{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4051},{"trials":4030,"activeCount":119},[],{"trials":4032,"activeCount":119},[],{"trials":4034,"activeCount":119},[],{"trials":4036,"activeCount":119},[],{"trials":4038,"activeCount":119},[4039],{"nctId":4040,"briefTitle":4041,"status":164,"phases":4042,"primaryCompletion":4043,"completion":4043,"start":4044,"enrollment":4045,"conditions":4046,"interventions":4047},"NCT01324700","Antidepressant Treatment at an Inner City Asthma Clinic",[92],"2015-05","2010-07",139,[15,878],[4027,4048,4049,4050],"High severity group: Placebo","Low severity group: Escitalopram","Low severity group: Placebo",{"trials":4052,"activeCount":119},[],{"intervention":4048,"totalTrials":116,"cells":4054},{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4061,"PHASE4":4063,"NA":4069},{"trials":4056,"activeCount":119},[],{"trials":4058,"activeCount":119},[],{"trials":4060,"activeCount":119},[],{"trials":4062,"activeCount":119},[],{"trials":4064,"activeCount":119},[4065],{"nctId":4040,"briefTitle":4041,"status":164,"phases":4066,"primaryCompletion":4043,"completion":4043,"start":4044,"enrollment":4045,"conditions":4067,"interventions":4068},[92],[15,878],[4027,4048,4049,4050],{"trials":4070,"activeCount":119},[],{"intervention":4049,"totalTrials":116,"cells":4072},{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4079,"PHASE4":4081,"NA":4087},{"trials":4074,"activeCount":119},[],{"trials":4076,"activeCount":119},[],{"trials":4078,"activeCount":119},[],{"trials":4080,"activeCount":119},[],{"trials":4082,"activeCount":119},[4083],{"nctId":4040,"briefTitle":4041,"status":164,"phases":4084,"primaryCompletion":4043,"completion":4043,"start":4044,"enrollment":4045,"conditions":4085,"interventions":4086},[92],[15,878],[4027,4048,4049,4050],{"trials":4088,"activeCount":119},[],{"intervention":4050,"totalTrials":116,"cells":4090},{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4097,"PHASE4":4099,"NA":4105},{"trials":4092,"activeCount":119},[],{"trials":4094,"activeCount":119},[],{"trials":4096,"activeCount":119},[],{"trials":4098,"activeCount":119},[],{"trials":4100,"activeCount":119},[4101],{"nctId":4040,"briefTitle":4041,"status":164,"phases":4102,"primaryCompletion":4043,"completion":4043,"start":4044,"enrollment":4045,"conditions":4103,"interventions":4104},[92],[15,878],[4027,4048,4049,4050],{"trials":4106,"activeCount":119},[],{"intervention":4108,"totalTrials":116,"cells":4109},"Naltrexone",{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4114,"PHASE3":4116,"PHASE4":4118,"NA":4128},{"trials":4111,"activeCount":119},[],{"trials":4113,"activeCount":119},[],{"trials":4115,"activeCount":119},[],{"trials":4117,"activeCount":119},[],{"trials":4119,"activeCount":119},[4120],{"nctId":4121,"briefTitle":4122,"status":164,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":4125,"enrollment":702,"conditions":4126,"interventions":4127},"NCT00223275","Naltrexone for Bipolar Disorder and Alcohol Dependence",[92],"2007-09","2005-05",[26,2961],[4108],{"trials":4129,"activeCount":119},[],{"intervention":4131,"totalTrials":116,"cells":4132},"Alemtuzumab",{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4139,"PHASE4":4141,"NA":4152},{"trials":4134,"activeCount":119},[],{"trials":4136,"activeCount":119},[],{"trials":4138,"activeCount":119},[],{"trials":4140,"activeCount":119},[],{"trials":4142,"activeCount":119},[4143],{"nctId":4144,"briefTitle":4145,"status":164,"phases":4146,"primaryCompletion":4147,"completion":4147,"start":4148,"enrollment":430,"conditions":4149,"interventions":4151},"NCT03135249","Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis",[92],"2020-11-04","2018-05-01",[4150],"Multiple Sclerosis (MS)",[4131],{"trials":4153,"activeCount":119},[],{"intervention":4155,"totalTrials":116,"cells":4156},"Atomoxetine",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4177},{"trials":4158,"activeCount":119},[],{"trials":4160,"activeCount":119},[],{"trials":4162,"activeCount":119},[],{"trials":4164,"activeCount":119},[],{"trials":4166,"activeCount":119},[4167],{"nctId":4168,"briefTitle":4169,"status":164,"phases":4170,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":4173,"conditions":4174,"interventions":4176},"NCT00628394","Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation",[92],"2011-02","2003-09",119,[4175],"Cognition in Schizophrenia",[4155],{"trials":4178,"activeCount":119},[],{"intervention":4180,"totalTrials":116,"cells":4181},"Study#1: chlorthalidone (CTD), titrated dose",{"EARLY_PHASE1":4182,"PHASE1":4184,"PHASE2":4186,"PHASE3":4188,"PHASE4":4190,"NA":4205},{"trials":4183,"activeCount":119},[],{"trials":4185,"activeCount":119},[],{"trials":4187,"activeCount":119},[],{"trials":4189,"activeCount":119},[],{"trials":4191,"activeCount":119},[4192],{"nctId":4193,"briefTitle":4194,"status":164,"phases":4195,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":4198,"conditions":4199,"interventions":4200},"NCT00353652","Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension",[92],"2013-01","2005-01",166,[18],[4180,4201,4202,4203,4204],"Study #1: spironolactone (SP), titrated dose","Study# 2 chlorthalidone (CTD), fixed dose","Study# 2 spironolactone (SP), fixed dose","Study# 2 irbsesartan (IR), fixed dose",{"trials":4206,"activeCount":119},[],{"intervention":4201,"totalTrials":116,"cells":4208},{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4223},{"trials":4210,"activeCount":119},[],{"trials":4212,"activeCount":119},[],{"trials":4214,"activeCount":119},[],{"trials":4216,"activeCount":119},[],{"trials":4218,"activeCount":119},[4219],{"nctId":4193,"briefTitle":4194,"status":164,"phases":4220,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":4198,"conditions":4221,"interventions":4222},[92],[18],[4180,4201,4202,4203,4204],{"trials":4224,"activeCount":119},[],{"intervention":4202,"totalTrials":116,"cells":4226},{"EARLY_PHASE1":4227,"PHASE1":4229,"PHASE2":4231,"PHASE3":4233,"PHASE4":4235,"NA":4241},{"trials":4228,"activeCount":119},[],{"trials":4230,"activeCount":119},[],{"trials":4232,"activeCount":119},[],{"trials":4234,"activeCount":119},[],{"trials":4236,"activeCount":119},[4237],{"nctId":4193,"briefTitle":4194,"status":164,"phases":4238,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":4198,"conditions":4239,"interventions":4240},[92],[18],[4180,4201,4202,4203,4204],{"trials":4242,"activeCount":119},[],{"intervention":4203,"totalTrials":116,"cells":4244},{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4259},{"trials":4246,"activeCount":119},[],{"trials":4248,"activeCount":119},[],{"trials":4250,"activeCount":119},[],{"trials":4252,"activeCount":119},[],{"trials":4254,"activeCount":119},[4255],{"nctId":4193,"briefTitle":4194,"status":164,"phases":4256,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":4198,"conditions":4257,"interventions":4258},[92],[18],[4180,4201,4202,4203,4204],{"trials":4260,"activeCount":119},[],{"intervention":4204,"totalTrials":116,"cells":4262},{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4271,"NA":4277},{"trials":4264,"activeCount":119},[],{"trials":4266,"activeCount":119},[],{"trials":4268,"activeCount":119},[],{"trials":4270,"activeCount":119},[],{"trials":4272,"activeCount":119},[4273],{"nctId":4193,"briefTitle":4194,"status":164,"phases":4274,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":4198,"conditions":4275,"interventions":4276},[92],[18],[4180,4201,4202,4203,4204],{"trials":4278,"activeCount":119},[],{"intervention":4280,"totalTrials":116,"cells":4281},"Memantine 10 mg",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4288,"PHASE4":4290,"NA":4300},{"trials":4283,"activeCount":119},[],{"trials":4285,"activeCount":119},[],{"trials":4287,"activeCount":119},[],{"trials":4289,"activeCount":119},[],{"trials":4291,"activeCount":119},[4292],{"nctId":4293,"briefTitle":4294,"status":164,"phases":4295,"primaryCompletion":3319,"completion":3319,"start":3916,"enrollment":3126,"conditions":4296,"interventions":4298},"NCT01656187","Attenuation of Corticosteroid Induced Hippocampal Changes",[92],[4297],"Organic Memory Impairment",[4280,4299],"Memantine-matched Placebo",{"trials":4301,"activeCount":119},[],{"intervention":4299,"totalTrials":116,"cells":4303},{"EARLY_PHASE1":4304,"PHASE1":4306,"PHASE2":4308,"PHASE3":4310,"PHASE4":4312,"NA":4318},{"trials":4305,"activeCount":119},[],{"trials":4307,"activeCount":119},[],{"trials":4309,"activeCount":119},[],{"trials":4311,"activeCount":119},[],{"trials":4313,"activeCount":119},[4314],{"nctId":4293,"briefTitle":4294,"status":164,"phases":4315,"primaryCompletion":3319,"completion":3319,"start":3916,"enrollment":3126,"conditions":4316,"interventions":4317},[92],[4297],[4280,4299],{"trials":4319,"activeCount":119},[],{"intervention":4321,"totalTrials":116,"cells":4322},"Premarin",{"EARLY_PHASE1":4323,"PHASE1":4325,"PHASE2":4327,"PHASE3":4329,"PHASE4":4331,"NA":4342},{"trials":4324,"activeCount":119},[],{"trials":4326,"activeCount":119},[],{"trials":4328,"activeCount":119},[],{"trials":4330,"activeCount":119},[],{"trials":4332,"activeCount":119},[4333],{"nctId":4334,"briefTitle":4335,"status":164,"phases":4336,"primaryCompletion":4337,"completion":4338,"start":2892,"enrollment":617,"conditions":4339,"interventions":4341},"NCT01778985","Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor",[92],"2013-03","2013-04",[4340,3074],"Pelvic Organ Prolapse",[4321],{"trials":4343,"activeCount":119},[],{"intervention":3391,"totalTrials":116,"cells":4345},{"EARLY_PHASE1":4346,"PHASE1":4348,"PHASE2":4350,"PHASE3":4352,"PHASE4":4354,"NA":4360},{"trials":4347,"activeCount":119},[],{"trials":4349,"activeCount":119},[],{"trials":4351,"activeCount":119},[],{"trials":4353,"activeCount":119},[],{"trials":4355,"activeCount":119},[4356],{"nctId":3383,"briefTitle":3384,"status":164,"phases":4357,"primaryCompletion":3386,"completion":3386,"start":3387,"enrollment":3126,"conditions":4358,"interventions":4359},[92],[18],[3370,3390,3391],{"trials":4361,"activeCount":119},[],{"intervention":4363,"totalTrials":116,"cells":4364},"Ondansetron",{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4369,"PHASE3":4371,"PHASE4":4373,"NA":4386},{"trials":4366,"activeCount":119},[],{"trials":4368,"activeCount":119},[],{"trials":4370,"activeCount":119},[],{"trials":4372,"activeCount":119},[],{"trials":4374,"activeCount":119},[4375],{"nctId":4376,"briefTitle":4377,"status":164,"phases":4378,"primaryCompletion":4379,"completion":4379,"start":4380,"enrollment":4381,"conditions":4382,"interventions":4385},"NCT02082678","Ondansetron for Bipolar Disorder and Alcohol Use Disorders",[92],"2018-05","2014-02",70,[26,4383,4384],"Alcohol Use Disorder","Dual Diagnosis",[4363],{"trials":4387,"activeCount":119},[],{"intervention":4389,"totalTrials":116,"cells":4390},"Lurasidone",{"EARLY_PHASE1":4391,"PHASE1":4393,"PHASE2":4395,"PHASE3":4397,"PHASE4":4399,"NA":4411},{"trials":4392,"activeCount":119},[],{"trials":4394,"activeCount":119},[],{"trials":4396,"activeCount":119},[],{"trials":4398,"activeCount":119},[],{"trials":4400,"activeCount":119},[4401],{"nctId":4402,"briefTitle":4403,"status":164,"phases":4404,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":2663,"conditions":4407,"interventions":4408},"NCT02199743","Lurasidone Effects on Tissue Glutamate in Schizophrenia",[92],"2016-06","2013-02",[289,290],[4389,4409,4410],"Haloperidol","Perphenazine",{"trials":4412,"activeCount":119},[],{"intervention":4409,"totalTrials":116,"cells":4414},{"EARLY_PHASE1":4415,"PHASE1":4417,"PHASE2":4419,"PHASE3":4421,"PHASE4":4423,"NA":4429},{"trials":4416,"activeCount":119},[],{"trials":4418,"activeCount":119},[],{"trials":4420,"activeCount":119},[],{"trials":4422,"activeCount":119},[],{"trials":4424,"activeCount":119},[4425],{"nctId":4402,"briefTitle":4403,"status":164,"phases":4426,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":2663,"conditions":4427,"interventions":4428},[92],[289,290],[4389,4409,4410],{"trials":4430,"activeCount":119},[],{"intervention":4410,"totalTrials":116,"cells":4432},{"EARLY_PHASE1":4433,"PHASE1":4435,"PHASE2":4437,"PHASE3":4439,"PHASE4":4441,"NA":4447},{"trials":4434,"activeCount":119},[],{"trials":4436,"activeCount":119},[],{"trials":4438,"activeCount":119},[],{"trials":4440,"activeCount":119},[],{"trials":4442,"activeCount":119},[4443],{"nctId":4402,"briefTitle":4403,"status":164,"phases":4444,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":2663,"conditions":4445,"interventions":4446},[92],[289,290],[4389,4409,4410],{"trials":4448,"activeCount":119},[],{"intervention":4450,"totalTrials":116,"cells":4451},"Amoxicillin",{"EARLY_PHASE1":4452,"PHASE1":4454,"PHASE2":4456,"PHASE3":4458,"PHASE4":4460,"NA":4473},{"trials":4453,"activeCount":119},[],{"trials":4455,"activeCount":119},[],{"trials":4457,"activeCount":119},[],{"trials":4459,"activeCount":119},[],{"trials":4461,"activeCount":119},[4462],{"nctId":4463,"briefTitle":4464,"status":164,"phases":4465,"primaryCompletion":4466,"completion":4467,"start":4468,"enrollment":796,"conditions":4469,"interventions":4472},"NCT05010304","Penicillin De-labeling in the Pediatric Primary Care Setting",[92],"2023-10-31","2023-11-30","2021-12-09",[4470,4471],"Penicillin Allergy","Penicillin Reaction",[4450],{"trials":4474,"activeCount":119},[],{"intervention":4476,"totalTrials":116,"cells":4477},"Valsartan",{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4484,"PHASE4":4486,"NA":4499},{"trials":4479,"activeCount":119},[],{"trials":4481,"activeCount":119},[],{"trials":4483,"activeCount":119},[],{"trials":4485,"activeCount":119},[],{"trials":4487,"activeCount":119},[4488],{"nctId":4489,"briefTitle":4490,"status":951,"phases":4491,"primaryCompletion":4492,"completion":4492,"start":4493,"enrollment":119,"conditions":4494,"interventions":4497},"NCT00745953","Regression of Fatty Heart by Valsartan Therapy",[92],"2009-08","2007-08",[4495,4496],"Metabolic Syndrome","Lipotoxicity",[4476,4498],"Hydrochlorothiazide",{"trials":4500,"activeCount":119},[],{"intervention":4498,"totalTrials":116,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4509,"PHASE4":4511,"NA":4517},{"trials":4504,"activeCount":119},[],{"trials":4506,"activeCount":119},[],{"trials":4508,"activeCount":119},[],{"trials":4510,"activeCount":119},[],{"trials":4512,"activeCount":119},[4513],{"nctId":4489,"briefTitle":4490,"status":951,"phases":4514,"primaryCompletion":4492,"completion":4492,"start":4493,"enrollment":119,"conditions":4515,"interventions":4516},[92],[4495,4496],[4476,4498],{"trials":4518,"activeCount":119},[],{"intervention":904,"totalTrials":116,"cells":4520},{"EARLY_PHASE1":4521,"PHASE1":4523,"PHASE2":4525,"PHASE3":4527,"PHASE4":4529,"NA":4535},{"trials":4522,"activeCount":119},[],{"trials":4524,"activeCount":119},[],{"trials":4526,"activeCount":119},[],{"trials":4528,"activeCount":119},[],{"trials":4530,"activeCount":119},[4531],{"nctId":896,"briefTitle":897,"status":385,"phases":4532,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":4533,"interventions":4534},[92],[15],[862,904],{"trials":4536,"activeCount":119},[],{"intervention":4538,"totalTrials":116,"cells":4539},"Veregen only",{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4544,"PHASE3":4546,"PHASE4":4548,"NA":4558},{"trials":4541,"activeCount":119},[],{"trials":4543,"activeCount":119},[],{"trials":4545,"activeCount":119},[],{"trials":4547,"activeCount":119},[],{"trials":4549,"activeCount":119},[4550],{"nctId":4551,"briefTitle":4552,"status":164,"phases":4553,"primaryCompletion":4405,"completion":4405,"start":4554,"enrollment":1100,"conditions":4555,"interventions":4557},"NCT02622568","Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study",[92],"2015-07",[4556],"Verruca, Warts",[4538],{"trials":4559,"activeCount":119},[],{"intervention":4561,"totalTrials":116,"cells":4562},"Belatacept",{"EARLY_PHASE1":4563,"PHASE1":4565,"PHASE2":4567,"PHASE3":4569,"PHASE4":4571,"NA":4583},{"trials":4564,"activeCount":119},[],{"trials":4566,"activeCount":119},[],{"trials":4568,"activeCount":119},[],{"trials":4570,"activeCount":119},[],{"trials":4572,"activeCount":119},[4573],{"nctId":4574,"briefTitle":4575,"status":164,"phases":4576,"primaryCompletion":4577,"completion":4578,"start":4579,"enrollment":16,"conditions":4580,"interventions":4582},"NCT04786067","Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression",[92],"2025-07-10","2025-07-30","2021-07-28",[4581],"Kidney Transplant Immunosuppression",[4561],{"trials":4584,"activeCount":119},[],{"intervention":4586,"totalTrials":116,"cells":4587},"Tecfidera",{"EARLY_PHASE1":4588,"PHASE1":4590,"PHASE2":4592,"PHASE3":4594,"PHASE4":4596,"NA":4607},{"trials":4589,"activeCount":119},[],{"trials":4591,"activeCount":119},[],{"trials":4593,"activeCount":119},[],{"trials":4595,"activeCount":119},[],{"trials":4597,"activeCount":119},[4598],{"nctId":4599,"briefTitle":4600,"status":164,"phases":4601,"primaryCompletion":4602,"completion":4602,"start":4603,"enrollment":4604,"conditions":4605,"interventions":4606},"NCT02739542","Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)",[92],"2021-03-31","2016-03-19",87,[4150],[4586],{"trials":4608,"activeCount":119},[],{"intervention":4610,"totalTrials":116,"cells":4611},"Ropivacaine 0.35%",{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4616,"PHASE3":4618,"PHASE4":4620,"NA":4631},{"trials":4613,"activeCount":119},[],{"trials":4615,"activeCount":119},[],{"trials":4617,"activeCount":119},[],{"trials":4619,"activeCount":119},[],{"trials":4621,"activeCount":119},[4622],{"nctId":4623,"briefTitle":4624,"status":164,"phases":4625,"primaryCompletion":4626,"completion":4626,"start":4627,"enrollment":2916,"conditions":4628,"interventions":4630},"NCT03154658","Serratus Anterior Plane Block in Patients Undergoing Mastectomy",[92],"2020-03-01","2017-04-01",[4629],"Pain, Post-operative",[4610],{"trials":4632,"activeCount":119},[],{"intervention":4634,"totalTrials":116,"cells":4635},"20-30% Salicylic Acid peels to the right side of the face",{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4640,"PHASE3":4642,"PHASE4":4644,"NA":4655},{"trials":4637,"activeCount":119},[],{"trials":4639,"activeCount":119},[],{"trials":4641,"activeCount":119},[],{"trials":4643,"activeCount":119},[],{"trials":4645,"activeCount":119},[4646],{"nctId":4647,"briefTitle":4648,"status":164,"phases":4649,"primaryCompletion":4650,"completion":4650,"start":2904,"enrollment":1020,"conditions":4651,"interventions":4653},"NCT00616239","Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women",[92],"2018-03",[4652],"Melasma",[4634,4654],"20-30% Salicylic Acid peels to the left side of the face",{"trials":4656,"activeCount":119},[],{"intervention":4654,"totalTrials":116,"cells":4658},{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4673},{"trials":4660,"activeCount":119},[],{"trials":4662,"activeCount":119},[],{"trials":4664,"activeCount":119},[],{"trials":4666,"activeCount":119},[],{"trials":4668,"activeCount":119},[4669],{"nctId":4647,"briefTitle":4648,"status":164,"phases":4670,"primaryCompletion":4650,"completion":4650,"start":2904,"enrollment":1020,"conditions":4671,"interventions":4672},[92],[4652],[4634,4654],{"trials":4674,"activeCount":119},[],{"intervention":3455,"totalTrials":116,"cells":4676},{"EARLY_PHASE1":4677,"PHASE1":4679,"PHASE2":4681,"PHASE3":4683,"PHASE4":4685,"NA":4691},{"trials":4678,"activeCount":119},[],{"trials":4680,"activeCount":119},[],{"trials":4682,"activeCount":119},[],{"trials":4684,"activeCount":119},[],{"trials":4686,"activeCount":119},[4687],{"nctId":3447,"briefTitle":3448,"status":951,"phases":4688,"primaryCompletion":3450,"completion":3450,"start":1029,"enrollment":119,"conditions":4689,"interventions":4690},[92],[3452],[3424,3454,3455,3456],{"trials":4692,"activeCount":119},[],{"intervention":3456,"totalTrials":116,"cells":4694},{"EARLY_PHASE1":4695,"PHASE1":4697,"PHASE2":4699,"PHASE3":4701,"PHASE4":4703,"NA":4709},{"trials":4696,"activeCount":119},[],{"trials":4698,"activeCount":119},[],{"trials":4700,"activeCount":119},[],{"trials":4702,"activeCount":119},[],{"trials":4704,"activeCount":119},[4705],{"nctId":3447,"briefTitle":3448,"status":951,"phases":4706,"primaryCompletion":3450,"completion":3450,"start":1029,"enrollment":119,"conditions":4707,"interventions":4708},[92],[3452],[3424,3454,3455,3456],{"trials":4710,"activeCount":119},[],{"intervention":4712,"totalTrials":116,"cells":4713},"[U-13C3] glycerol",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4720,"PHASE4":4722,"NA":4733},{"trials":4715,"activeCount":119},[],{"trials":4717,"activeCount":119},[],{"trials":4719,"activeCount":119},[],{"trials":4721,"activeCount":119},[],{"trials":4723,"activeCount":119},[4724],{"nctId":4725,"briefTitle":4726,"status":164,"phases":4727,"primaryCompletion":4728,"completion":4729,"start":3622,"enrollment":353,"conditions":4730,"interventions":4731},"NCT02833415","Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging",[92],"2018-01","2018-11",[3321],[4712,4732],"Empagliflozin",{"trials":4734,"activeCount":119},[],{"intervention":4732,"totalTrials":116,"cells":4736},{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4741,"PHASE3":4743,"PHASE4":4745,"NA":4751},{"trials":4738,"activeCount":119},[],{"trials":4740,"activeCount":119},[],{"trials":4742,"activeCount":119},[],{"trials":4744,"activeCount":119},[],{"trials":4746,"activeCount":119},[4747],{"nctId":4725,"briefTitle":4726,"status":164,"phases":4748,"primaryCompletion":4728,"completion":4729,"start":3622,"enrollment":353,"conditions":4749,"interventions":4750},[92],[3321],[4712,4732],{"trials":4752,"activeCount":119},[],{"intervention":3131,"totalTrials":116,"cells":4754},{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4759,"PHASE3":4761,"PHASE4":4763,"NA":4769},{"trials":4756,"activeCount":119},[],{"trials":4758,"activeCount":119},[],{"trials":4760,"activeCount":119},[],{"trials":4762,"activeCount":119},[],{"trials":4764,"activeCount":119},[4765],{"nctId":3120,"briefTitle":3121,"status":385,"phases":4766,"primaryCompletion":3123,"completion":3124,"start":3125,"enrollment":3126,"conditions":4767,"interventions":4768},[92],[3128],[3130,3131,3100],{"trials":4770,"activeCount":119},[],{"intervention":3212,"totalTrials":116,"cells":4772},{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4781,"NA":4787},{"trials":4774,"activeCount":119},[],{"trials":4776,"activeCount":119},[],{"trials":4778,"activeCount":119},[],{"trials":4780,"activeCount":119},[],{"trials":4782,"activeCount":119},[4783],{"nctId":3203,"briefTitle":3204,"status":164,"phases":4784,"primaryCompletion":3206,"completion":3207,"start":3208,"enrollment":833,"conditions":4785,"interventions":4786},[92],[3210],[3212,3180],{"trials":4788,"activeCount":119},[],{"intervention":4790,"totalTrials":116,"cells":4791},"sofosbuvir\u002Fledipasvir",{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4814},{"trials":4793,"activeCount":119},[],{"trials":4795,"activeCount":119},[],{"trials":4797,"activeCount":119},[],{"trials":4799,"activeCount":119},[],{"trials":4801,"activeCount":119},[4802],{"nctId":4803,"briefTitle":4804,"status":385,"phases":4805,"primaryCompletion":4806,"completion":4807,"start":4808,"enrollment":116,"conditions":4809,"interventions":4811},"NCT02717949","Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study",[92],"2017-06-05","2017-07-18","2016-02-25",[4810],"Liver Disease",[4790,4812,4813],"sofosbuvir","Ribavirin",{"trials":4815,"activeCount":119},[],{"intervention":4812,"totalTrials":116,"cells":4817},{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4832},{"trials":4819,"activeCount":119},[],{"trials":4821,"activeCount":119},[],{"trials":4823,"activeCount":119},[],{"trials":4825,"activeCount":119},[],{"trials":4827,"activeCount":119},[4828],{"nctId":4803,"briefTitle":4804,"status":385,"phases":4829,"primaryCompletion":4806,"completion":4807,"start":4808,"enrollment":116,"conditions":4830,"interventions":4831},[92],[4810],[4790,4812,4813],{"trials":4833,"activeCount":119},[],{"intervention":4813,"totalTrials":116,"cells":4835},{"EARLY_PHASE1":4836,"PHASE1":4838,"PHASE2":4840,"PHASE3":4842,"PHASE4":4844,"NA":4850},{"trials":4837,"activeCount":119},[],{"trials":4839,"activeCount":119},[],{"trials":4841,"activeCount":119},[],{"trials":4843,"activeCount":119},[],{"trials":4845,"activeCount":119},[4846],{"nctId":4803,"briefTitle":4804,"status":385,"phases":4847,"primaryCompletion":4806,"completion":4807,"start":4808,"enrollment":116,"conditions":4848,"interventions":4849},[92],[4810],[4790,4812,4813],{"trials":4851,"activeCount":119},[],{"intervention":4853,"totalTrials":116,"cells":4854},"recombinant B-type, natriuretic peptide",{"EARLY_PHASE1":4855,"PHASE1":4857,"PHASE2":4859,"PHASE3":4861,"PHASE4":4863,"NA":4875},{"trials":4856,"activeCount":119},[],{"trials":4858,"activeCount":119},[],{"trials":4860,"activeCount":119},[],{"trials":4862,"activeCount":119},[],{"trials":4864,"activeCount":119},[4865],{"nctId":4866,"briefTitle":4867,"status":164,"phases":4868,"completion":4869,"start":4870,"enrollment":2310,"conditions":4871,"interventions":4874},"NCT00559338","Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department",[92],"2005-04","2003-12",[4872,4873],"Heart Failure, Congestive","Cardiomyopathy",[4853],{"trials":4876,"activeCount":119},[],{"intervention":4878,"totalTrials":116,"cells":4879},"elemental iron",{"EARLY_PHASE1":4880,"PHASE1":4882,"PHASE2":4884,"PHASE3":4886,"PHASE4":4888,"NA":4898},{"trials":4881,"activeCount":119},[],{"trials":4883,"activeCount":119},[],{"trials":4885,"activeCount":119},[],{"trials":4887,"activeCount":119},[],{"trials":4889,"activeCount":119},[4890],{"nctId":4891,"briefTitle":4892,"status":164,"phases":4893,"primaryCompletion":1109,"completion":1109,"start":4894,"enrollment":1221,"conditions":4895,"interventions":4897},"NCT01904864","Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia",[92],"2013-07",[4896],"Iron Deficiency Anemia",[4878,4878],{"trials":4899,"activeCount":119},[],{"intervention":4901,"totalTrials":116,"cells":4902},"Phenytoin 200 mg",{"EARLY_PHASE1":4903,"PHASE1":4905,"PHASE2":4907,"PHASE3":4909,"PHASE4":4911,"NA":4925},{"trials":4904,"activeCount":119},[],{"trials":4906,"activeCount":119},[],{"trials":4908,"activeCount":119},[],{"trials":4910,"activeCount":119},[],{"trials":4912,"activeCount":119},[4913],{"nctId":4914,"briefTitle":4915,"status":164,"phases":4916,"primaryCompletion":3172,"completion":4917,"start":4554,"enrollment":4918,"conditions":4919,"interventions":4921},"NCT02595723","Phenytoin for Memory Impairment Secondary to Megestrol",[92],"2016-12",21,[4920],"Cognitive Impairment",[4901,4922,4923,4924],"Megestrol 800 mg liquid","Phenytoin-matched Placebo","Megestrol-matched liquid Placebo",{"trials":4926,"activeCount":119},[],{"intervention":4922,"totalTrials":116,"cells":4928},{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4933,"PHASE3":4935,"PHASE4":4937,"NA":4943},{"trials":4930,"activeCount":119},[],{"trials":4932,"activeCount":119},[],{"trials":4934,"activeCount":119},[],{"trials":4936,"activeCount":119},[],{"trials":4938,"activeCount":119},[4939],{"nctId":4914,"briefTitle":4915,"status":164,"phases":4940,"primaryCompletion":3172,"completion":4917,"start":4554,"enrollment":4918,"conditions":4941,"interventions":4942},[92],[4920],[4901,4922,4923,4924],{"trials":4944,"activeCount":119},[],{"intervention":4923,"totalTrials":116,"cells":4946},{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4953,"PHASE4":4955,"NA":4961},{"trials":4948,"activeCount":119},[],{"trials":4950,"activeCount":119},[],{"trials":4952,"activeCount":119},[],{"trials":4954,"activeCount":119},[],{"trials":4956,"activeCount":119},[4957],{"nctId":4914,"briefTitle":4915,"status":164,"phases":4958,"primaryCompletion":3172,"completion":4917,"start":4554,"enrollment":4918,"conditions":4959,"interventions":4960},[92],[4920],[4901,4922,4923,4924],{"trials":4962,"activeCount":119},[],{"intervention":4924,"totalTrials":116,"cells":4964},{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4971,"PHASE4":4973,"NA":4979},{"trials":4966,"activeCount":119},[],{"trials":4968,"activeCount":119},[],{"trials":4970,"activeCount":119},[],{"trials":4972,"activeCount":119},[],{"trials":4974,"activeCount":119},[4975],{"nctId":4914,"briefTitle":4915,"status":164,"phases":4976,"primaryCompletion":3172,"completion":4917,"start":4554,"enrollment":4918,"conditions":4977,"interventions":4978},[92],[4920],[4901,4922,4923,4924],{"trials":4980,"activeCount":119},[],{"intervention":4982,"totalTrials":116,"cells":4983},"Metformin continue",{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4988,"PHASE3":4990,"PHASE4":4992,"NA":5006},{"trials":4985,"activeCount":119},[],{"trials":4987,"activeCount":119},[],{"trials":4989,"activeCount":119},[],{"trials":4991,"activeCount":119},[],{"trials":4993,"activeCount":119},[4994],{"nctId":4995,"briefTitle":4996,"status":164,"phases":4997,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5002,"interventions":5004},"NCT03179254","Type 2 Diabetes and Ambulatory Surgery Patients",[92],"2014-01-10","2014-08-26","2010-03-22",160,[5003],"Diabetes Type 2",[4982,5005],"Metformin discontinue",{"trials":5007,"activeCount":119},[],{"intervention":5005,"totalTrials":116,"cells":5009},{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5024},{"trials":5011,"activeCount":119},[],{"trials":5013,"activeCount":119},[],{"trials":5015,"activeCount":119},[],{"trials":5017,"activeCount":119},[],{"trials":5019,"activeCount":119},[5020],{"nctId":4995,"briefTitle":4996,"status":164,"phases":5021,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5022,"interventions":5023},[92],[5003],[4982,5005],{"trials":5025,"activeCount":119},[],{"intervention":5027,"totalTrials":116,"cells":5028},"Tenapanor",{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5037,"NA":5048},{"trials":5030,"activeCount":119},[],{"trials":5032,"activeCount":119},[],{"trials":5034,"activeCount":119},[],{"trials":5036,"activeCount":119},[],{"trials":5038,"activeCount":119},[5039],{"nctId":5040,"briefTitle":5041,"status":164,"phases":5042,"primaryCompletion":5043,"completion":5043,"start":5044,"enrollment":901,"conditions":5045,"interventions":5047},"NCT06481150","A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.",[92],"2025-09-14","2024-07-01",[5046],"Hyperoxaluria",[5027],{"trials":5049,"activeCount":119},[],{"intervention":5051,"totalTrials":116,"cells":5052},"cephalosporin",{"EARLY_PHASE1":5053,"PHASE1":5055,"PHASE2":5057,"PHASE3":5059,"PHASE4":5061,"NA":5073},{"trials":5054,"activeCount":119},[],{"trials":5056,"activeCount":119},[],{"trials":5058,"activeCount":119},[],{"trials":5060,"activeCount":119},[],{"trials":5062,"activeCount":119},[5063],{"nctId":5064,"briefTitle":5065,"status":951,"phases":5066,"primaryCompletion":593,"completion":593,"start":5067,"enrollment":119,"conditions":5068,"interventions":5071},"NCT04401553","Prophylactic Antibiotics for Surgical Site Infections and Beta-Lactam Allergy",[92],"2024-08-16",[5069,5070],"Surgical Site Infection","Beta-lactam Allergy",[5051,5072],"Second tier antibiotic",{"trials":5074,"activeCount":119},[],{"intervention":5072,"totalTrials":116,"cells":5076},{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5081,"PHASE3":5083,"PHASE4":5085,"NA":5091},{"trials":5078,"activeCount":119},[],{"trials":5080,"activeCount":119},[],{"trials":5082,"activeCount":119},[],{"trials":5084,"activeCount":119},[],{"trials":5086,"activeCount":119},[5087],{"nctId":5064,"briefTitle":5065,"status":951,"phases":5088,"primaryCompletion":593,"completion":593,"start":5067,"enrollment":119,"conditions":5089,"interventions":5090},[92],[5069,5070],[5051,5072],{"trials":5092,"activeCount":119},[],{"intervention":5094,"totalTrials":116,"cells":5095},"Febuxostat",{"EARLY_PHASE1":5096,"PHASE1":5098,"PHASE2":5100,"PHASE3":5102,"PHASE4":5104,"NA":5113},{"trials":5097,"activeCount":119},[],{"trials":5099,"activeCount":119},[],{"trials":5101,"activeCount":119},[],{"trials":5103,"activeCount":119},[],{"trials":5105,"activeCount":119},[5106],{"nctId":5107,"briefTitle":5108,"status":164,"phases":5109,"primaryCompletion":3504,"completion":3504,"start":3827,"enrollment":2893,"conditions":5110,"interventions":5112},"NCT01654276","Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome",[92],[5111],"Gout",[5094],{"trials":5114,"activeCount":119},[],{"intervention":5116,"totalTrials":116,"cells":5117},"Epidural Bupivacaine plus fentanyl",{"EARLY_PHASE1":5118,"PHASE1":5120,"PHASE2":5122,"PHASE3":5124,"PHASE4":5126,"NA":5139},{"trials":5119,"activeCount":119},[],{"trials":5121,"activeCount":119},[],{"trials":5123,"activeCount":119},[],{"trials":5125,"activeCount":119},[],{"trials":5127,"activeCount":119},[5128],{"nctId":5129,"briefTitle":5130,"status":164,"phases":5131,"primaryCompletion":5132,"completion":4894,"start":5133,"enrollment":5134,"conditions":5135,"interventions":5137},"NCT01621230","Effects of Bupivacaine Induced Motor Blockade During the Second Stage of Labor",[92],"2012-07","2009-09",481,[5136],"Pregnancy",[5116,5138],"Epidural fentanyl",{"trials":5140,"activeCount":119},[],{"intervention":5138,"totalTrials":116,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5149,"PHASE4":5151,"NA":5157},{"trials":5144,"activeCount":119},[],{"trials":5146,"activeCount":119},[],{"trials":5148,"activeCount":119},[],{"trials":5150,"activeCount":119},[],{"trials":5152,"activeCount":119},[5153],{"nctId":5129,"briefTitle":5130,"status":164,"phases":5154,"primaryCompletion":5132,"completion":4894,"start":5133,"enrollment":5134,"conditions":5155,"interventions":5156},[92],[5136],[5116,5138],{"trials":5158,"activeCount":119},[],{"intervention":3576,"totalTrials":116,"cells":5160},{"EARLY_PHASE1":5161,"PHASE1":5163,"PHASE2":5165,"PHASE3":5167,"PHASE4":5169,"NA":5175},{"trials":5162,"activeCount":119},[],{"trials":5164,"activeCount":119},[],{"trials":5166,"activeCount":119},[],{"trials":5168,"activeCount":119},[],{"trials":5170,"activeCount":119},[5171],{"nctId":3569,"briefTitle":3570,"status":164,"phases":5172,"primaryCompletion":3137,"completion":3137,"start":3450,"enrollment":3572,"conditions":5173,"interventions":5174},[92],[3574],[3547,3576],{"trials":5176,"activeCount":119},[],{"intervention":3337,"totalTrials":116,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5193},{"trials":5180,"activeCount":119},[],{"trials":5182,"activeCount":119},[],{"trials":5184,"activeCount":119},[],{"trials":5186,"activeCount":119},[],{"trials":5188,"activeCount":119},[5189],{"nctId":3326,"briefTitle":3327,"status":164,"phases":5190,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":5191,"interventions":5192},[92],[3333,3334],[3336,3337,3302,3338],{"trials":5194,"activeCount":119},[],{"intervention":3338,"totalTrials":116,"cells":5196},{"EARLY_PHASE1":5197,"PHASE1":5199,"PHASE2":5201,"PHASE3":5203,"PHASE4":5205,"NA":5211},{"trials":5198,"activeCount":119},[],{"trials":5200,"activeCount":119},[],{"trials":5202,"activeCount":119},[],{"trials":5204,"activeCount":119},[],{"trials":5206,"activeCount":119},[5207],{"nctId":3326,"briefTitle":3327,"status":164,"phases":5208,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":5209,"interventions":5210},[92],[3333,3334],[3336,3337,3302,3338],{"trials":5212,"activeCount":119},[],{"intervention":5214,"totalTrials":116,"cells":5215},"Drug: Acetaminophen, Drug: Placebo",{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5220,"PHASE3":5222,"PHASE4":5224,"NA":5235},{"trials":5217,"activeCount":119},[],{"trials":5219,"activeCount":119},[],{"trials":5221,"activeCount":119},[],{"trials":5223,"activeCount":119},[],{"trials":5225,"activeCount":119},[5226],{"nctId":5227,"briefTitle":5228,"status":164,"phases":5229,"primaryCompletion":5230,"completion":5230,"start":5231,"enrollment":617,"conditions":5232,"interventions":5234},"NCT00377364","Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy",[92],"2008-10","2006-11",[878,5233],"Rheumatic Disease",[5214],{"trials":5236,"activeCount":119},[],{"intervention":5238,"totalTrials":116,"cells":5239},"Empagliflozin 10 MG",{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5244,"PHASE3":5246,"PHASE4":5248,"NA":5263},{"trials":5241,"activeCount":119},[],{"trials":5243,"activeCount":119},[],{"trials":5245,"activeCount":119},[],{"trials":5247,"activeCount":119},[],{"trials":5249,"activeCount":119},[5250],{"nctId":5251,"briefTitle":5252,"status":164,"phases":5253,"primaryCompletion":5254,"completion":5255,"start":5256,"enrollment":5257,"conditions":5258,"interventions":5262},"NCT05139472","Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction",[92],"2023-09-20","2024-02-19","2021-11-09",8,[5259,5260,5261],"Heart Failure with Preserved Ejection Fraction","Heart Failure, Diastolic","Diabetes Mellitus",[5238],{"trials":5264,"activeCount":119},[],{"intervention":5266,"totalTrials":116,"cells":5267},"IV Atropine and Fentanyl Premedication Arm",{"EARLY_PHASE1":5268,"PHASE1":5270,"PHASE2":5272,"PHASE3":5274,"PHASE4":5276,"NA":5288},{"trials":5269,"activeCount":119},[],{"trials":5271,"activeCount":119},[],{"trials":5273,"activeCount":119},[],{"trials":5275,"activeCount":119},[],{"trials":5277,"activeCount":119},[5278],{"nctId":5279,"briefTitle":5280,"status":164,"phases":5281,"primaryCompletion":5282,"completion":5282,"start":5283,"enrollment":1267,"conditions":5284,"interventions":5286},"NCT05065424","Premedication for Less Invasive Surfactant Administration Study (PRELISA)",[92],"2026-03-02","2022-04-06",[5285],"Respiratory Distress Syndrome, Newborn",[5266,5287],"IV Normal Saline Placebo Arm",{"trials":5289,"activeCount":119},[],{"intervention":5287,"totalTrials":116,"cells":5291},{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5298,"PHASE4":5300,"NA":5306},{"trials":5293,"activeCount":119},[],{"trials":5295,"activeCount":119},[],{"trials":5297,"activeCount":119},[],{"trials":5299,"activeCount":119},[],{"trials":5301,"activeCount":119},[5302],{"nctId":5279,"briefTitle":5280,"status":164,"phases":5303,"primaryCompletion":5282,"completion":5282,"start":5283,"enrollment":1267,"conditions":5304,"interventions":5305},[92],[5285],[5266,5287],{"trials":5307,"activeCount":119},[],{"intervention":5309,"totalTrials":116,"cells":5310},"Brexpiprazole",{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5317,"PHASE4":5319,"NA":5330},{"trials":5312,"activeCount":119},[],{"trials":5314,"activeCount":119},[],{"trials":5316,"activeCount":119},[],{"trials":5318,"activeCount":119},[],{"trials":5320,"activeCount":119},[5321],{"nctId":5322,"briefTitle":5323,"status":164,"phases":5324,"primaryCompletion":5325,"completion":5325,"start":5326,"enrollment":4918,"conditions":5327,"interventions":5329},"NCT03427892","Brexpiprazole for Bipolar Depression",[92],"2018-03-15","2017-03-01",[5328],"Bipolar Depression",[5309],{"trials":5331,"activeCount":119},[],{"intervention":2864,"totalTrials":116,"cells":5333},{"EARLY_PHASE1":5334,"PHASE1":5336,"PHASE2":5338,"PHASE3":5340,"PHASE4":5342,"NA":5348},{"trials":5335,"activeCount":119},[],{"trials":5337,"activeCount":119},[],{"trials":5339,"activeCount":119},[],{"trials":5341,"activeCount":119},[],{"trials":5343,"activeCount":119},[5344],{"nctId":2854,"briefTitle":2855,"status":164,"phases":5345,"primaryCompletion":2857,"completion":2857,"start":2858,"enrollment":2859,"conditions":5346,"interventions":5347},[92],[2861,2862],[2864,2810],{"trials":5349,"activeCount":119},[],{"intervention":5351,"totalTrials":116,"cells":5352},"Water-Based Vaginal Lubricant",{"EARLY_PHASE1":5353,"PHASE1":5355,"PHASE2":5357,"PHASE3":5359,"PHASE4":5361,"NA":5380},{"trials":5354,"activeCount":119},[],{"trials":5356,"activeCount":119},[],{"trials":5358,"activeCount":119},[],{"trials":5360,"activeCount":119},[],{"trials":5362,"activeCount":119},[5363],{"nctId":5364,"briefTitle":5365,"status":164,"phases":5366,"primaryCompletion":5367,"completion":5367,"start":5368,"enrollment":5369,"conditions":5370,"interventions":5378},"NCT04038099","Lessons on Urethral Lidocaine in Urodynamics",[92],"2021-08-18","2019-08-14",63,[5371,4340,5372,5373,5374,5375,5376,5377],"Urethra Issue","Urinary Incontinence","Vaginal Vault Prolapse","Cystocele","Uterine Prolapse","Vaginal Prolapse","Pelvic Floor Disorders",[5351,5379],"lidocaine topical",{"trials":5381,"activeCount":119},[],{"intervention":5379,"totalTrials":116,"cells":5383},{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5388,"PHASE3":5390,"PHASE4":5392,"NA":5398},{"trials":5385,"activeCount":119},[],{"trials":5387,"activeCount":119},[],{"trials":5389,"activeCount":119},[],{"trials":5391,"activeCount":119},[],{"trials":5393,"activeCount":119},[5394],{"nctId":5364,"briefTitle":5365,"status":164,"phases":5395,"primaryCompletion":5367,"completion":5367,"start":5368,"enrollment":5369,"conditions":5396,"interventions":5397},[92],[5371,4340,5372,5373,5374,5375,5376,5377],[5351,5379],{"trials":5399,"activeCount":119},[],{"intervention":5401,"totalTrials":116,"cells":5402},"Conjugated Estrogens Cream",{"EARLY_PHASE1":5403,"PHASE1":5405,"PHASE2":5407,"PHASE3":5409,"PHASE4":5411,"NA":5422},{"trials":5404,"activeCount":119},[],{"trials":5406,"activeCount":119},[],{"trials":5408,"activeCount":119},[],{"trials":5410,"activeCount":119},[],{"trials":5412,"activeCount":119},[5413],{"nctId":5414,"briefTitle":5415,"status":164,"phases":5416,"primaryCompletion":445,"completion":5417,"start":4917,"enrollment":5418,"conditions":5419,"interventions":5421},"NCT02431897","Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen",[92],"2023-05-17",206,[4340,5420,5373,5374,5375,5376,5377],"Urogenital Prolapse",[5401],{"trials":5423,"activeCount":119},[],{"intervention":3054,"totalTrials":116,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5432,"PHASE4":5434,"NA":5440},{"trials":5427,"activeCount":119},[],{"trials":5429,"activeCount":119},[],{"trials":5431,"activeCount":119},[],{"trials":5433,"activeCount":119},[],{"trials":5435,"activeCount":119},[5436],{"nctId":3046,"briefTitle":3047,"status":164,"phases":5437,"primaryCompletion":3049,"completion":3049,"start":3050,"enrollment":3051,"conditions":5438,"interventions":5439},[92],[3040],[3007,3054],{"trials":5441,"activeCount":119},[],{"intervention":5443,"totalTrials":116,"cells":5444},"Amlodipine besylate",{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5451,"PHASE4":5453,"NA":5463},{"trials":5446,"activeCount":119},[],{"trials":5448,"activeCount":119},[],{"trials":5450,"activeCount":119},[],{"trials":5452,"activeCount":119},[],{"trials":5454,"activeCount":119},[5455],{"nctId":5456,"briefTitle":5457,"status":164,"phases":5458,"primaryCompletion":3362,"completion":5459,"start":3517,"enrollment":30,"conditions":5460,"interventions":5462},"NCT02353806","Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation",[92],"2016-09",[5461],"Chronic Hypertension in Pregnancy",[5443],{"trials":5464,"activeCount":119},[],{"intervention":5466,"totalTrials":116,"cells":5467},"Micafungin",{"EARLY_PHASE1":5468,"PHASE1":5470,"PHASE2":5472,"PHASE3":5474,"PHASE4":5476,"NA":5488},{"trials":5469,"activeCount":119},[],{"trials":5471,"activeCount":119},[],{"trials":5473,"activeCount":119},[],{"trials":5475,"activeCount":119},[],{"trials":5477,"activeCount":119},[5478],{"nctId":5479,"briefTitle":5480,"status":164,"phases":5481,"primaryCompletion":886,"completion":1064,"start":5482,"enrollment":5483,"conditions":5484,"interventions":5487},"NCT01090141","Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers",[92],"2009-11",36,[23,5485,5486],"Nutrition Disorders","Overweight",[5466,5466],{"trials":5489,"activeCount":119},[],{"intervention":5491,"totalTrials":116,"cells":5492},"Low Osmolar Contrast Material, 300-399 Mg\u002FMl Iodine Concentration, Per Ml",{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5499,"PHASE4":5501,"NA":5511},{"trials":5494,"activeCount":119},[],{"trials":5496,"activeCount":119},[],{"trials":5498,"activeCount":119},[],{"trials":5500,"activeCount":119},[],{"trials":5502,"activeCount":119},[5503],{"nctId":5504,"briefTitle":5505,"status":385,"phases":5506,"primaryCompletion":5507,"completion":5507,"start":5508,"enrollment":2832,"conditions":5509,"interventions":5510},"NCT04625517","Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)",[92],"2022-06-15","2020-01-22",[20],[5491],{"trials":5512,"activeCount":119},[],{"intervention":5514,"totalTrials":116,"cells":5515},"Levothyroxine",{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5520,"PHASE3":5522,"PHASE4":5524,"NA":5536},{"trials":5517,"activeCount":119},[],{"trials":5519,"activeCount":119},[],{"trials":5521,"activeCount":119},[],{"trials":5523,"activeCount":119},[],{"trials":5525,"activeCount":119},[5526],{"nctId":5527,"briefTitle":5528,"status":385,"phases":5529,"primaryCompletion":5530,"completion":5530,"start":5531,"enrollment":3598,"conditions":5532,"interventions":5535},"NCT02946918","Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy",[92],"2019-11-04","2017-02-01",[5533,5534],"Thyroid Cancer","Postsurgical Hypothyroidism",[5514],{"trials":5537,"activeCount":119},[],{"intervention":3298,"totalTrials":116,"cells":5539},{"EARLY_PHASE1":5540,"PHASE1":5542,"PHASE2":5544,"PHASE3":5546,"PHASE4":5548,"NA":5554},{"trials":5541,"activeCount":119},[],{"trials":5543,"activeCount":119},[],{"trials":5545,"activeCount":119},[],{"trials":5547,"activeCount":119},[],{"trials":5549,"activeCount":119},[5550],{"nctId":3290,"briefTitle":3291,"status":385,"phases":5551,"primaryCompletion":3293,"completion":3293,"start":2940,"enrollment":1020,"conditions":5552,"interventions":5553},[92],[3295,3296],[3270,3298],{"trials":5555,"activeCount":119},[],{"intervention":5557,"totalTrials":116,"cells":5558},"GrafixPL PRIME",{"EARLY_PHASE1":5559,"PHASE1":5561,"PHASE2":5563,"PHASE3":5565,"PHASE4":5567,"NA":5577},{"trials":5560,"activeCount":119},[],{"trials":5562,"activeCount":119},[],{"trials":5564,"activeCount":119},[],{"trials":5566,"activeCount":119},[],{"trials":5568,"activeCount":119},[5569],{"nctId":5570,"briefTitle":5571,"status":164,"phases":5572,"primaryCompletion":4626,"completion":4626,"start":5573,"enrollment":353,"conditions":5574,"interventions":5576},"NCT03742440","GrafixPL PRIME Evaluation Case Study",[92],"2018-11-20",[5575],"Diabetic Foot Ulcer",[5557],{"trials":5578,"activeCount":119},[],{"intervention":5580,"totalTrials":116,"cells":5581},"Pioglitazone 45 mg",{"EARLY_PHASE1":5582,"PHASE1":5584,"PHASE2":5586,"PHASE3":5588,"PHASE4":5590,"NA":5601},{"trials":5583,"activeCount":119},[],{"trials":5585,"activeCount":119},[],{"trials":5587,"activeCount":119},[],{"trials":5589,"activeCount":119},[],{"trials":5591,"activeCount":119},[5592],{"nctId":5593,"briefTitle":5594,"status":164,"phases":5595,"primaryCompletion":5596,"completion":5596,"start":5597,"enrollment":888,"conditions":5598,"interventions":5600},"NCT04370093","Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone\u002FWeight Loss",[92],"2025-05-28","2019-10-17",[5599],"Nephrolithiasis, Uric Acid",[5580],{"trials":5602,"activeCount":119},[],{"intervention":5604,"totalTrials":724,"cells":5605},"Mycophenolate Mofetil",{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5610,"PHASE3":5633,"PHASE4":5642,"NA":5644},{"trials":5607,"activeCount":119},[],{"trials":5609,"activeCount":119},[],{"trials":5611,"activeCount":119},[5612,5619,5623],{"nctId":5613,"briefTitle":5614,"status":164,"phases":5615,"primaryCompletion":3161,"completion":3161,"start":5616,"enrollment":9,"conditions":5617,"interventions":5618},"NCT00324506","Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis",[90],"2006-05",[355],[5604],{"nctId":2170,"briefTitle":2171,"status":385,"phases":5620,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":5621,"interventions":5622},[90],[2176,2177],[2179,2148,2180,2181,2182,2183,2184],{"nctId":5624,"briefTitle":5625,"status":164,"phases":5626,"primaryCompletion":5231,"completion":5231,"start":5627,"conditions":5628,"interventions":5632},"NCT00044954","Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[90],"1999-11",[2176,2177,5629,5630,5631],"Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Diseases",[2179,2180,2181,2183],{"trials":5634,"activeCount":119},[5635],{"nctId":5636,"briefTitle":5637,"status":164,"phases":5638,"primaryCompletion":2959,"completion":2959,"start":5639,"enrollment":2893,"conditions":5640,"interventions":5641},"NCT00223301","Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis",[90,91],"2004-07",[355],[5604],{"trials":5643,"activeCount":119},[],{"trials":5645,"activeCount":119},[],{"intervention":5647,"totalTrials":360,"cells":5648},"Leptin",{"EARLY_PHASE1":5649,"PHASE1":5651,"PHASE2":5660,"PHASE3":5669,"PHASE4":5681,"NA":5683},{"trials":5650,"activeCount":119},[],{"trials":5652,"activeCount":119},[5653],{"nctId":5654,"briefTitle":5655,"status":385,"phases":5656,"primaryCompletion":4196,"completion":5657,"start":3160,"enrollment":5257,"conditions":5658,"interventions":5659},"NCT01268644","Effects of Metreleptin in Type 1 Diabetes Mellitus",[89],"2014-08",[3452],[5647],{"trials":5661,"activeCount":119},[5662],{"nctId":5663,"briefTitle":5664,"status":164,"phases":5665,"primaryCompletion":3206,"completion":3206,"start":2173,"enrollment":796,"conditions":5666,"interventions":5668},"NCT00461552","Therapeutic Approaches to HAART-Induced Lipodystrophy",[90],[3746,5667],"Lipodystrophy",[5647],{"trials":5670,"activeCount":119},[5671],{"nctId":5672,"briefTitle":5673,"status":164,"phases":5674,"primaryCompletion":3330,"completion":3330,"start":3092,"enrollment":16,"conditions":5675,"interventions":5680},"NCT00896298","Trial of Leptin Replacement Therapy in Patients With Lipodystrophy",[90,91],[5676,5677,5678,5679],"Hypoleptinemia","Generalized Lipodystrophy","Partial Lipodystrophy","Insulin Resistance",[5647],{"trials":5682,"activeCount":119},[],{"trials":5684,"activeCount":119},[],{"intervention":2835,"totalTrials":360,"cells":5686},{"EARLY_PHASE1":5687,"PHASE1":5689,"PHASE2":5695,"PHASE3":5707,"PHASE4":5720,"NA":5722},{"trials":5688,"activeCount":119},[],{"trials":5690,"activeCount":119},[5691],{"nctId":2827,"briefTitle":2828,"status":385,"phases":5692,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":5693,"interventions":5694},[89],[718],[2810,2835],{"trials":5696,"activeCount":119},[5697],{"nctId":5698,"briefTitle":5699,"status":385,"phases":5700,"primaryCompletion":5701,"completion":5701,"start":5702,"enrollment":360,"conditions":5703,"interventions":5705},"NCT03835728","Efficacy of Ocrelizumab in Autoimmune Encephalitis",[90],"2020-10-02","2019-01-22",[5704],"Autoimmune Encephalitis",[5706,2835],"Ocrelizumab",{"trials":5708,"activeCount":119},[5709],{"nctId":5710,"briefTitle":5711,"status":385,"phases":5712,"primaryCompletion":5713,"completion":5714,"start":5715,"enrollment":360,"conditions":5716,"interventions":5718},"NCT02219321","Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients",[91],"2015-05-14","2019-09-20","2014-12",[5717],"Chronic Pain",[5719,2835],"Lidocaine",{"trials":5721,"activeCount":119},[],{"trials":5723,"activeCount":119},[],{"intervention":5725,"totalTrials":97,"cells":5726},"Clopidogrel",{"EARLY_PHASE1":5727,"PHASE1":5729,"PHASE2":5740,"PHASE3":5742,"PHASE4":5754,"NA":5756},{"trials":5728,"activeCount":119},[],{"trials":5730,"activeCount":119},[5731],{"nctId":5732,"briefTitle":5733,"status":164,"phases":5734,"primaryCompletion":2891,"completion":5735,"start":4196,"enrollment":168,"conditions":5736,"interventions":5738},"NCT01768637","Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study",[89],"2014-06",[5737],"Chronic Kidney Disease",[5739,5725],"Aspirin",{"trials":5741,"activeCount":119},[],{"trials":5743,"activeCount":119},[5744],{"nctId":5745,"briefTitle":5746,"status":164,"phases":5747,"primaryCompletion":5748,"completion":5748,"start":1109,"enrollment":5749,"conditions":5750,"interventions":5752},"NCT02217501","Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities",[91],"2020-01-30",159,[5751],"Peripheral Arterial Disease",[5725,5753],"Acetylsalicylic acid",{"trials":5755,"activeCount":119},[],{"trials":5757,"activeCount":119},[],{"intervention":5719,"totalTrials":97,"cells":5759},{"EARLY_PHASE1":5760,"PHASE1":5762,"PHASE2":5764,"PHASE3":5780,"PHASE4":5786,"NA":5788},{"trials":5761,"activeCount":119},[],{"trials":5763,"activeCount":119},[],{"trials":5765,"activeCount":119},[5766],{"nctId":5767,"briefTitle":5768,"status":164,"phases":5769,"primaryCompletion":5770,"completion":5771,"start":5772,"enrollment":5773,"conditions":5774,"interventions":5778},"NCT05809453","Intranasal Cocaine and Temperature Regulation During Exercise",[89,90],"2024-06-05","2024-08-01","2023-09-01",27,[5775,5776,5777],"Hyperthermia","Cocaine Use","Exercise",[5779,5719],"Cocaine",{"trials":5781,"activeCount":119},[5782],{"nctId":5710,"briefTitle":5711,"status":385,"phases":5783,"primaryCompletion":5713,"completion":5714,"start":5715,"enrollment":360,"conditions":5784,"interventions":5785},[91],[5717],[5719,2835],{"trials":5787,"activeCount":119},[],{"trials":5789,"activeCount":119},[],{"intervention":5791,"totalTrials":97,"cells":5792},"Icariin",{"EARLY_PHASE1":5793,"PHASE1":5795,"PHASE2":5804,"PHASE3":5806,"PHASE4":5816,"NA":5818},{"trials":5794,"activeCount":119},[],{"trials":5796,"activeCount":119},[5797],{"nctId":5798,"briefTitle":5799,"status":164,"phases":5800,"primaryCompletion":5459,"completion":4917,"start":2891,"enrollment":2893,"conditions":5801,"interventions":5803},"NCT02112123","Icariin to Prevent Corticosteroid-related Memory Changes",[89],[5802],"the Pharmacokinetic Profile of Icariin in Humans",[5791],{"trials":5805,"activeCount":119},[],{"trials":5807,"activeCount":119},[5808],{"nctId":5809,"briefTitle":5810,"status":164,"phases":5811,"primaryCompletion":2820,"completion":2820,"start":5812,"enrollment":660,"conditions":5813,"interventions":5815},"NCT01979133","Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders",[91],"2013-10",[26,5814],"Substance Use Disorder",[5791],{"trials":5817,"activeCount":119},[],{"trials":5819,"activeCount":119},[],{"intervention":5821,"totalTrials":116,"cells":5822},"Low Dose Naloxone",{"EARLY_PHASE1":5823,"PHASE1":5825,"PHASE2":5827,"PHASE3":5829,"PHASE4":5838,"NA":5840},{"trials":5824,"activeCount":119},[],{"trials":5826,"activeCount":119},[],{"trials":5828,"activeCount":119},[],{"trials":5830,"activeCount":119},[5831],{"nctId":5832,"briefTitle":5833,"status":164,"phases":5834,"completion":2948,"start":5835,"enrollment":193,"conditions":5836,"interventions":5837},"NCT00286052","Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients",[91],"2002-12",[2824],[5821],{"trials":5839,"activeCount":119},[],{"trials":5841,"activeCount":119},[],{"intervention":5843,"totalTrials":116,"cells":5844},"Nifedipine",{"EARLY_PHASE1":5845,"PHASE1":5847,"PHASE2":5849,"PHASE3":5851,"PHASE4":5863,"NA":5865},{"trials":5846,"activeCount":119},[],{"trials":5848,"activeCount":119},[],{"trials":5850,"activeCount":119},[],{"trials":5852,"activeCount":119},[5853],{"nctId":5854,"briefTitle":5855,"status":164,"phases":5856,"primaryCompletion":5857,"completion":5857,"start":5858,"enrollment":5859,"conditions":5860,"interventions":5862},"NCT02132533","Nifedipine for Acute Tocolysis of Preterm Labor",[91],"2018-10-29","2014-05-05",88,[5861],"Preterm Labor",[5843],{"trials":5864,"activeCount":119},[],{"trials":5866,"activeCount":119},[],{"intervention":2907,"totalTrials":116,"cells":5868},{"EARLY_PHASE1":5869,"PHASE1":5871,"PHASE2":5873,"PHASE3":5875,"PHASE4":5881,"NA":5883},{"trials":5870,"activeCount":119},[],{"trials":5872,"activeCount":119},[],{"trials":5874,"activeCount":119},[],{"trials":5876,"activeCount":119},[5877],{"nctId":2901,"briefTitle":2902,"status":164,"phases":5878,"primaryCompletion":1028,"completion":1028,"start":2904,"enrollment":27,"conditions":5879,"interventions":5880},[91],[718],[2907,2868],{"trials":5882,"activeCount":119},[],{"trials":5884,"activeCount":119},[],{"intervention":5753,"totalTrials":116,"cells":5886},{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5893,"PHASE4":5899,"NA":5901},{"trials":5888,"activeCount":119},[],{"trials":5890,"activeCount":119},[],{"trials":5892,"activeCount":119},[],{"trials":5894,"activeCount":119},[5895],{"nctId":5745,"briefTitle":5746,"status":164,"phases":5896,"primaryCompletion":5748,"completion":5748,"start":1109,"enrollment":5749,"conditions":5897,"interventions":5898},[91],[5751],[5725,5753],{"trials":5900,"activeCount":119},[],{"trials":5902,"activeCount":119},[],{"intervention":5904,"totalTrials":116,"cells":5905},"Nuvigil",{"EARLY_PHASE1":5906,"PHASE1":5908,"PHASE2":5910,"PHASE3":5912,"PHASE4":5923,"NA":5925},{"trials":5907,"activeCount":119},[],{"trials":5909,"activeCount":119},[],{"trials":5911,"activeCount":119},[],{"trials":5913,"activeCount":119},[5914],{"nctId":5915,"briefTitle":5916,"status":164,"phases":5917,"primaryCompletion":3850,"completion":5918,"start":3440,"enrollment":5919,"conditions":5920,"interventions":5922},"NCT02478580","Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients",[91],"2016-01",67,[23,5921],"Premature Recovery From Anesthesia",[5904],{"trials":5924,"activeCount":119},[],{"trials":5926,"activeCount":119},[],{"intervention":5928,"totalTrials":116,"cells":5929},"Continuation phase fluoxetine",{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5934,"PHASE3":5936,"PHASE4":5947,"NA":5949},{"trials":5931,"activeCount":119},[],{"trials":5933,"activeCount":119},[],{"trials":5935,"activeCount":119},[],{"trials":5937,"activeCount":119},[5938],{"nctId":5939,"briefTitle":5940,"status":164,"phases":5941,"primaryCompletion":5942,"completion":5942,"start":5943,"enrollment":5944,"conditions":5945,"interventions":5946},"NCT00118404","Cognitive Therapy for Recurrent Depression",[91],"2008-07","2000-03",523,[15],[5928],{"trials":5948,"activeCount":119},[],{"trials":5950,"activeCount":119},[],{"intervention":5952,"totalTrials":116,"cells":5953},"Tranexamic Acid",{"EARLY_PHASE1":5954,"PHASE1":5956,"PHASE2":5958,"PHASE3":5960,"PHASE4":5974,"NA":5976},{"trials":5955,"activeCount":119},[],{"trials":5957,"activeCount":119},[],{"trials":5959,"activeCount":119},[],{"trials":5961,"activeCount":119},[5962],{"nctId":5963,"briefTitle":5964,"status":164,"phases":5965,"primaryCompletion":5966,"completion":5967,"start":5968,"enrollment":3941,"conditions":5969,"interventions":5973},"NCT03856164","Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery",[90,91],"2020-01-10","2020-08-31","2019-06-17",[5970,5971,5972],"Post Partum Hemorrhage","Fibrinolysis; Hemorrhage","Blood Loss",[5952],{"trials":5975,"activeCount":119},[],{"trials":5977,"activeCount":119},[],{"intervention":2850,"totalTrials":116,"cells":5979},{"EARLY_PHASE1":5980,"PHASE1":5982,"PHASE2":5984,"PHASE3":5986,"PHASE4":5992,"NA":5994},{"trials":5981,"activeCount":119},[],{"trials":5983,"activeCount":119},[],{"trials":5985,"activeCount":119},[],{"trials":5987,"activeCount":119},[5988],{"nctId":2841,"briefTitle":2842,"status":951,"phases":5989,"primaryCompletion":2844,"completion":2845,"start":2846,"enrollment":119,"conditions":5990,"interventions":5991},[91],[2848],[2850,2810],{"trials":5993,"activeCount":119},[],{"trials":5995,"activeCount":119},[],{"intervention":5997,"totalTrials":116,"cells":5998},"Deferasirox",{"EARLY_PHASE1":5999,"PHASE1":6001,"PHASE2":6003,"PHASE3":6005,"PHASE4":6015,"NA":6017},{"trials":6000,"activeCount":119},[],{"trials":6002,"activeCount":119},[],{"trials":6004,"activeCount":119},[],{"trials":6006,"activeCount":119},[6007],{"nctId":6008,"briefTitle":6009,"status":164,"phases":6010,"primaryCompletion":6011,"completion":6011,"start":2904,"enrollment":660,"conditions":6012,"interventions":6014},"NCT00599326","Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda",[91],"2010-04",[6013],"Porphyria Cutanea Tarda",[5997],{"trials":6016,"activeCount":119},[],{"trials":6018,"activeCount":119},[],{"intervention":6020,"totalTrials":116,"cells":6021},"PCA plus methadone",{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6026,"PHASE3":6028,"PHASE4":6043,"NA":6045},{"trials":6023,"activeCount":119},[],{"trials":6025,"activeCount":119},[],{"trials":6027,"activeCount":119},[],{"trials":6029,"activeCount":119},[6030],{"nctId":6031,"briefTitle":6032,"status":6033,"phases":6034,"primaryCompletion":6035,"completion":736,"start":6036,"enrollment":833,"conditions":6037,"interventions":6041},"NCT06940570","Methadone as an Alternative Treatment for Children Underdoing HSCT","SUSPENDED",[91],"2029-08","2028-01-01",[2176,6038,6039,6040],"Aplastic Anemia","Bone Marrow Failure Syndromes","SCID",[6020,6042],"PCA Alone",{"trials":6044,"activeCount":119},[],{"trials":6046,"activeCount":119},[],{"intervention":6042,"totalTrials":116,"cells":6048},{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6055,"PHASE4":6061,"NA":6063},{"trials":6050,"activeCount":119},[],{"trials":6052,"activeCount":119},[],{"trials":6054,"activeCount":119},[],{"trials":6056,"activeCount":119},[6057],{"nctId":6031,"briefTitle":6032,"status":6033,"phases":6058,"primaryCompletion":6035,"completion":736,"start":6036,"enrollment":833,"conditions":6059,"interventions":6060},[91],[2176,6038,6039,6040],[6020,6042],{"trials":6062,"activeCount":119},[],{"trials":6064,"activeCount":119},[],{"intervention":6066,"totalTrials":116,"cells":6067},"Naltrexone: Vivitrol®",{"EARLY_PHASE1":6068,"PHASE1":6070,"PHASE2":6072,"PHASE3":6074,"PHASE4":6087,"NA":6089},{"trials":6069,"activeCount":119},[],{"trials":6071,"activeCount":119},[],{"trials":6073,"activeCount":119},[],{"trials":6075,"activeCount":119},[6076],{"nctId":6077,"briefTitle":6078,"status":164,"phases":6079,"primaryCompletion":6080,"completion":6081,"start":6082,"enrollment":6083,"conditions":6084,"interventions":6085},"NCT03078075","Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder",[91],"2019-07-03","2019-07-25","2017-05-05",403,[1312],[6066,6086],"Bupropion: Wellbutrin XL®",{"trials":6088,"activeCount":119},[],{"trials":6090,"activeCount":119},[],{"intervention":6086,"totalTrials":116,"cells":6092},{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6099,"PHASE4":6105,"NA":6107},{"trials":6094,"activeCount":119},[],{"trials":6096,"activeCount":119},[],{"trials":6098,"activeCount":119},[],{"trials":6100,"activeCount":119},[6101],{"nctId":6077,"briefTitle":6078,"status":164,"phases":6102,"primaryCompletion":6080,"completion":6081,"start":6082,"enrollment":6083,"conditions":6103,"interventions":6104},[91],[1312],[6066,6086],{"trials":6106,"activeCount":119},[],{"trials":6108,"activeCount":119},[],{"intervention":6110,"totalTrials":116,"cells":6111},"Eltrombopag",{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6118,"PHASE4":6130,"NA":6132},{"trials":6113,"activeCount":119},[],{"trials":6115,"activeCount":119},[],{"trials":6117,"activeCount":119},[],{"trials":6119,"activeCount":119},[6120],{"nctId":6121,"briefTitle":6122,"status":385,"phases":6123,"primaryCompletion":6124,"completion":6125,"start":4338,"enrollment":975,"conditions":6126,"interventions":6129},"NCT01821625","Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C",[90,91],"2015-04","2016-04",[6127,6128],"Thrombocytopenia","Hepatitis C",[6110],{"trials":6131,"activeCount":119},[],{"trials":6133,"activeCount":119},[],{"intervention":6135,"totalTrials":116,"cells":6136},"Nutropin",{"EARLY_PHASE1":6137,"PHASE1":6139,"PHASE2":6141,"PHASE3":6143,"PHASE4":6153,"NA":6155},{"trials":6138,"activeCount":119},[],{"trials":6140,"activeCount":119},[],{"trials":6142,"activeCount":119},[],{"trials":6144,"activeCount":119},[6145],{"nctId":6146,"briefTitle":6147,"status":951,"phases":6148,"primaryCompletion":6149,"completion":6149,"start":6149,"enrollment":119,"conditions":6150,"interventions":6152},"NCT00286676","The Use of Nutropin Depot in HIV-infected Adult Males",[90,91],"2006-02-01",[6151],"HIV Infection",[6135],{"trials":6154,"activeCount":119},[],{"trials":6156,"activeCount":119},[],{"intervention":6158,"totalTrials":116,"cells":6159},"Probio-Tec BG-VCap-6.5",{"EARLY_PHASE1":6160,"PHASE1":6162,"PHASE2":6164,"PHASE3":6166,"PHASE4":6177,"NA":6179},{"trials":6161,"activeCount":119},[],{"trials":6163,"activeCount":119},[],{"trials":6165,"activeCount":119},[],{"trials":6167,"activeCount":119},[6168],{"nctId":6169,"briefTitle":6170,"status":164,"phases":6171,"primaryCompletion":6172,"completion":6172,"start":6173,"enrollment":5919,"conditions":6174,"interventions":6176},"NCT03383874","A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania",[91],"2024-09-23","2018-09-06",[6175],"Mania (Neurotic)",[6158],{"trials":6178,"activeCount":119},[],{"trials":6180,"activeCount":119},[],{"intervention":6182,"totalTrials":116,"cells":6183},"Nutropin AQ",{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6190,"PHASE4":6200,"NA":6202},{"trials":6185,"activeCount":119},[],{"trials":6187,"activeCount":119},[],{"trials":6189,"activeCount":119},[],{"trials":6191,"activeCount":119},[6192],{"nctId":6193,"briefTitle":6194,"status":951,"phases":6195,"primaryCompletion":6196,"completion":6196,"start":6197,"enrollment":119,"conditions":6198,"interventions":6199},"NCT00256555","Growth Hormone Treatment Study in Children With Cystic Fibrosis",[90,91],"2018-12-12","2000-02",[264],[6182],{"trials":6201,"activeCount":119},[],{"trials":6203,"activeCount":119},[],{"intervention":6205,"totalTrials":116,"cells":6206},"Angiotensin II receptor blocker",{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6213,"PHASE4":6228,"NA":6230},{"trials":6208,"activeCount":119},[],{"trials":6210,"activeCount":119},[],{"trials":6212,"activeCount":119},[],{"trials":6214,"activeCount":119},[6215],{"nctId":6216,"briefTitle":6217,"status":164,"phases":6218,"primaryCompletion":6219,"completion":6220,"start":6221,"enrollment":6222,"conditions":6223,"interventions":6227},"NCT02913664","Risk Reduction for Alzheimer's Disease",[90,91],"2021-11-30","2022-01-31","2017-02-02",513,[6224,18,6225,6226],"Cognitively Normal Older Adults","Subjective Cognitive Decline","Family History of Alzheimer's Disease",[6205],{"trials":6229,"activeCount":119},[],{"trials":6231,"activeCount":119},[],{"intervention":6233,"totalTrials":116,"cells":6234},"lyrica",{"EARLY_PHASE1":6235,"PHASE1":6237,"PHASE2":6239,"PHASE3":6241,"PHASE4":6252,"NA":6254},{"trials":6236,"activeCount":119},[],{"trials":6238,"activeCount":119},[],{"trials":6240,"activeCount":119},[],{"trials":6242,"activeCount":119},[6243],{"nctId":6244,"briefTitle":6245,"status":164,"phases":6246,"primaryCompletion":6247,"completion":3386,"start":6248,"enrollment":1221,"conditions":6249,"interventions":6251},"NCT01391858","Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica",[91],"2012-11","2006-12",[6250],"Post-operative Pain",[6233],{"trials":6253,"activeCount":119},[],{"trials":6255,"activeCount":119},[],{"intervention":6257,"totalTrials":116,"cells":6258},"13C-Methacetin",{"EARLY_PHASE1":6259,"PHASE1":6261,"PHASE2":6263,"PHASE3":6265,"PHASE4":6276,"NA":6278},{"trials":6260,"activeCount":119},[],{"trials":6262,"activeCount":119},[],{"trials":6264,"activeCount":119},[],{"trials":6266,"activeCount":119},[6267],{"nctId":6268,"briefTitle":6269,"status":164,"phases":6270,"primaryCompletion":6271,"completion":6271,"start":6272,"enrollment":6273,"conditions":6274,"interventions":6275},"NCT02786836","13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF",[90,91],"2019-09-18","2016-06-10",76,[3625],[6257],{"trials":6277,"activeCount":119},[],{"trials":6279,"activeCount":119},[],{"intervention":6281,"totalTrials":650,"cells":6282},"Nab-Paclitaxel",{"EARLY_PHASE1":6283,"PHASE1":6285,"PHASE2":6291,"PHASE3":6319,"PHASE4":6321,"NA":6323},{"trials":6284,"activeCount":119},[],{"trials":6286,"activeCount":119},[6287],{"nctId":411,"briefTitle":412,"status":385,"phases":6288,"primaryCompletion":414,"completion":415,"start":416,"enrollment":27,"conditions":6289,"interventions":6290},[89],[418],[420,404,421],{"trials":6292,"activeCount":119},[6293,6297,6305,6309],{"nctId":425,"briefTitle":426,"status":385,"phases":6294,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":6295,"interventions":6296},[89,90],[432],[434,435,404,436],{"nctId":6298,"briefTitle":6299,"status":164,"phases":6300,"primaryCompletion":3850,"completion":6301,"start":3450,"enrollment":1918,"conditions":6302,"interventions":6303},"NCT00833261","Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer",[90],"2016-05",[1688],[6304,1072,6281],"cetuximab",{"nctId":999,"briefTitle":1000,"status":164,"phases":6306,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":1004,"conditions":6307,"interventions":6308},[89,90],[1006],[1008,1009,1008],{"nctId":6310,"briefTitle":6311,"status":164,"phases":6312,"primaryCompletion":6313,"completion":6314,"start":6315,"enrollment":1918,"conditions":6316,"interventions":6317},"NCT00851877","Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer",[89,90],"2013-10-01","2015-08-03","2009-03-01",[1688],[6318,436,6281],"Cetuximab",{"trials":6320,"activeCount":119},[],{"trials":6322,"activeCount":119},[],{"trials":6324,"activeCount":119},[],{"intervention":436,"totalTrials":724,"cells":6326},{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6331,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6328,"activeCount":119},[],{"trials":6330,"activeCount":119},[],{"trials":6332,"activeCount":119},[6333,6337,6341,6345],{"nctId":425,"briefTitle":426,"status":385,"phases":6334,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":6335,"interventions":6336},[89,90],[432],[434,435,404,436],{"nctId":1061,"briefTitle":1062,"status":164,"phases":6338,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":6339,"interventions":6340},[90],[1069],[1071,1072,1073],{"nctId":6298,"briefTitle":6299,"status":164,"phases":6342,"primaryCompletion":3850,"completion":6301,"start":3450,"enrollment":1918,"conditions":6343,"interventions":6344},[90],[1688],[6304,1072,6281],{"nctId":6310,"briefTitle":6311,"status":164,"phases":6346,"primaryCompletion":6313,"completion":6314,"start":6315,"enrollment":1918,"conditions":6347,"interventions":6348},[89,90],[1688],[6318,436,6281],{"trials":6350,"activeCount":119},[],{"trials":6352,"activeCount":119},[],{"trials":6354,"activeCount":119},[],{"intervention":6356,"totalTrials":360,"cells":6357},"Capecitabine",{"EARLY_PHASE1":6358,"PHASE1":6360,"PHASE2":6373,"PHASE3":6394,"PHASE4":6396,"NA":6398},{"trials":6359,"activeCount":119},[],{"trials":6361,"activeCount":119},[6362],{"nctId":6363,"briefTitle":6364,"status":164,"phases":6365,"primaryCompletion":6366,"completion":6367,"start":6368,"enrollment":109,"conditions":6369,"interventions":6371},"NCT01634685","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma",[89],"2015-10-30","2017-10-06","2012-08-08",[6370],"Rectal Adenocarcinoma",[6372,6356],"Bavituximab",{"trials":6374,"activeCount":119},[6375,6383],{"nctId":6376,"briefTitle":6377,"status":164,"phases":6378,"primaryCompletion":5133,"completion":5482,"start":6379,"enrollment":702,"conditions":6380,"interventions":6381},"NCT00562718","Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery",[90],"2004-09",[20],[6382],"capecitabine",{"nctId":6384,"briefTitle":6385,"status":951,"phases":6386,"primaryCompletion":6247,"completion":6247,"start":3648,"enrollment":119,"conditions":6387,"interventions":6390},"NCT01302613","Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma",[89,90],[6388,6389],"Stage II Rectal Cancer","Stage III Rectal Cancer",[6356,6391,6392,6393],"5-FU","Leucovorin","Oxaliplatin",{"trials":6395,"activeCount":119},[],{"trials":6397,"activeCount":119},[],{"trials":6399,"activeCount":119},[],{"intervention":6401,"totalTrials":97,"cells":6402},"Ceritinib",{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6407,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6404,"activeCount":119},[],{"trials":6406,"activeCount":119},[],{"trials":6408,"activeCount":119},[6409,6418],{"nctId":6410,"briefTitle":6411,"status":385,"phases":6412,"primaryCompletion":6413,"completion":6414,"start":1109,"enrollment":3598,"conditions":6415,"interventions":6417},"NCT02513667","Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma",[90],"2020-05-29","2021-05-29",[6416],"ALK-positive Non-small Cell Lung Cancer",[6401],{"nctId":6419,"briefTitle":6420,"status":951,"phases":6421,"primaryCompletion":6422,"completion":6422,"start":2820,"enrollment":119,"conditions":6423,"interventions":6426},"NCT02289144","Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer",[90],"2019-01",[6424,6425],"Metastatic Anaplastic Thyroid Cancer","Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer",[6401],{"trials":6428,"activeCount":119},[],{"trials":6430,"activeCount":119},[],{"trials":6432,"activeCount":119},[],{"intervention":2885,"totalTrials":97,"cells":6434},{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6447,"PHASE3":6453,"PHASE4":6455,"NA":6457},{"trials":6436,"activeCount":119},[],{"trials":6438,"activeCount":119},[6439],{"nctId":6440,"briefTitle":6441,"status":385,"phases":6442,"primaryCompletion":6443,"completion":6443,"start":6444,"enrollment":724,"conditions":6445,"interventions":6446},"NCT02574910","Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1",[89],"2023-06-03","2017-08-01",[2883],[2885],{"trials":6448,"activeCount":119},[6449],{"nctId":2877,"briefTitle":2878,"status":951,"phases":6450,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":119,"conditions":6451,"interventions":6452},[90],[2883],[2885,2868,2886],{"trials":6454,"activeCount":119},[],{"trials":6456,"activeCount":119},[],{"trials":6458,"activeCount":119},[],{"intervention":6460,"totalTrials":97,"cells":6461},"Premarin IV",{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6481,"PHASE4":6483,"NA":6485},{"trials":6463,"activeCount":119},[],{"trials":6465,"activeCount":119},[],{"trials":6467,"activeCount":119},[6468,6474],{"nctId":6469,"briefTitle":6470,"status":164,"phases":6471,"primaryCompletion":3916,"completion":3827,"start":1028,"enrollment":702,"conditions":6472,"interventions":6473},"NCT00973674","Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury",[90],[662],[6460],{"nctId":6475,"briefTitle":6476,"status":164,"phases":6477,"primaryCompletion":3916,"completion":3827,"start":1028,"enrollment":702,"conditions":6478,"interventions":6480},"NCT00973102","Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)",[90],[6479],"Hemorrhagic Shock",[6460],{"trials":6482,"activeCount":119},[],{"trials":6484,"activeCount":119},[],{"trials":6486,"activeCount":119},[],{"intervention":6488,"totalTrials":97,"cells":6489},"Durvalumab",{"EARLY_PHASE1":6490,"PHASE1":6492,"PHASE2":6494,"PHASE3":6514,"PHASE4":6516,"NA":6518},{"trials":6491,"activeCount":119},[],{"trials":6493,"activeCount":119},[],{"trials":6495,"activeCount":119},[6496,6505],{"nctId":6497,"briefTitle":6498,"status":951,"phases":6499,"primaryCompletion":6500,"completion":6500,"start":6501,"enrollment":119,"conditions":6502,"interventions":6504},"NCT04889066","Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases",[90],"2025-01","2024-10-01",[6503],"Brain Metastases from Non-small Cell Lung Cancer",[6488],{"nctId":6506,"briefTitle":6507,"status":385,"phases":6508,"primaryCompletion":6509,"completion":6509,"start":6510,"enrollment":116,"conditions":6511,"interventions":6513},"NCT04786093","Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC",[90],"2022-06-09","2021-07-27",[6512],"Non Small Cell Lung Cancer",[6488],{"trials":6515,"activeCount":119},[],{"trials":6517,"activeCount":119},[],{"trials":6519,"activeCount":119},[],{"intervention":6521,"totalTrials":97,"cells":6522},"Avelumab",{"EARLY_PHASE1":6523,"PHASE1":6525,"PHASE2":6527,"PHASE3":6549,"PHASE4":6551,"NA":6553},{"trials":6524,"activeCount":119},[],{"trials":6526,"activeCount":119},[],{"trials":6528,"activeCount":119},[6529,6540],{"nctId":6530,"briefTitle":6531,"status":385,"phases":6532,"primaryCompletion":6533,"completion":6533,"start":6534,"enrollment":650,"conditions":6535,"interventions":6539},"NCT03312114","Anti-PD-L1 and SAbR for Ovarian Cancer",[90],"2019-03-19","2017-11-09",[6536,6537,6538],"Recurrent Epithelial Cancer of Ovary","Primary Peritoneal Carcinoma","Fallopian Tube Cancer",[6521],{"nctId":6541,"briefTitle":6542,"status":385,"phases":6543,"primaryCompletion":6544,"completion":6544,"start":6545,"enrollment":116,"conditions":6546,"interventions":6547},"NCT05249569","Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma",[90],"2022-12-30","2022-11-04",[1272],[6548,6521,6372],"Axitinib",{"trials":6550,"activeCount":119},[],{"trials":6552,"activeCount":119},[],{"trials":6554,"activeCount":119},[],{"intervention":6556,"totalTrials":97,"cells":6557},"Triheptanoin",{"EARLY_PHASE1":6558,"PHASE1":6560,"PHASE2":6562,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6559,"activeCount":119},[],{"trials":6561,"activeCount":119},[],{"trials":6563,"activeCount":119},[6564,6574],{"nctId":6565,"briefTitle":6566,"status":164,"phases":6567,"primaryCompletion":6568,"completion":6569,"start":6570,"enrollment":660,"conditions":6571,"interventions":6573},"NCT03301532","Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D",[90],"2021-06-18","2022-07-31","2018-06-05",[6572],"GLUT1DS1",[6556],{"nctId":6575,"briefTitle":6576,"status":164,"phases":6577,"primaryCompletion":6578,"completion":6578,"start":6579,"enrollment":1310,"conditions":6580,"interventions":6586},"NCT03181399","Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)",[90],"2023-09-10","2018-04-18",[6572,2415,6581,6582,6583,6584,6585],"Glut1 Deficiency Syndrome 1, Autosomal Recessive","Glucose Metabolism Disorders","Glucose Transport Defect","Glucose Transporter Type 1 Deficiency Syndrome","Glucose Transporter Protein Type 1 Deficiency Syndrome",[6556],{"trials":6588,"activeCount":119},[],{"trials":6590,"activeCount":119},[],{"trials":6592,"activeCount":119},[],{"intervention":6594,"totalTrials":97,"cells":6595},"Docetaxel",{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6609,"PHASE3":6622,"PHASE4":6624,"NA":6626},{"trials":6597,"activeCount":119},[],{"trials":6599,"activeCount":119},[6600],{"nctId":6601,"briefTitle":6602,"status":164,"phases":6603,"primaryCompletion":6604,"completion":3124,"start":3172,"enrollment":796,"conditions":6605,"interventions":6607},"NCT02922777","Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.",[89],"2023-02-06",[6606],"Non-Small Cell Lung Carcinoma",[6608,6594],"BGB324",{"trials":6610,"activeCount":119},[6611],{"nctId":6612,"briefTitle":6613,"status":385,"phases":6614,"primaryCompletion":6615,"completion":6616,"start":6617,"enrollment":1483,"conditions":6618,"interventions":6620},"NCT03095612","Phase 1\u002F2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)",[89,90],"2022-11-08","2023-03-03","2018-03-22",[6619],"Non-small Cell Lung Cancer",[6621,6594],"Selinexor",{"trials":6623,"activeCount":119},[],{"trials":6625,"activeCount":119},[],{"trials":6627,"activeCount":119},[],{"intervention":6304,"totalTrials":97,"cells":6629},{"EARLY_PHASE1":6630,"PHASE1":6632,"PHASE2":6634,"PHASE3":6644,"PHASE4":6646,"NA":6648},{"trials":6631,"activeCount":119},[],{"trials":6633,"activeCount":119},[],{"trials":6635,"activeCount":119},[6636,6640],{"nctId":6298,"briefTitle":6299,"status":164,"phases":6637,"primaryCompletion":3850,"completion":6301,"start":3450,"enrollment":1918,"conditions":6638,"interventions":6639},[90],[1688],[6304,1072,6281],{"nctId":6310,"briefTitle":6311,"status":164,"phases":6641,"primaryCompletion":6313,"completion":6314,"start":6315,"enrollment":1918,"conditions":6642,"interventions":6643},[89,90],[1688],[6318,436,6281],{"trials":6645,"activeCount":119},[],{"trials":6647,"activeCount":119},[],{"trials":6649,"activeCount":119},[],{"intervention":2182,"totalTrials":97,"cells":6651},{"EARLY_PHASE1":6652,"PHASE1":6654,"PHASE2":6656,"PHASE3":6676,"PHASE4":6678,"NA":6680},{"trials":6653,"activeCount":119},[],{"trials":6655,"activeCount":119},[],{"trials":6657,"activeCount":119},[6658,6672],{"nctId":6659,"briefTitle":6660,"status":951,"phases":6661,"primaryCompletion":6662,"completion":6662,"start":6663,"enrollment":119,"conditions":6664,"interventions":6668},"NCT00621036","Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma",[90],"2008-12-08","2007-10-19",[6665,2177,6666,6667],"Brain and Central Nervous System Tumors","Lymphoproliferative Disorder","Small Intestine Cancer",[6669,6670,2182,6671],"autologous immunoglobulin idiotype-KLH conjugate vaccine","sargramostim","thiotepa",{"nctId":2170,"briefTitle":2171,"status":385,"phases":6673,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":6674,"interventions":6675},[90],[2176,2177],[2179,2148,2180,2181,2182,2183,2184],{"trials":6677,"activeCount":119},[],{"trials":6679,"activeCount":119},[],{"trials":6681,"activeCount":119},[],{"intervention":2179,"totalTrials":97,"cells":6683},{"EARLY_PHASE1":6684,"PHASE1":6686,"PHASE2":6688,"PHASE3":6698,"PHASE4":6700,"NA":6702},{"trials":6685,"activeCount":119},[],{"trials":6687,"activeCount":119},[],{"trials":6689,"activeCount":119},[6690,6694],{"nctId":2170,"briefTitle":2171,"status":385,"phases":6691,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":6692,"interventions":6693},[90],[2176,2177],[2179,2148,2180,2181,2182,2183,2184],{"nctId":5624,"briefTitle":5625,"status":164,"phases":6695,"primaryCompletion":5231,"completion":5231,"start":5627,"conditions":6696,"interventions":6697},[90],[2176,2177,5629,5630,5631],[2179,2180,2181,2183],{"trials":6699,"activeCount":119},[],{"trials":6701,"activeCount":119},[],{"trials":6703,"activeCount":119},[],{"intervention":2180,"totalTrials":97,"cells":6705},{"EARLY_PHASE1":6706,"PHASE1":6708,"PHASE2":6710,"PHASE3":6720,"PHASE4":6722,"NA":6724},{"trials":6707,"activeCount":119},[],{"trials":6709,"activeCount":119},[],{"trials":6711,"activeCount":119},[6712,6716],{"nctId":2170,"briefTitle":2171,"status":385,"phases":6713,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":6714,"interventions":6715},[90],[2176,2177],[2179,2148,2180,2181,2182,2183,2184],{"nctId":5624,"briefTitle":5625,"status":164,"phases":6717,"primaryCompletion":5231,"completion":5231,"start":5627,"conditions":6718,"interventions":6719},[90],[2176,2177,5629,5630,5631],[2179,2180,2181,2183],{"trials":6721,"activeCount":119},[],{"trials":6723,"activeCount":119},[],{"trials":6725,"activeCount":119},[],{"intervention":2181,"totalTrials":97,"cells":6727},{"EARLY_PHASE1":6728,"PHASE1":6730,"PHASE2":6732,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6729,"activeCount":119},[],{"trials":6731,"activeCount":119},[],{"trials":6733,"activeCount":119},[6734,6738],{"nctId":2170,"briefTitle":2171,"status":385,"phases":6735,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":6736,"interventions":6737},[90],[2176,2177],[2179,2148,2180,2181,2182,2183,2184],{"nctId":5624,"briefTitle":5625,"status":164,"phases":6739,"primaryCompletion":5231,"completion":5231,"start":5627,"conditions":6740,"interventions":6741},[90],[2176,2177,5629,5630,5631],[2179,2180,2181,2183],{"trials":6743,"activeCount":119},[],{"trials":6745,"activeCount":119},[],{"trials":6747,"activeCount":119},[],{"intervention":6372,"totalTrials":97,"cells":6749},{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6758,"PHASE3":6764,"PHASE4":6766,"NA":6768},{"trials":6751,"activeCount":119},[],{"trials":6753,"activeCount":119},[6754],{"nctId":6363,"briefTitle":6364,"status":164,"phases":6755,"primaryCompletion":6366,"completion":6367,"start":6368,"enrollment":109,"conditions":6756,"interventions":6757},[89],[6370],[6372,6356],{"trials":6759,"activeCount":119},[6760],{"nctId":6541,"briefTitle":6542,"status":385,"phases":6761,"primaryCompletion":6544,"completion":6544,"start":6545,"enrollment":116,"conditions":6762,"interventions":6763},[90],[1272],[6548,6521,6372],{"trials":6765,"activeCount":119},[],{"trials":6767,"activeCount":119},[],{"trials":6769,"activeCount":119},[],{"intervention":6771,"totalTrials":97,"cells":6772},"enoxaparin",{"EARLY_PHASE1":6773,"PHASE1":6775,"PHASE2":6785,"PHASE3":6802,"PHASE4":6804,"NA":6806},{"trials":6774,"activeCount":119},[],{"trials":6776,"activeCount":119},[6777],{"nctId":6778,"briefTitle":6779,"status":164,"phases":6780,"primaryCompletion":6781,"completion":6781,"start":5482,"enrollment":389,"conditions":6782,"interventions":6784},"NCT01014403","Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)",[89],"2011-05",[6783,662],"Venous Thromboembolism",[6771],{"trials":6786,"activeCount":119},[6787],{"nctId":6788,"briefTitle":6789,"status":385,"phases":6790,"primaryCompletion":3136,"completion":6791,"start":6792,"enrollment":6793,"conditions":6794,"interventions":6800},"NCT00633061","Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer",[90],"2011-12","2008-06",136,[6795,6796,6797,6798,6799],"Childhood Cancer","Central Venous Catheters","Deep Vein Thrombosis","Catheter-related Infection","Catheter-related Occlusion",[6801],"Enoxaparin",{"trials":6803,"activeCount":119},[],{"trials":6805,"activeCount":119},[],{"trials":6807,"activeCount":119},[],{"intervention":6809,"totalTrials":97,"cells":6810},"ixabepilone",{"EARLY_PHASE1":6811,"PHASE1":6813,"PHASE2":6815,"PHASE3":6834,"PHASE4":6836,"NA":6838},{"trials":6812,"activeCount":119},[],{"trials":6814,"activeCount":119},[],{"trials":6816,"activeCount":119},[6817,6825],{"nctId":6818,"briefTitle":6819,"status":951,"phases":6820,"primaryCompletion":6821,"completion":6821,"start":6822,"enrollment":119,"conditions":6823,"interventions":6824},"NCT01079793","Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery",[89,90],"2011-10-17","2010-05-26",[32],[6809],{"nctId":6826,"briefTitle":6827,"status":951,"phases":6828,"primaryCompletion":6124,"completion":6124,"start":6829,"enrollment":119,"conditions":6830,"interventions":6832},"NCT01818999","Ixabepilone and SBRT For Metastatic Breast Cancer",[90],"2013-08",[6831],"METASTATIC BREAST CANCER",[6833],"IXABEPILONE",{"trials":6835,"activeCount":119},[],{"trials":6837,"activeCount":119},[],{"trials":6839,"activeCount":119},[],{"intervention":1033,"totalTrials":97,"cells":6841},{"EARLY_PHASE1":6842,"PHASE1":6844,"PHASE2":6846,"PHASE3":6862,"PHASE4":6864,"NA":6866},{"trials":6843,"activeCount":119},[],{"trials":6845,"activeCount":119},[],{"trials":6847,"activeCount":119},[6848,6858],{"nctId":6849,"briefTitle":6850,"status":951,"phases":6851,"primaryCompletion":6852,"completion":6852,"start":6853,"enrollment":119,"conditions":6854,"interventions":6856},"NCT00562185","Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer",[89,90],"2009-03","2008-05",[6855],"Ovarian Cancer",[1033,6857],"doxorubicin hydrochloride",{"nctId":1025,"briefTitle":1026,"status":951,"phases":6859,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":119,"conditions":6860,"interventions":6861},[89,90],[1031],[1033,990,1023],{"trials":6863,"activeCount":119},[],{"trials":6865,"activeCount":119},[],{"trials":6867,"activeCount":119},[],{"intervention":1023,"totalTrials":97,"cells":6869},{"EARLY_PHASE1":6870,"PHASE1":6872,"PHASE2":6874,"PHASE3":6884,"PHASE4":6886,"NA":6888},{"trials":6871,"activeCount":119},[],{"trials":6873,"activeCount":119},[],{"trials":6875,"activeCount":119},[6876,6880],{"nctId":1015,"briefTitle":1016,"status":385,"phases":6877,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":6878,"interventions":6879},[90],[20],[990,1023],{"nctId":1025,"briefTitle":1026,"status":951,"phases":6881,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":119,"conditions":6882,"interventions":6883},[89,90],[1031],[1033,990,1023],{"trials":6885,"activeCount":119},[],{"trials":6887,"activeCount":119},[],{"trials":6889,"activeCount":119},[],{"intervention":6891,"totalTrials":116,"cells":6892},"Furoscix",{"EARLY_PHASE1":6893,"PHASE1":6895,"PHASE2":6897,"PHASE3":6908,"PHASE4":6910,"NA":6912},{"trials":6894,"activeCount":119},[],{"trials":6896,"activeCount":119},[],{"trials":6898,"activeCount":119},[6899],{"nctId":6900,"briefTitle":6901,"status":164,"phases":6902,"primaryCompletion":6903,"completion":5044,"start":6904,"enrollment":4381,"conditions":6905,"interventions":6906},"NCT05528588","Furoscix in Heart Failure Patients With Diuretic Resistance",[90],"2024-04-22","2023-06-02",[35],[6891,6907],"Diuretic Therapy",{"trials":6909,"activeCount":119},[],{"trials":6911,"activeCount":119},[],{"trials":6913,"activeCount":119},[],{"intervention":6907,"totalTrials":116,"cells":6915},{"EARLY_PHASE1":6916,"PHASE1":6918,"PHASE2":6920,"PHASE3":6926,"PHASE4":6928,"NA":6930},{"trials":6917,"activeCount":119},[],{"trials":6919,"activeCount":119},[],{"trials":6921,"activeCount":119},[6922],{"nctId":6900,"briefTitle":6901,"status":164,"phases":6923,"primaryCompletion":6903,"completion":5044,"start":6904,"enrollment":4381,"conditions":6924,"interventions":6925},[90],[35],[6891,6907],{"trials":6927,"activeCount":119},[],{"trials":6929,"activeCount":119},[],{"trials":6931,"activeCount":119},[],{"intervention":6933,"totalTrials":116,"cells":6934},"Cisatracurium + Neostigmine",{"EARLY_PHASE1":6935,"PHASE1":6937,"PHASE2":6939,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6936,"activeCount":119},[],{"trials":6938,"activeCount":119},[],{"trials":6940,"activeCount":119},[6941],{"nctId":6942,"briefTitle":6943,"status":164,"phases":6944,"primaryCompletion":6945,"completion":3874,"start":6946,"enrollment":6947,"conditions":6948,"interventions":6950},"NCT03904550","Neuromuscular Blockade in Patients With Severe Renal Impairment",[90],"2022-08-11","2019-12-10",49,[3040,6949],"Renal Impairment",[6933,6951],"Rocuronium + Sugammadex",{"trials":6953,"activeCount":119},[],{"trials":6955,"activeCount":119},[],{"trials":6957,"activeCount":119},[],{"intervention":6951,"totalTrials":116,"cells":6959},{"EARLY_PHASE1":6960,"PHASE1":6962,"PHASE2":6964,"PHASE3":6970,"PHASE4":6972,"NA":6974},{"trials":6961,"activeCount":119},[],{"trials":6963,"activeCount":119},[],{"trials":6965,"activeCount":119},[6966],{"nctId":6942,"briefTitle":6943,"status":164,"phases":6967,"primaryCompletion":6945,"completion":3874,"start":6946,"enrollment":6947,"conditions":6968,"interventions":6969},[90],[3040,6949],[6933,6951],{"trials":6971,"activeCount":119},[],{"trials":6973,"activeCount":119},[],{"trials":6975,"activeCount":119},[],{"intervention":6977,"totalTrials":116,"cells":6978},"Anakinra",{"EARLY_PHASE1":6979,"PHASE1":6981,"PHASE2":6983,"PHASE3":6992,"PHASE4":6994,"NA":6996},{"trials":6980,"activeCount":119},[],{"trials":6982,"activeCount":119},[],{"trials":6984,"activeCount":119},[6985],{"nctId":6986,"briefTitle":6987,"status":164,"phases":6988,"primaryCompletion":5133,"completion":5133,"start":910,"enrollment":109,"conditions":6989,"interventions":6991},"NCT00645840","Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes",[89,90],[6990],"Type 1 Diabetes Mellitus",[6977],{"trials":6993,"activeCount":119},[],{"trials":6995,"activeCount":119},[],{"trials":6997,"activeCount":119},[],{"intervention":6999,"totalTrials":116,"cells":7000},"Atezolizumab and bevacizumab",{"EARLY_PHASE1":7001,"PHASE1":7003,"PHASE2":7005,"PHASE3":7015,"PHASE4":7017,"NA":7019},{"trials":7002,"activeCount":119},[],{"trials":7004,"activeCount":119},[],{"trials":7006,"activeCount":119},[7007],{"nctId":7008,"briefTitle":7009,"status":385,"phases":7010,"primaryCompletion":7011,"completion":7011,"start":7012,"enrollment":116,"conditions":7013,"interventions":7014},"NCT05537402","LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC",[90],"2025-06-06","2023-09-27",[1272],[6999],{"trials":7016,"activeCount":119},[],{"trials":7018,"activeCount":119},[],{"trials":7020,"activeCount":119},[],{"intervention":434,"totalTrials":116,"cells":7022},{"EARLY_PHASE1":7023,"PHASE1":7025,"PHASE2":7027,"PHASE3":7033,"PHASE4":7035,"NA":7037},{"trials":7024,"activeCount":119},[],{"trials":7026,"activeCount":119},[],{"trials":7028,"activeCount":119},[7029],{"nctId":425,"briefTitle":426,"status":385,"phases":7030,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":7031,"interventions":7032},[89,90],[432],[434,435,404,436],{"trials":7034,"activeCount":119},[],{"trials":7036,"activeCount":119},[],{"trials":7038,"activeCount":119},[],{"intervention":7040,"totalTrials":116,"cells":7041},"Cholic Acid",{"EARLY_PHASE1":7042,"PHASE1":7044,"PHASE2":7046,"PHASE3":7056,"PHASE4":7058,"NA":7060},{"trials":7043,"activeCount":119},[],{"trials":7045,"activeCount":119},[],{"trials":7047,"activeCount":119},[7048],{"nctId":7049,"briefTitle":7050,"status":164,"phases":7051,"primaryCompletion":7052,"completion":7052,"start":3092,"enrollment":901,"conditions":7053,"interventions":7055},"NCT00457639","Cholic Acid for Hepatic Steatosis in Lipodystrophy",[90],"2011-04",[7054],"Hepatic Steatosis",[7040],{"trials":7057,"activeCount":119},[],{"trials":7059,"activeCount":119},[],{"trials":7061,"activeCount":119},[],{"intervention":7063,"totalTrials":116,"cells":7064},"Nivolumab\u002FIpilimumab",{"EARLY_PHASE1":7065,"PHASE1":7067,"PHASE2":7069,"PHASE3":7082,"PHASE4":7084,"NA":7086},{"trials":7066,"activeCount":119},[],{"trials":7068,"activeCount":119},[],{"trials":7070,"activeCount":119},[7071],{"nctId":7072,"briefTitle":7073,"status":164,"phases":7074,"primaryCompletion":7075,"completion":7076,"start":5326,"enrollment":888,"conditions":7077,"interventions":7081},"NCT03065179","SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab\u002FIpilimumab in Renal Cell Carcinoma (RCC) \u002F Kidney Cancer Patients",[90],"2020-02-20","2020-11-17",[7078,7079,7080],"Kidney Cancer Metastatic","Kidney Cancer","Kidney Cancer, Stage IV",[7063],{"trials":7083,"activeCount":119},[],{"trials":7085,"activeCount":119},[],{"trials":7087,"activeCount":119},[],{"intervention":7089,"totalTrials":116,"cells":7090},"IDH305",{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7095,"PHASE3":7104,"PHASE4":7106,"NA":7108},{"trials":7092,"activeCount":119},[],{"trials":7094,"activeCount":119},[],{"trials":7096,"activeCount":119},[7097],{"nctId":7098,"briefTitle":7099,"status":951,"phases":7100,"primaryCompletion":6422,"completion":6422,"start":3319,"enrollment":119,"conditions":7101,"interventions":7103},"NCT02987010","Phase 2 Study of IDH305 in Low Grade Gliomas",[90],[7102],"Glioma",[7089],{"trials":7105,"activeCount":119},[],{"trials":7107,"activeCount":119},[],{"trials":7109,"activeCount":119},[],{"intervention":7111,"totalTrials":116,"cells":7112},"Erlotinib",{"EARLY_PHASE1":7113,"PHASE1":7115,"PHASE2":7117,"PHASE3":7128,"PHASE4":7130,"NA":7132},{"trials":7114,"activeCount":119},[],{"trials":7116,"activeCount":119},[],{"trials":7118,"activeCount":119},[7119],{"nctId":7120,"briefTitle":7121,"status":164,"phases":7122,"primaryCompletion":7123,"completion":7124,"start":7125,"enrollment":2893,"conditions":7126,"interventions":7127},"NCT00547105","Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[90],"2016-07-06","2017-07-06","2007-06-25",[1031],[7111],{"trials":7129,"activeCount":119},[],{"trials":7131,"activeCount":119},[],{"trials":7133,"activeCount":119},[],{"intervention":7135,"totalTrials":116,"cells":7136},"BF2.649",{"EARLY_PHASE1":7137,"PHASE1":7139,"PHASE2":7141,"PHASE3":7151,"PHASE4":7153,"NA":7155},{"trials":7138,"activeCount":119},[],{"trials":7140,"activeCount":119},[],{"trials":7142,"activeCount":119},[7143],{"nctId":7144,"briefTitle":7145,"status":164,"phases":7146,"primaryCompletion":7147,"completion":7147,"start":6792,"enrollment":7148,"conditions":7149,"interventions":7150},"NCT00690274","Study to Demonstrate Cognitive Enhancing Effects of BF2.649",[90],"2011-10",52,[289],[7135],{"trials":7152,"activeCount":119},[],{"trials":7154,"activeCount":119},[],{"trials":7156,"activeCount":119},[],{"intervention":7158,"totalTrials":116,"cells":7159},"Alagebrium",{"EARLY_PHASE1":7160,"PHASE1":7162,"PHASE2":7164,"PHASE3":7174,"PHASE4":7176,"NA":7178},{"trials":7161,"activeCount":119},[],{"trials":7163,"activeCount":119},[],{"trials":7165,"activeCount":119},[7166],{"nctId":7167,"briefTitle":7168,"status":164,"phases":7169,"primaryCompletion":3828,"completion":7170,"start":5942,"enrollment":389,"conditions":7171,"interventions":7173},"NCT01014572","The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart",[90],"2013-12",[7172],"Ventricular Function",[7158],{"trials":7175,"activeCount":119},[],{"trials":7177,"activeCount":119},[],{"trials":7179,"activeCount":119},[],{"intervention":1073,"totalTrials":116,"cells":7181},{"EARLY_PHASE1":7182,"PHASE1":7184,"PHASE2":7186,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7183,"activeCount":119},[],{"trials":7185,"activeCount":119},[],{"trials":7187,"activeCount":119},[7188],{"nctId":1061,"briefTitle":1062,"status":164,"phases":7189,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":7190,"interventions":7191},[90],[1069],[1071,1072,1073],{"trials":7193,"activeCount":119},[],{"trials":7195,"activeCount":119},[],{"trials":7197,"activeCount":119},[],{"intervention":7199,"totalTrials":116,"cells":7200},"EPO",{"EARLY_PHASE1":7201,"PHASE1":7203,"PHASE2":7205,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7202,"activeCount":119},[],{"trials":7204,"activeCount":119},[],{"trials":7206,"activeCount":119},[7207],{"nctId":7208,"briefTitle":7209,"status":385,"phases":7210,"primaryCompletion":7211,"completion":7211,"start":7212,"enrollment":650,"conditions":7213,"interventions":7216},"NCT02189889","Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery",[89,90],"2019-07-26","2013-04-09",[7214,7215],"Anemia","Cardiovascular Disease",[7199,7217],"Feraheme",{"trials":7219,"activeCount":119},[],{"trials":7221,"activeCount":119},[],{"trials":7223,"activeCount":119},[],{"intervention":7217,"totalTrials":116,"cells":7225},{"EARLY_PHASE1":7226,"PHASE1":7228,"PHASE2":7230,"PHASE3":7236,"PHASE4":7238,"NA":7240},{"trials":7227,"activeCount":119},[],{"trials":7229,"activeCount":119},[],{"trials":7231,"activeCount":119},[7232],{"nctId":7208,"briefTitle":7209,"status":385,"phases":7233,"primaryCompletion":7211,"completion":7211,"start":7212,"enrollment":650,"conditions":7234,"interventions":7235},[89,90],[7214,7215],[7199,7217],{"trials":7237,"activeCount":119},[],{"trials":7239,"activeCount":119},[],{"trials":7241,"activeCount":119},[],{"intervention":7243,"totalTrials":116,"cells":7244},"RFT5pdgA",{"EARLY_PHASE1":7245,"PHASE1":7247,"PHASE2":7249,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7246,"activeCount":119},[],{"trials":7248,"activeCount":119},[],{"trials":7250,"activeCount":119},[7251],{"nctId":7252,"briefTitle":7253,"status":164,"phases":7254,"primaryCompletion":7255,"completion":7255,"start":3092,"enrollment":1483,"conditions":7256,"interventions":7257},"NCT00314093","RFT-5-dgA in Patients With Metastatic Melanoma",[90],"2008-11",[957],[7243],{"trials":7259,"activeCount":119},[],{"trials":7261,"activeCount":119},[],{"trials":7263,"activeCount":119},[],{"intervention":7265,"totalTrials":116,"cells":7266},"Maintenance chemotherapy",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7282,"PHASE4":7284,"NA":7286},{"trials":7268,"activeCount":119},[],{"trials":7270,"activeCount":119},[],{"trials":7272,"activeCount":119},[7273],{"nctId":7274,"briefTitle":7275,"status":164,"phases":7276,"primaryCompletion":7277,"completion":7278,"start":4380,"enrollment":888,"conditions":7279,"interventions":7281},"NCT02045446","Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial",[90],"2022-02-17","2022-05-02",[7280],"Stage IV Non-Small Cell Lung Cancer",[7265],{"trials":7283,"activeCount":119},[],{"trials":7285,"activeCount":119},[],{"trials":7287,"activeCount":119},[],{"intervention":7289,"totalTrials":116,"cells":7290},"Extended-Release Naltrexone",{"EARLY_PHASE1":7291,"PHASE1":7293,"PHASE2":7295,"PHASE3":7308,"PHASE4":7310,"NA":7312},{"trials":7292,"activeCount":119},[],{"trials":7294,"activeCount":119},[],{"trials":7296,"activeCount":119},[7297],{"nctId":7298,"briefTitle":7299,"status":164,"phases":7300,"primaryCompletion":7301,"completion":7302,"start":795,"enrollment":7303,"conditions":7304,"interventions":7306},"NCT05262270","Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)",[90],"2025-06-27","2025-07-21",427,[7305],"Cocaine Use Disorder",[7289,7307],"Extended Release Buprenorphine",{"trials":7309,"activeCount":119},[],{"trials":7311,"activeCount":119},[],{"trials":7313,"activeCount":119},[],{"intervention":7307,"totalTrials":116,"cells":7315},{"EARLY_PHASE1":7316,"PHASE1":7318,"PHASE2":7320,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7317,"activeCount":119},[],{"trials":7319,"activeCount":119},[],{"trials":7321,"activeCount":119},[7322],{"nctId":7298,"briefTitle":7299,"status":164,"phases":7323,"primaryCompletion":7301,"completion":7302,"start":795,"enrollment":7303,"conditions":7324,"interventions":7325},[90],[7305],[7289,7307],{"trials":7327,"activeCount":119},[],{"trials":7329,"activeCount":119},[],{"trials":7331,"activeCount":119},[],{"intervention":7333,"totalTrials":116,"cells":7334},"Resveratrol",{"EARLY_PHASE1":7335,"PHASE1":7337,"PHASE2":7339,"PHASE3":7348,"PHASE4":7350,"NA":7352},{"trials":7336,"activeCount":119},[],{"trials":7338,"activeCount":119},[],{"trials":7340,"activeCount":119},[7341],{"nctId":7342,"briefTitle":7343,"status":164,"phases":7344,"primaryCompletion":3085,"completion":3085,"start":3648,"enrollment":1577,"conditions":7345,"interventions":7347},"NCT01321151","Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers",[89,90],[7346],"Sports Concussion",[7333],{"trials":7349,"activeCount":119},[],{"trials":7351,"activeCount":119},[],{"trials":7353,"activeCount":119},[],{"intervention":7355,"totalTrials":116,"cells":7356},"chemotherapy",{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7361,"PHASE3":7376,"PHASE4":7378,"NA":7380},{"trials":7358,"activeCount":119},[],{"trials":7360,"activeCount":119},[],{"trials":7362,"activeCount":119},[7363],{"nctId":7364,"briefTitle":7365,"status":164,"phases":7366,"primaryCompletion":7367,"completion":7368,"start":7369,"enrollment":7370,"conditions":7371,"interventions":7375},"NCT03067610","Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer",[90],"2020-12-21","2021-03-09","2017-01-20",72,[1688,7372,7373,7374],"Carcinoma, Squamous Cell","Neoplasms, Oral","Neoplasms, Pharyngeal",[7355],{"trials":7377,"activeCount":119},[],{"trials":7379,"activeCount":119},[],{"trials":7381,"activeCount":119},[],{"intervention":7383,"totalTrials":116,"cells":7384},"Sufentanil",{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7389,"PHASE3":7398,"PHASE4":7400,"NA":7402},{"trials":7386,"activeCount":119},[],{"trials":7388,"activeCount":119},[],{"trials":7390,"activeCount":119},[7391],{"nctId":7392,"briefTitle":7393,"status":164,"phases":7394,"primaryCompletion":7395,"completion":7395,"start":286,"enrollment":3126,"conditions":7396,"interventions":7397},"NCT04959812","Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil",[89,90],"2023-09-08",[718],[7383],{"trials":7399,"activeCount":119},[],{"trials":7401,"activeCount":119},[],{"trials":7403,"activeCount":119},[],{"intervention":5779,"totalTrials":116,"cells":7405},{"EARLY_PHASE1":7406,"PHASE1":7408,"PHASE2":7410,"PHASE3":7416,"PHASE4":7418,"NA":7420},{"trials":7407,"activeCount":119},[],{"trials":7409,"activeCount":119},[],{"trials":7411,"activeCount":119},[7412],{"nctId":5767,"briefTitle":5768,"status":164,"phases":7413,"primaryCompletion":5770,"completion":5771,"start":5772,"enrollment":5773,"conditions":7414,"interventions":7415},[89,90],[5775,5776,5777],[5779,5719],{"trials":7417,"activeCount":119},[],{"trials":7419,"activeCount":119},[],{"trials":7421,"activeCount":119},[],{"intervention":7423,"totalTrials":116,"cells":7424},"APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days",{"EARLY_PHASE1":7425,"PHASE1":7427,"PHASE2":7429,"PHASE3":7441,"PHASE4":7443,"NA":7445},{"trials":7426,"activeCount":119},[],{"trials":7428,"activeCount":119},[],{"trials":7430,"activeCount":119},[7431],{"nctId":7432,"briefTitle":7433,"status":164,"phases":7434,"primaryCompletion":7435,"completion":7435,"start":7436,"enrollment":1267,"conditions":7437,"interventions":7439},"NCT04130854","INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer",[90],"2026-01-30","2020-04-24",[7438],"Locally Advanced Rectal Adenocarcinoma",[7423,7440],"mFOLFOX and Radiation Therapy 5Gy x 5 days",{"trials":7442,"activeCount":119},[],{"trials":7444,"activeCount":119},[],{"trials":7446,"activeCount":119},[],{"intervention":7440,"totalTrials":116,"cells":7448},{"EARLY_PHASE1":7449,"PHASE1":7451,"PHASE2":7453,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7450,"activeCount":119},[],{"trials":7452,"activeCount":119},[],{"trials":7454,"activeCount":119},[7455],{"nctId":7432,"briefTitle":7433,"status":164,"phases":7456,"primaryCompletion":7435,"completion":7435,"start":7436,"enrollment":1267,"conditions":7457,"interventions":7458},[90],[7438],[7423,7440],{"trials":7460,"activeCount":119},[],{"trials":7462,"activeCount":119},[],{"trials":7464,"activeCount":119},[],{"intervention":7466,"totalTrials":116,"cells":7467},"Sipuleucel-T",{"EARLY_PHASE1":7468,"PHASE1":7470,"PHASE2":7472,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7469,"activeCount":119},[],{"trials":7471,"activeCount":119},[],{"trials":7473,"activeCount":119},[7474],{"nctId":7475,"briefTitle":7476,"status":164,"phases":7477,"primaryCompletion":7478,"completion":7479,"start":7480,"enrollment":1020,"conditions":7481,"interventions":7484},"NCT01818986","Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)",[90],"2019-12-20","2021-05-25","2013-07-10",[7482,7483],"Metastatic Castrate-resistant Prostate Cancer","mCRPC",[7466],{"trials":7486,"activeCount":119},[],{"trials":7488,"activeCount":119},[],{"trials":7490,"activeCount":119},[],{"intervention":6669,"totalTrials":116,"cells":7492},{"EARLY_PHASE1":7493,"PHASE1":7495,"PHASE2":7497,"PHASE3":7503,"PHASE4":7505,"NA":7507},{"trials":7494,"activeCount":119},[],{"trials":7496,"activeCount":119},[],{"trials":7498,"activeCount":119},[7499],{"nctId":6659,"briefTitle":6660,"status":951,"phases":7500,"primaryCompletion":6662,"completion":6662,"start":6663,"enrollment":119,"conditions":7501,"interventions":7502},[90],[6665,2177,6666,6667],[6669,6670,2182,6671],{"trials":7504,"activeCount":119},[],{"trials":7506,"activeCount":119},[],{"trials":7508,"activeCount":119},[],{"intervention":6670,"totalTrials":116,"cells":7510},{"EARLY_PHASE1":7511,"PHASE1":7513,"PHASE2":7515,"PHASE3":7521,"PHASE4":7523,"NA":7525},{"trials":7512,"activeCount":119},[],{"trials":7514,"activeCount":119},[],{"trials":7516,"activeCount":119},[7517],{"nctId":6659,"briefTitle":6660,"status":951,"phases":7518,"primaryCompletion":6662,"completion":6662,"start":6663,"enrollment":119,"conditions":7519,"interventions":7520},[90],[6665,2177,6666,6667],[6669,6670,2182,6671],{"trials":7522,"activeCount":119},[],{"trials":7524,"activeCount":119},[],{"trials":7526,"activeCount":119},[],{"intervention":6671,"totalTrials":116,"cells":7528},{"EARLY_PHASE1":7529,"PHASE1":7531,"PHASE2":7533,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7530,"activeCount":119},[],{"trials":7532,"activeCount":119},[],{"trials":7534,"activeCount":119},[7535],{"nctId":6659,"briefTitle":6660,"status":951,"phases":7536,"primaryCompletion":6662,"completion":6662,"start":6663,"enrollment":119,"conditions":7537,"interventions":7538},[90],[6665,2177,6666,6667],[6669,6670,2182,6671],{"trials":7540,"activeCount":119},[],{"trials":7542,"activeCount":119},[],{"trials":7544,"activeCount":119},[],{"intervention":7546,"totalTrials":116,"cells":7547},"Vitamin C",{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7552,"PHASE3":7562,"PHASE4":7564,"NA":7566},{"trials":7549,"activeCount":119},[],{"trials":7551,"activeCount":119},[],{"trials":7553,"activeCount":119},[7554],{"nctId":7555,"briefTitle":7556,"status":951,"phases":7557,"primaryCompletion":7558,"completion":3329,"start":7558,"enrollment":119,"conditions":7559,"interventions":7561},"NCT01587261","Vitamin C for Severe Thermal Injuries",[90],"2017-06",[7560],"Severe Thermal Injury, Greater Than 20% TBSA",[7546],{"trials":7563,"activeCount":119},[],{"trials":7565,"activeCount":119},[],{"trials":7567,"activeCount":119},[],{"intervention":7569,"totalTrials":116,"cells":7570},"Sertraline",{"EARLY_PHASE1":7571,"PHASE1":7573,"PHASE2":7575,"PHASE3":7586,"PHASE4":7588,"NA":7590},{"trials":7572,"activeCount":119},[],{"trials":7574,"activeCount":119},[],{"trials":7576,"activeCount":119},[7577],{"nctId":7578,"briefTitle":7579,"status":164,"phases":7580,"primaryCompletion":6125,"completion":6125,"start":7581,"enrollment":7582,"conditions":7583,"interventions":7584},"NCT01407094","Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression",[90],"2011-07-29",296,[15],[7569,7585],"BupropionXL",{"trials":7587,"activeCount":119},[],{"trials":7589,"activeCount":119},[],{"trials":7591,"activeCount":119},[],{"intervention":7585,"totalTrials":116,"cells":7593},{"EARLY_PHASE1":7594,"PHASE1":7596,"PHASE2":7598,"PHASE3":7604,"PHASE4":7606,"NA":7608},{"trials":7595,"activeCount":119},[],{"trials":7597,"activeCount":119},[],{"trials":7599,"activeCount":119},[7600],{"nctId":7578,"briefTitle":7579,"status":164,"phases":7601,"primaryCompletion":6125,"completion":6125,"start":7581,"enrollment":7582,"conditions":7602,"interventions":7603},[90],[15],[7569,7585],{"trials":7605,"activeCount":119},[],{"trials":7607,"activeCount":119},[],{"trials":7609,"activeCount":119},[],{"intervention":7611,"totalTrials":116,"cells":7612},"Sildenafil Citrate",{"EARLY_PHASE1":7613,"PHASE1":7615,"PHASE2":7617,"PHASE3":7630,"PHASE4":7632,"NA":7634},{"trials":7614,"activeCount":119},[],{"trials":7616,"activeCount":119},[],{"trials":7618,"activeCount":119},[7619],{"nctId":7620,"briefTitle":7621,"status":385,"phases":7622,"primaryCompletion":7623,"completion":7623,"start":7624,"enrollment":21,"conditions":7625,"interventions":7629},"NCT03598140","Sildenafil Treatment for Mild TBI",[90],"2019-05-29","2018-07-25",[7626,7627,7628],"Vascular System Injuries","Concussion, Brain","Post-Concussion Syndrome",[7611],{"trials":7631,"activeCount":119},[],{"trials":7633,"activeCount":119},[],{"trials":7635,"activeCount":119},[],{"intervention":7637,"totalTrials":116,"cells":7638},"L-Leucine",{"EARLY_PHASE1":7639,"PHASE1":7641,"PHASE2":7643,"PHASE3":7653,"PHASE4":7655,"NA":7657},{"trials":7640,"activeCount":119},[],{"trials":7642,"activeCount":119},[],{"trials":7644,"activeCount":119},[7645],{"nctId":7646,"briefTitle":7647,"status":385,"phases":7648,"primaryCompletion":7649,"completion":7649,"start":7650,"enrollment":30,"conditions":7651,"interventions":7652},"NCT03079297","Rapid Antidepressant Effects of Leucine",[90],"2021-10-04","2017-03-09",[29],[7637],{"trials":7654,"activeCount":119},[],{"trials":7656,"activeCount":119},[],{"trials":7658,"activeCount":119},[],{"intervention":2184,"totalTrials":116,"cells":7660},{"EARLY_PHASE1":7661,"PHASE1":7663,"PHASE2":7665,"PHASE3":7671,"PHASE4":7673,"NA":7675},{"trials":7662,"activeCount":119},[],{"trials":7664,"activeCount":119},[],{"trials":7666,"activeCount":119},[7667],{"nctId":2170,"briefTitle":2171,"status":385,"phases":7668,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":660,"conditions":7669,"interventions":7670},[90],[2176,2177],[2179,2148,2180,2181,2182,2183,2184],{"trials":7672,"activeCount":119},[],{"trials":7674,"activeCount":119},[],{"trials":7676,"activeCount":119},[],{"intervention":3509,"totalTrials":116,"cells":7678},{"EARLY_PHASE1":7679,"PHASE1":7681,"PHASE2":7683,"PHASE3":7689,"PHASE4":7691,"NA":7693},{"trials":7680,"activeCount":119},[],{"trials":7682,"activeCount":119},[],{"trials":7684,"activeCount":119},[7685],{"nctId":3501,"briefTitle":3502,"status":164,"phases":7686,"primaryCompletion":3504,"completion":3504,"start":3505,"enrollment":2663,"conditions":7687,"interventions":7688},[90],[18],[3492,3508,3509],{"trials":7690,"activeCount":119},[],{"trials":7692,"activeCount":119},[],{"trials":7694,"activeCount":119},[],{"intervention":7696,"totalTrials":116,"cells":7697},"cisplatin, cetuximab, or carboplatin-paclitaxel",{"EARLY_PHASE1":7698,"PHASE1":7700,"PHASE2":7702,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7699,"activeCount":119},[],{"trials":7701,"activeCount":119},[],{"trials":7703,"activeCount":119},[7704],{"nctId":7705,"briefTitle":7706,"status":164,"phases":7707,"primaryCompletion":7708,"completion":7709,"start":7710,"enrollment":702,"conditions":7711,"interventions":7712},"NCT04883281","A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer",[90],"2024-09-04","2026-03-11","2022-02-23",[1688],[7696],{"trials":7714,"activeCount":119},[],{"trials":7716,"activeCount":119},[],{"trials":7718,"activeCount":119},[],{"intervention":7720,"totalTrials":116,"cells":7721},"methylprednisolone",{"EARLY_PHASE1":7722,"PHASE1":7724,"PHASE2":7726,"PHASE3":7734,"PHASE4":7736,"NA":7738},{"trials":7723,"activeCount":119},[],{"trials":7725,"activeCount":119},[],{"trials":7727,"activeCount":119},[7728],{"nctId":7729,"briefTitle":7730,"status":951,"phases":7731,"primaryCompletion":7170,"completion":7170,"start":4894,"enrollment":119,"conditions":7732,"interventions":7733},"NCT01710228","Alternative Treatment Paradigm for Natalizumab Trial",[90],[4150],[7720],{"trials":7735,"activeCount":119},[],{"trials":7737,"activeCount":119},[],{"trials":7739,"activeCount":119},[],{"intervention":7741,"totalTrials":116,"cells":7742},"Eplerenone",{"EARLY_PHASE1":7743,"PHASE1":7745,"PHASE2":7747,"PHASE3":7757,"PHASE4":7759,"NA":7761},{"trials":7744,"activeCount":119},[],{"trials":7746,"activeCount":119},[],{"trials":7748,"activeCount":119},[7749],{"nctId":7750,"briefTitle":7751,"status":164,"phases":7752,"primaryCompletion":7753,"completion":7753,"start":4894,"enrollment":3598,"conditions":7754,"interventions":7755},"NCT01996449","The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension",[90],"2021-04",[18],[7741,7756],"Amlodipine",{"trials":7758,"activeCount":119},[],{"trials":7760,"activeCount":119},[],{"trials":7762,"activeCount":119},[],{"intervention":7756,"totalTrials":116,"cells":7764},{"EARLY_PHASE1":7765,"PHASE1":7767,"PHASE2":7769,"PHASE3":7775,"PHASE4":7777,"NA":7779},{"trials":7766,"activeCount":119},[],{"trials":7768,"activeCount":119},[],{"trials":7770,"activeCount":119},[7771],{"nctId":7750,"briefTitle":7751,"status":164,"phases":7772,"primaryCompletion":7753,"completion":7753,"start":4894,"enrollment":3598,"conditions":7773,"interventions":7774},[90],[18],[7741,7756],{"trials":7776,"activeCount":119},[],{"trials":7778,"activeCount":119},[],{"trials":7780,"activeCount":119},[],{"intervention":7782,"totalTrials":116,"cells":7783},"F-18 Fluoroestradiol",{"EARLY_PHASE1":7784,"PHASE1":7786,"PHASE2":7788,"PHASE3":7799,"PHASE4":7801,"NA":7803},{"trials":7785,"activeCount":119},[],{"trials":7787,"activeCount":119},[],{"trials":7789,"activeCount":119},[7790],{"nctId":7791,"briefTitle":7792,"status":951,"phases":7793,"primaryCompletion":7794,"completion":7795,"start":7796,"enrollment":119,"conditions":7797,"interventions":7798},"NCT03065712","Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET",[90],"2020-02-22","2021-02-20","2017-02-22",[20],[7782],{"trials":7800,"activeCount":119},[],{"trials":7802,"activeCount":119},[],{"trials":7804,"activeCount":119},[],{"intervention":7806,"totalTrials":116,"cells":7807},"Linezolid",{"EARLY_PHASE1":7808,"PHASE1":7810,"PHASE2":7812,"PHASE3":7820,"PHASE4":7822,"NA":7824},{"trials":7809,"activeCount":119},[],{"trials":7811,"activeCount":119},[],{"trials":7813,"activeCount":119},[7814],{"nctId":7815,"briefTitle":7816,"status":164,"phases":7817,"primaryCompletion":6781,"completion":6781,"start":3647,"enrollment":1310,"conditions":7818,"interventions":7819},"NCT00625703","Pharmacokinetics of Linezolid in Children With Cystic Fibrosis",[90],[264],[7806],{"trials":7821,"activeCount":119},[],{"trials":7823,"activeCount":119},[],{"trials":7825,"activeCount":119},[],{"intervention":7827,"totalTrials":116,"cells":7828},"Potassium, Magnesium, Citrate",{"EARLY_PHASE1":7829,"PHASE1":7831,"PHASE2":7833,"PHASE3":7843,"PHASE4":7845,"NA":7847},{"trials":7830,"activeCount":119},[],{"trials":7832,"activeCount":119},[],{"trials":7834,"activeCount":119},[7835],{"nctId":7836,"briefTitle":7837,"status":951,"phases":7838,"primaryCompletion":3518,"completion":2892,"start":5133,"enrollment":119,"conditions":7839,"interventions":7841},"NCT01074918","Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients",[89,90],[7840,18],"Pre-hypertension",[7827,7842],"Potassium Chloride",{"trials":7844,"activeCount":119},[],{"trials":7846,"activeCount":119},[],{"trials":7848,"activeCount":119},[],{"intervention":7850,"totalTrials":116,"cells":7851},"DT388IL3",{"EARLY_PHASE1":7852,"PHASE1":7854,"PHASE2":7856,"PHASE3":7868,"PHASE4":7870,"NA":7872},{"trials":7853,"activeCount":119},[],{"trials":7855,"activeCount":119},[],{"trials":7857,"activeCount":119},[7858],{"nctId":7859,"briefTitle":7860,"status":164,"phases":7861,"primaryCompletion":7862,"completion":7862,"start":7863,"enrollment":7864,"conditions":7865,"interventions":7867},"NCT00397579","DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes",[89,90],"2017-07-27","2013-05",11,[2176,5630,7866],"Blastic Plasmacytoid Dendritic Cell Neoplasm",[7850],{"trials":7869,"activeCount":119},[],{"trials":7871,"activeCount":119},[],{"trials":7873,"activeCount":119},[],{"intervention":6548,"totalTrials":116,"cells":7875},{"EARLY_PHASE1":7876,"PHASE1":7878,"PHASE2":7880,"PHASE3":7886,"PHASE4":7888,"NA":7890},{"trials":7877,"activeCount":119},[],{"trials":7879,"activeCount":119},[],{"trials":7881,"activeCount":119},[7882],{"nctId":6541,"briefTitle":6542,"status":385,"phases":7883,"primaryCompletion":6544,"completion":6544,"start":6545,"enrollment":116,"conditions":7884,"interventions":7885},[90],[1272],[6548,6521,6372],{"trials":7887,"activeCount":119},[],{"trials":7889,"activeCount":119},[],{"trials":7891,"activeCount":119},[],{"intervention":7893,"totalTrials":116,"cells":7894},"Consolidative Durvalumab",{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7899,"PHASE3":7910,"PHASE4":7912,"NA":7914},{"trials":7896,"activeCount":119},[],{"trials":7898,"activeCount":119},[],{"trials":7900,"activeCount":119},[7901],{"nctId":7902,"briefTitle":7903,"status":164,"phases":7904,"primaryCompletion":5507,"completion":7905,"start":7906,"enrollment":660,"conditions":7907,"interventions":7909},"NCT04003246","Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer",[90],"2024-11-05","2020-04-03",[6512,7908],"Lung Cancer Stage III",[7893],{"trials":7911,"activeCount":119},[],{"trials":7913,"activeCount":119},[],{"trials":7915,"activeCount":119},[],{"intervention":7917,"totalTrials":116,"cells":7918},"RFT5-dgA immunotoxin",{"EARLY_PHASE1":7919,"PHASE1":7921,"PHASE2":7923,"PHASE3":7933,"PHASE4":7935,"NA":7937},{"trials":7920,"activeCount":119},[],{"trials":7922,"activeCount":119},[],{"trials":7924,"activeCount":119},[7925],{"nctId":7926,"briefTitle":7927,"status":385,"phases":7928,"primaryCompletion":7929,"completion":7929,"start":7930,"enrollment":116,"conditions":7931,"interventions":7932},"NCT00667017","RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",[90],"2010-02","2008-11-07",[2177],[7917],{"trials":7934,"activeCount":119},[],{"trials":7936,"activeCount":119},[],{"trials":7938,"activeCount":119},[],{"intervention":7940,"totalTrials":116,"cells":7941},"Morphine",{"EARLY_PHASE1":7942,"PHASE1":7944,"PHASE2":7946,"PHASE3":7956,"PHASE4":7958,"NA":7960},{"trials":7943,"activeCount":119},[],{"trials":7945,"activeCount":119},[],{"trials":7947,"activeCount":119},[7948],{"nctId":7949,"briefTitle":7950,"status":164,"phases":7951,"primaryCompletion":7952,"completion":7952,"start":636,"enrollment":7953,"conditions":7954,"interventions":7955},"NCT04138615","Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine",[89,90],"2022-01-04",44,[718],[7940],{"trials":7957,"activeCount":119},[],{"trials":7959,"activeCount":119},[],{"trials":7961,"activeCount":119},[],{"intervention":7963,"totalTrials":116,"cells":7964},"Nintedanib",{"EARLY_PHASE1":7965,"PHASE1":7967,"PHASE2":7969,"PHASE3":7979,"PHASE4":7981,"NA":7983},{"trials":7966,"activeCount":119},[],{"trials":7968,"activeCount":119},[],{"trials":7970,"activeCount":119},[7971],{"nctId":7972,"briefTitle":7973,"status":385,"phases":7974,"primaryCompletion":7975,"completion":7975,"start":7976,"enrollment":3598,"conditions":7977,"interventions":7978},"NCT02902484","Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer",[89,90],"2021-10-26","2017-09-07",[432],[7963],{"trials":7980,"activeCount":119},[],{"trials":7982,"activeCount":119},[],{"trials":7984,"activeCount":119},[],{"intervention":7986,"totalTrials":116,"cells":7987},"Gemfibrozil",{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":7992,"PHASE3":8002,"PHASE4":8004,"NA":8006},{"trials":7989,"activeCount":119},[],{"trials":7991,"activeCount":119},[],{"trials":7993,"activeCount":119},[7994],{"nctId":7995,"briefTitle":7996,"status":164,"phases":7997,"primaryCompletion":7998,"completion":7998,"start":3207,"enrollment":30,"conditions":7999,"interventions":8001},"NCT02638597","Gemfibrozil for Nicotine Smoking Cessation",[90],"2016-12-23",[8000],"Smoking Cessation",[7986],{"trials":8003,"activeCount":119},[],{"trials":8005,"activeCount":119},[],{"trials":8007,"activeCount":119},[],{"intervention":1113,"totalTrials":116,"cells":8009},{"EARLY_PHASE1":8010,"PHASE1":8012,"PHASE2":8014,"PHASE3":8020,"PHASE4":8022,"NA":8024},{"trials":8011,"activeCount":119},[],{"trials":8013,"activeCount":119},[],{"trials":8015,"activeCount":119},[8016],{"nctId":1105,"briefTitle":1106,"status":385,"phases":8017,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":650,"conditions":8018,"interventions":8019},[90],[1111],[1113,1114,1085,1115],{"trials":8021,"activeCount":119},[],{"trials":8023,"activeCount":119},[],{"trials":8025,"activeCount":119},[],{"intervention":1114,"totalTrials":116,"cells":8027},{"EARLY_PHASE1":8028,"PHASE1":8030,"PHASE2":8032,"PHASE3":8038,"PHASE4":8040,"NA":8042},{"trials":8029,"activeCount":119},[],{"trials":8031,"activeCount":119},[],{"trials":8033,"activeCount":119},[8034],{"nctId":1105,"briefTitle":1106,"status":385,"phases":8035,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":650,"conditions":8036,"interventions":8037},[90],[1111],[1113,1114,1085,1115],{"trials":8039,"activeCount":119},[],{"trials":8041,"activeCount":119},[],{"trials":8043,"activeCount":119},[],{"intervention":1115,"totalTrials":116,"cells":8045},{"EARLY_PHASE1":8046,"PHASE1":8048,"PHASE2":8050,"PHASE3":8056,"PHASE4":8058,"NA":8060},{"trials":8047,"activeCount":119},[],{"trials":8049,"activeCount":119},[],{"trials":8051,"activeCount":119},[8052],{"nctId":1105,"briefTitle":1106,"status":385,"phases":8053,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":650,"conditions":8054,"interventions":8055},[90],[1111],[1113,1114,1085,1115],{"trials":8057,"activeCount":119},[],{"trials":8059,"activeCount":119},[],{"trials":8061,"activeCount":119},[],{"intervention":8063,"totalTrials":116,"cells":8064},"Amantadine",{"EARLY_PHASE1":8065,"PHASE1":8067,"PHASE2":8069,"PHASE3":8082,"PHASE4":8084,"NA":8086},{"trials":8066,"activeCount":119},[],{"trials":8068,"activeCount":119},[],{"trials":8070,"activeCount":119},[8071],{"nctId":8072,"briefTitle":8073,"status":951,"phases":8074,"primaryCompletion":8075,"completion":8076,"start":8077,"enrollment":119,"conditions":8078,"interventions":8081},"NCT06234462","A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid",[90],"2025-09-01","2025-10-01","2025-06",[8079,8080],"Long COVID","Post-Acute COVID-19 Syndrome",[8063],{"trials":8083,"activeCount":119},[],{"trials":8085,"activeCount":119},[],{"trials":8087,"activeCount":119},[],{"intervention":8089,"totalTrials":116,"cells":8090},"Ibuprofen",{"EARLY_PHASE1":8091,"PHASE1":8093,"PHASE2":8095,"PHASE3":8106,"PHASE4":8108,"NA":8110},{"trials":8092,"activeCount":119},[],{"trials":8094,"activeCount":119},[],{"trials":8096,"activeCount":119},[8097],{"nctId":8098,"briefTitle":8099,"status":385,"phases":8100,"primaryCompletion":8101,"completion":8101,"start":3206,"enrollment":8102,"conditions":8103,"interventions":8105},"NCT02241512","IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis",[90],"2018-09",69,[8104],"Post-ERCP Acute Pancreatitis",[8089],{"trials":8107,"activeCount":119},[],{"trials":8109,"activeCount":119},[],{"trials":8111,"activeCount":119},[],{"intervention":8113,"totalTrials":116,"cells":8114},"Esmolol",{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8119,"PHASE3":8133,"PHASE4":8135,"NA":8137},{"trials":8116,"activeCount":119},[],{"trials":8118,"activeCount":119},[],{"trials":8120,"activeCount":119},[8121],{"nctId":8122,"briefTitle":8123,"status":8124,"phases":8125,"completion":3557,"start":8126,"enrollment":8127,"conditions":8128,"interventions":8131},"NCT00302692","Use of Beta Blockers in Elderly Trauma Patients","UNKNOWN",[90],"2005-12",148,[8129,3322,8130],"Multiple Trauma","Aged",[8113,8132],"Metoprolol",{"trials":8134,"activeCount":119},[],{"trials":8136,"activeCount":119},[],{"trials":8138,"activeCount":119},[],{"intervention":8132,"totalTrials":116,"cells":8140},{"EARLY_PHASE1":8141,"PHASE1":8143,"PHASE2":8145,"PHASE3":8151,"PHASE4":8153,"NA":8155},{"trials":8142,"activeCount":119},[],{"trials":8144,"activeCount":119},[],{"trials":8146,"activeCount":119},[8147],{"nctId":8122,"briefTitle":8123,"status":8124,"phases":8148,"completion":3557,"start":8126,"enrollment":8127,"conditions":8149,"interventions":8150},[90],[8129,3322,8130],[8113,8132],{"trials":8152,"activeCount":119},[],{"trials":8154,"activeCount":119},[],{"trials":8156,"activeCount":119},[],{"intervention":8158,"totalTrials":116,"cells":8159},"IL-2",{"EARLY_PHASE1":8160,"PHASE1":8162,"PHASE2":8164,"PHASE3":8175,"PHASE4":8177,"NA":8179},{"trials":8161,"activeCount":119},[],{"trials":8163,"activeCount":119},[],{"trials":8165,"activeCount":119},[8166],{"nctId":8167,"briefTitle":8168,"status":164,"phases":8169,"primaryCompletion":8170,"completion":8171,"start":8172,"enrollment":617,"conditions":8173,"interventions":8174},"NCT01896271","High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer",[90],"2020-08-25","2021-04-20","2013-10-02",[977],[8158],{"trials":8176,"activeCount":119},[],{"trials":8178,"activeCount":119},[],{"trials":8180,"activeCount":119},[],{"intervention":6391,"totalTrials":116,"cells":8182},{"EARLY_PHASE1":8183,"PHASE1":8185,"PHASE2":8187,"PHASE3":8193,"PHASE4":8195,"NA":8197},{"trials":8184,"activeCount":119},[],{"trials":8186,"activeCount":119},[],{"trials":8188,"activeCount":119},[8189],{"nctId":6384,"briefTitle":6385,"status":951,"phases":8190,"primaryCompletion":6247,"completion":6247,"start":3648,"enrollment":119,"conditions":8191,"interventions":8192},[89,90],[6388,6389],[6356,6391,6392,6393],{"trials":8194,"activeCount":119},[],{"trials":8196,"activeCount":119},[],{"trials":8198,"activeCount":119},[],{"intervention":6392,"totalTrials":116,"cells":8200},{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8205,"PHASE3":8211,"PHASE4":8213,"NA":8215},{"trials":8202,"activeCount":119},[],{"trials":8204,"activeCount":119},[],{"trials":8206,"activeCount":119},[8207],{"nctId":6384,"briefTitle":6385,"status":951,"phases":8208,"primaryCompletion":6247,"completion":6247,"start":3648,"enrollment":119,"conditions":8209,"interventions":8210},[89,90],[6388,6389],[6356,6391,6392,6393],{"trials":8212,"activeCount":119},[],{"trials":8214,"activeCount":119},[],{"trials":8216,"activeCount":119},[],{"intervention":6393,"totalTrials":116,"cells":8218},{"EARLY_PHASE1":8219,"PHASE1":8221,"PHASE2":8223,"PHASE3":8229,"PHASE4":8231,"NA":8233},{"trials":8220,"activeCount":119},[],{"trials":8222,"activeCount":119},[],{"trials":8224,"activeCount":119},[8225],{"nctId":6384,"briefTitle":6385,"status":951,"phases":8226,"primaryCompletion":6247,"completion":6247,"start":3648,"enrollment":119,"conditions":8227,"interventions":8228},[89,90],[6388,6389],[6356,6391,6392,6393],{"trials":8230,"activeCount":119},[],{"trials":8232,"activeCount":119},[],{"trials":8234,"activeCount":119},[],{"intervention":2886,"totalTrials":116,"cells":8236},{"EARLY_PHASE1":8237,"PHASE1":8239,"PHASE2":8241,"PHASE3":8247,"PHASE4":8249,"NA":8251},{"trials":8238,"activeCount":119},[],{"trials":8240,"activeCount":119},[],{"trials":8242,"activeCount":119},[8243],{"nctId":2877,"briefTitle":2878,"status":951,"phases":8244,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":119,"conditions":8245,"interventions":8246},[90],[2883],[2885,2868,2886],{"trials":8248,"activeCount":119},[],{"trials":8250,"activeCount":119},[],{"trials":8252,"activeCount":119},[],{"intervention":692,"totalTrials":116,"cells":8254},{"EARLY_PHASE1":8255,"PHASE1":8257,"PHASE2":8259,"PHASE3":8265,"PHASE4":8267,"NA":8269},{"trials":8256,"activeCount":119},[],{"trials":8258,"activeCount":119},[],{"trials":8260,"activeCount":119},[8261],{"nctId":683,"briefTitle":684,"status":164,"phases":8262,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":8263,"interventions":8264},[90],[29,690],[649,692],{"trials":8266,"activeCount":119},[],{"trials":8268,"activeCount":119},[],{"trials":8270,"activeCount":119},[],{"intervention":8272,"totalTrials":116,"cells":8273},"Triheptanoin oil",{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8278,"PHASE3":8288,"PHASE4":8290,"NA":8292},{"trials":8275,"activeCount":119},[],{"trials":8277,"activeCount":119},[],{"trials":8279,"activeCount":119},[8280],{"nctId":8281,"briefTitle":8282,"status":951,"phases":8283,"primaryCompletion":4380,"completion":4380,"start":4406,"enrollment":119,"conditions":8284,"interventions":8287},"NCT01787851","Study of the Acute Effects of Triheptanoin in Heart Failure",[89,90],[8285,8286],"Congestive Heart Failure","Non-ischemic Cardiomyopathy",[8272],{"trials":8289,"activeCount":119},[],{"trials":8291,"activeCount":119},[],{"trials":8293,"activeCount":119},[],{"intervention":5706,"totalTrials":116,"cells":8295},{"EARLY_PHASE1":8296,"PHASE1":8298,"PHASE2":8300,"PHASE3":8306,"PHASE4":8308,"NA":8310},{"trials":8297,"activeCount":119},[],{"trials":8299,"activeCount":119},[],{"trials":8301,"activeCount":119},[8302],{"nctId":5698,"briefTitle":5699,"status":385,"phases":8303,"primaryCompletion":5701,"completion":5701,"start":5702,"enrollment":360,"conditions":8304,"interventions":8305},[90],[5704],[5706,2835],{"trials":8307,"activeCount":119},[],{"trials":8309,"activeCount":119},[],{"trials":8311,"activeCount":119},[],{"intervention":8313,"totalTrials":116,"cells":8314},"Ketorolac",{"EARLY_PHASE1":8315,"PHASE1":8317,"PHASE2":8319,"PHASE3":8334,"PHASE4":8336,"NA":8338},{"trials":8316,"activeCount":119},[],{"trials":8318,"activeCount":119},[],{"trials":8320,"activeCount":119},[8321],{"nctId":8322,"briefTitle":8323,"status":164,"phases":8324,"primaryCompletion":8325,"completion":8326,"start":8327,"enrollment":8328,"conditions":8329,"interventions":8332},"NCT04112160","Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal",[90],"2019-06-30","2019-08-30","2018-06-28",125,[3128,8330,8331],"Urinary Stone","Urinary Calculi",[8313,8333],"normal saline",{"trials":8335,"activeCount":119},[],{"trials":8337,"activeCount":119},[],{"trials":8339,"activeCount":119},[],{"intervention":8333,"totalTrials":116,"cells":8341},{"EARLY_PHASE1":8342,"PHASE1":8344,"PHASE2":8346,"PHASE3":8352,"PHASE4":8354,"NA":8356},{"trials":8343,"activeCount":119},[],{"trials":8345,"activeCount":119},[],{"trials":8347,"activeCount":119},[8348],{"nctId":8322,"briefTitle":8323,"status":164,"phases":8349,"primaryCompletion":8325,"completion":8326,"start":8327,"enrollment":8328,"conditions":8350,"interventions":8351},[90],[3128,8330,8331],[8313,8333],{"trials":8353,"activeCount":119},[],{"trials":8355,"activeCount":119},[],{"trials":8357,"activeCount":119},[],{"intervention":8359,"totalTrials":116,"cells":8360},"Donor Stem Cell Transplantation",{"EARLY_PHASE1":8361,"PHASE1":8363,"PHASE2":8365,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8362,"activeCount":119},[],{"trials":8364,"activeCount":119},[],{"trials":8366,"activeCount":119},[8367],{"nctId":8368,"briefTitle":8369,"status":951,"phases":8370,"primaryCompletion":8371,"completion":8372,"start":3208,"enrollment":119,"conditions":8373,"interventions":8375},"NCT02038478","Allograft for Sickle Cell Disease and Thalassemia",[90],"2021-01","2021-05",[8374],"Sickle Cell Disease and Thalassemia",[8359],{"trials":8377,"activeCount":119},[],{"trials":8379,"activeCount":119},[],{"trials":8381,"activeCount":119},[],{"intervention":2897,"totalTrials":116,"cells":8383},{"EARLY_PHASE1":8384,"PHASE1":8386,"PHASE2":8388,"PHASE3":8394,"PHASE4":8396,"NA":8398},{"trials":8385,"activeCount":119},[],{"trials":8387,"activeCount":119},[],{"trials":8389,"activeCount":119},[8390],{"nctId":2888,"briefTitle":2889,"status":164,"phases":8391,"primaryCompletion":2891,"completion":2891,"start":2892,"enrollment":2893,"conditions":8392,"interventions":8393},[90],[2895],[2897,2868],{"trials":8395,"activeCount":119},[],{"trials":8397,"activeCount":119},[],{"trials":8399,"activeCount":119},[],{"intervention":754,"totalTrials":116,"cells":8401},{"EARLY_PHASE1":8402,"PHASE1":8404,"PHASE2":8406,"PHASE3":8412,"PHASE4":8414,"NA":8416},{"trials":8403,"activeCount":119},[],{"trials":8405,"activeCount":119},[],{"trials":8407,"activeCount":119},[8408],{"nctId":743,"briefTitle":744,"status":164,"phases":8409,"primaryCompletion":746,"completion":747,"start":748,"enrollment":749,"conditions":8410,"interventions":8411},[90],[740,751,752],[723,754],{"trials":8413,"activeCount":119},[],{"trials":8415,"activeCount":119},[],{"trials":8417,"activeCount":119},[],{"intervention":8419,"totalTrials":116,"cells":8420},"tamoxifen citrate",{"EARLY_PHASE1":8421,"PHASE1":8423,"PHASE2":8425,"PHASE3":8435,"PHASE4":8437,"NA":8439},{"trials":8422,"activeCount":119},[],{"trials":8424,"activeCount":119},[],{"trials":8426,"activeCount":119},[8427],{"nctId":8428,"briefTitle":8429,"status":385,"phases":8430,"primaryCompletion":8431,"completion":8431,"start":6197,"enrollment":8432,"conditions":8433,"interventions":8434},"NCT00096369","Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer",[90],"2007-03-15",130,[20],[8419],{"trials":8436,"activeCount":119},[],{"trials":8438,"activeCount":119},[],{"trials":8440,"activeCount":119},[],{"intervention":8442,"totalTrials":116,"cells":8443},"bavituximab (0.3 mg\u002Fkg) and sorafenib",{"EARLY_PHASE1":8444,"PHASE1":8446,"PHASE2":8448,"PHASE3":8460,"PHASE4":8462,"NA":8464},{"trials":8445,"activeCount":119},[],{"trials":8447,"activeCount":119},[],{"trials":8449,"activeCount":119},[8450],{"nctId":8451,"briefTitle":8452,"status":164,"phases":8453,"primaryCompletion":8454,"completion":8454,"start":3137,"enrollment":8455,"conditions":8456,"interventions":8457},"NCT01264705","Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer",[89,90],"2018-04",47,[1272,1270],[8442,8458,8459],"bavituximab (1.0 mg\u002Fkg ) and sorafenib","bavituximab (3.0 mg\u002Fkg) and sorafenib",{"trials":8461,"activeCount":119},[],{"trials":8463,"activeCount":119},[],{"trials":8465,"activeCount":119},[],{"intervention":8458,"totalTrials":116,"cells":8467},{"EARLY_PHASE1":8468,"PHASE1":8470,"PHASE2":8472,"PHASE3":8478,"PHASE4":8480,"NA":8482},{"trials":8469,"activeCount":119},[],{"trials":8471,"activeCount":119},[],{"trials":8473,"activeCount":119},[8474],{"nctId":8451,"briefTitle":8452,"status":164,"phases":8475,"primaryCompletion":8454,"completion":8454,"start":3137,"enrollment":8455,"conditions":8476,"interventions":8477},[89,90],[1272,1270],[8442,8458,8459],{"trials":8479,"activeCount":119},[],{"trials":8481,"activeCount":119},[],{"trials":8483,"activeCount":119},[],{"intervention":8459,"totalTrials":116,"cells":8485},{"EARLY_PHASE1":8486,"PHASE1":8488,"PHASE2":8490,"PHASE3":8496,"PHASE4":8498,"NA":8500},{"trials":8487,"activeCount":119},[],{"trials":8489,"activeCount":119},[],{"trials":8491,"activeCount":119},[8492],{"nctId":8451,"briefTitle":8452,"status":164,"phases":8493,"primaryCompletion":8454,"completion":8454,"start":3137,"enrollment":8455,"conditions":8494,"interventions":8495},[89,90],[1272,1270],[8442,8458,8459],{"trials":8497,"activeCount":119},[],{"trials":8499,"activeCount":119},[],{"trials":8501,"activeCount":119},[],{"intervention":8503,"totalTrials":116,"cells":8504},"Everolimus",{"EARLY_PHASE1":8505,"PHASE1":8507,"PHASE2":8509,"PHASE3":8519,"PHASE4":8521,"NA":8523},{"trials":8506,"activeCount":119},[],{"trials":8508,"activeCount":119},[],{"trials":8510,"activeCount":119},[8511],{"nctId":8512,"briefTitle":8513,"status":164,"phases":8514,"primaryCompletion":8515,"completion":8515,"start":3207,"enrollment":7864,"conditions":8516,"interventions":8518},"NCT02155920","Everolimus for Children With Recurrent or Progressive Ependymoma",[90],"2023-07-14",[8517],"Recurrent Childhood Ependymoma",[8503],{"trials":8520,"activeCount":119},[],{"trials":8522,"activeCount":119},[],{"trials":8524,"activeCount":119},[],{"intervention":6857,"totalTrials":116,"cells":8526},{"EARLY_PHASE1":8527,"PHASE1":8529,"PHASE2":8531,"PHASE3":8537,"PHASE4":8539,"NA":8541},{"trials":8528,"activeCount":119},[],{"trials":8530,"activeCount":119},[],{"trials":8532,"activeCount":119},[8533],{"nctId":6849,"briefTitle":6850,"status":951,"phases":8534,"primaryCompletion":6852,"completion":6852,"start":6853,"enrollment":119,"conditions":8535,"interventions":8536},[89,90],[6855],[1033,6857],{"trials":8538,"activeCount":119},[],{"trials":8540,"activeCount":119},[],{"trials":8542,"activeCount":119},[],{"intervention":8544,"totalTrials":116,"cells":8545},"BPI",{"EARLY_PHASE1":8546,"PHASE1":8548,"PHASE2":8550,"PHASE3":8558,"PHASE4":8560,"NA":8562},{"trials":8547,"activeCount":119},[],{"trials":8549,"activeCount":119},[],{"trials":8551,"activeCount":119},[8552],{"nctId":8553,"briefTitle":8554,"status":385,"phases":8555,"primaryCompletion":3441,"completion":3441,"start":3092,"enrollment":724,"conditions":8556,"interventions":8557},"NCT00462904","Pharmacokinetic Response to BPI in Burns",[90],[171],[8544],{"trials":8559,"activeCount":119},[],{"trials":8561,"activeCount":119},[],{"trials":8563,"activeCount":119},[],{"intervention":8565,"totalTrials":116,"cells":8566},"Experimental Group",{"EARLY_PHASE1":8567,"PHASE1":8569,"PHASE2":8571,"PHASE3":8581,"PHASE4":8583,"NA":8585},{"trials":8568,"activeCount":119},[],{"trials":8570,"activeCount":119},[],{"trials":8572,"activeCount":119},[8573],{"nctId":8574,"briefTitle":8575,"status":164,"phases":8576,"primaryCompletion":8577,"completion":8577,"start":8578,"enrollment":833,"conditions":8579,"interventions":8580},"NCT04456153","Atovaquone for Treatment of COVID-19",[90],"2021-01-31","2020-07-22",[1392],[8565],{"trials":8582,"activeCount":119},[],{"trials":8584,"activeCount":119},[],{"trials":8586,"activeCount":119},[],{"intervention":8588,"totalTrials":116,"cells":8589},"3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT",{"EARLY_PHASE1":8590,"PHASE1":8592,"PHASE2":8594,"PHASE3":8605,"PHASE4":8607,"NA":8609},{"trials":8591,"activeCount":119},[],{"trials":8593,"activeCount":119},[],{"trials":8595,"activeCount":119},[8596],{"nctId":8597,"briefTitle":8598,"status":164,"phases":8599,"primaryCompletion":8600,"completion":8600,"start":8601,"enrollment":2832,"conditions":8602,"interventions":8604},"NCT03318497","Role of Interim 18F-FLT PET\u002FCT for Outcome Prediction in Pancreatic Adenocarcinoma",[90],"2021-06-15","2017-12-11",[8603],"Pancreatic Adenocarcinoma",[8588],{"trials":8606,"activeCount":119},[],{"trials":8608,"activeCount":119},[],{"trials":8610,"activeCount":119},[],{"intervention":8612,"totalTrials":116,"cells":8613},"Enzalutamide",{"EARLY_PHASE1":8614,"PHASE1":8616,"PHASE2":8618,"PHASE3":8629,"PHASE4":8631,"NA":8633},{"trials":8615,"activeCount":119},[],{"trials":8617,"activeCount":119},[],{"trials":8619,"activeCount":119},[8620],{"nctId":8621,"briefTitle":8622,"status":164,"phases":8623,"primaryCompletion":8624,"completion":8624,"start":8625,"enrollment":975,"conditions":8626,"interventions":8627},"NCT02064582","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",[90],"2018-06-09","2014-05",[32],[8612,8628],"Leuprolide acetate",{"trials":8630,"activeCount":119},[],{"trials":8632,"activeCount":119},[],{"trials":8634,"activeCount":119},[],{"intervention":8628,"totalTrials":116,"cells":8636},{"EARLY_PHASE1":8637,"PHASE1":8639,"PHASE2":8641,"PHASE3":8647,"PHASE4":8649,"NA":8651},{"trials":8638,"activeCount":119},[],{"trials":8640,"activeCount":119},[],{"trials":8642,"activeCount":119},[8643],{"nctId":8621,"briefTitle":8622,"status":164,"phases":8644,"primaryCompletion":8624,"completion":8624,"start":8625,"enrollment":975,"conditions":8645,"interventions":8646},[90],[32],[8612,8628],{"trials":8648,"activeCount":119},[],{"trials":8650,"activeCount":119},[],{"trials":8652,"activeCount":119},[],{"intervention":6621,"totalTrials":116,"cells":8654},{"EARLY_PHASE1":8655,"PHASE1":8657,"PHASE2":8659,"PHASE3":8665,"PHASE4":8667,"NA":8669},{"trials":8656,"activeCount":119},[],{"trials":8658,"activeCount":119},[],{"trials":8660,"activeCount":119},[8661],{"nctId":6612,"briefTitle":6613,"status":385,"phases":8662,"primaryCompletion":6615,"completion":6616,"start":6617,"enrollment":1483,"conditions":8663,"interventions":8664},[89,90],[6619],[6621,6594],{"trials":8666,"activeCount":119},[],{"trials":8668,"activeCount":119},[],{"trials":8670,"activeCount":119},[],{"intervention":8672,"totalTrials":116,"cells":8673},"IVIG",{"EARLY_PHASE1":8674,"PHASE1":8676,"PHASE2":8678,"PHASE3":8690,"PHASE4":8692,"NA":8694},{"trials":8675,"activeCount":119},[],{"trials":8677,"activeCount":119},[],{"trials":8679,"activeCount":119},[8680],{"nctId":8681,"briefTitle":8682,"status":164,"phases":8683,"primaryCompletion":8684,"completion":8685,"start":5857,"enrollment":617,"conditions":8686,"interventions":8688},"NCT03919773","IVIG (Gamunex-C) Treatment Study for POTS Subjects",[89,90],"2023-06-26","2023-12-01",[8687],"Postural Tachycardia Syndrome",[8672,8689],"Albumin",{"trials":8691,"activeCount":119},[],{"trials":8693,"activeCount":119},[],{"trials":8695,"activeCount":119},[],{"intervention":8689,"totalTrials":116,"cells":8697},{"EARLY_PHASE1":8698,"PHASE1":8700,"PHASE2":8702,"PHASE3":8708,"PHASE4":8710,"NA":8712},{"trials":8699,"activeCount":119},[],{"trials":8701,"activeCount":119},[],{"trials":8703,"activeCount":119},[8704],{"nctId":8681,"briefTitle":8682,"status":164,"phases":8705,"primaryCompletion":8684,"completion":8685,"start":5857,"enrollment":617,"conditions":8706,"interventions":8707},[89,90],[8687],[8672,8689],{"trials":8709,"activeCount":119},[],{"trials":8711,"activeCount":119},[],{"trials":8713,"activeCount":119},[],{"intervention":8715,"totalTrials":116,"cells":8716},"CPI-0610",{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8721,"PHASE3":8731,"PHASE4":8733,"NA":8735},{"trials":8718,"activeCount":119},[],{"trials":8720,"activeCount":119},[],{"trials":8722,"activeCount":119},[8723],{"nctId":8724,"briefTitle":8725,"status":951,"phases":8726,"primaryCompletion":8727,"completion":8727,"start":6082,"enrollment":119,"conditions":8728,"interventions":8730},"NCT02986919","Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors",[90],"2018-05-17",[8729],"Peripheral Nerve Tumors",[8715],{"trials":8732,"activeCount":119},[],{"trials":8734,"activeCount":119},[],{"trials":8736,"activeCount":119},[],{"intervention":775,"totalTrials":116,"cells":8738},{"EARLY_PHASE1":8739,"PHASE1":8741,"PHASE2":8743,"PHASE3":8749,"PHASE4":8751,"NA":8753},{"trials":8740,"activeCount":119},[],{"trials":8742,"activeCount":119},[],{"trials":8744,"activeCount":119},[8745],{"nctId":766,"briefTitle":767,"status":164,"phases":8746,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":8747,"interventions":8748},[90],[35],[723,775],{"trials":8750,"activeCount":119},[],{"trials":8752,"activeCount":119},[],{"trials":8754,"activeCount":119},[],{"intervention":8756,"totalTrials":116,"cells":8757},"LEE011",{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8762,"PHASE3":8771,"PHASE4":8773,"NA":8775},{"trials":8759,"activeCount":119},[],{"trials":8761,"activeCount":119},[],{"trials":8763,"activeCount":119},[8764],{"nctId":8765,"briefTitle":8766,"status":385,"phases":8767,"primaryCompletion":8768,"completion":8768,"start":6125,"enrollment":650,"conditions":8769,"interventions":8770},"NCT02524119","LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma",[90],"2020-09",[1272],[8756],{"trials":8772,"activeCount":119},[],{"trials":8774,"activeCount":119},[],{"trials":8776,"activeCount":119},[],{"intervention":8778,"totalTrials":97,"cells":8779},"Trametinib",{"EARLY_PHASE1":8780,"PHASE1":8782,"PHASE2":8801,"PHASE3":8803,"PHASE4":8805,"NA":8807},{"trials":8781,"activeCount":119},[],{"trials":8783,"activeCount":119},[8784,8793],{"nctId":8785,"briefTitle":8786,"status":951,"phases":8787,"primaryCompletion":8788,"completion":8788,"start":1018,"enrollment":119,"conditions":8789,"interventions":8790},"NCT02915666","A Clinical Trial of Patients With Melanoma",[89],"2017-07-17",[956],[8791,8792,8778],"Digoxin Combination","Dabrafenib",{"nctId":8794,"briefTitle":8795,"status":164,"phases":8796,"primaryCompletion":8797,"completion":8797,"start":8798,"enrollment":5773,"conditions":8799,"interventions":8800},"NCT02138292","A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma",[89],"2017-02-23","2014-07",[956],[8778],{"trials":8802,"activeCount":119},[],{"trials":8804,"activeCount":119},[],{"trials":8806,"activeCount":119},[],{"trials":8808,"activeCount":119},[],{"intervention":5739,"totalTrials":116,"cells":8810},{"EARLY_PHASE1":8811,"PHASE1":8813,"PHASE2":8819,"PHASE3":8821,"PHASE4":8823,"NA":8825},{"trials":8812,"activeCount":119},[],{"trials":8814,"activeCount":119},[8815],{"nctId":5732,"briefTitle":5733,"status":164,"phases":8816,"primaryCompletion":2891,"completion":5735,"start":4196,"enrollment":168,"conditions":8817,"interventions":8818},[89],[5737],[5739,5725],{"trials":8820,"activeCount":119},[],{"trials":8822,"activeCount":119},[],{"trials":8824,"activeCount":119},[],{"trials":8826,"activeCount":119},[],{"intervention":8828,"totalTrials":116,"cells":8829},"Standard Care Chemoradiation",{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8841,"PHASE3":8843,"PHASE4":8845,"NA":8847},{"trials":8831,"activeCount":119},[],{"trials":8833,"activeCount":119},[8834],{"nctId":8835,"briefTitle":8836,"status":385,"phases":8837,"primaryCompletion":5132,"completion":5132,"start":8838,"enrollment":660,"conditions":8839,"interventions":8840},"NCT00896350","MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer",[89],"2009-07-08",[1688],[8828],{"trials":8842,"activeCount":119},[],{"trials":8844,"activeCount":119},[],{"trials":8846,"activeCount":119},[],{"trials":8848,"activeCount":119},[],{"intervention":8850,"totalTrials":116,"cells":8851},"Arm A-Bavituximab 3mg\u002Fkg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg\u002Fkg IV over 90 minutes weekly x 12 plus ipilimumab 3mg\u002Fkg IV",{"EARLY_PHASE1":8852,"PHASE1":8854,"PHASE2":8863,"PHASE3":8865,"PHASE4":8867,"NA":8869},{"trials":8853,"activeCount":119},[],{"trials":8855,"activeCount":119},[8856],{"nctId":8857,"briefTitle":8858,"status":385,"phases":8859,"primaryCompletion":6125,"completion":6125,"start":2891,"enrollment":360,"conditions":8860,"interventions":8861},"NCT01984255","A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",[89],[956],[8850,8862],"Arm B-Ipilimumab 3mg\u002Fkg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.",{"trials":8864,"activeCount":119},[],{"trials":8866,"activeCount":119},[],{"trials":8868,"activeCount":119},[],{"trials":8870,"activeCount":119},[],{"intervention":8862,"totalTrials":116,"cells":8872},{"EARLY_PHASE1":8873,"PHASE1":8875,"PHASE2":8881,"PHASE3":8883,"PHASE4":8885,"NA":8887},{"trials":8874,"activeCount":119},[],{"trials":8876,"activeCount":119},[8877],{"nctId":8857,"briefTitle":8858,"status":385,"phases":8878,"primaryCompletion":6125,"completion":6125,"start":2891,"enrollment":360,"conditions":8879,"interventions":8880},[89],[956],[8850,8862],{"trials":8882,"activeCount":119},[],{"trials":8884,"activeCount":119},[],{"trials":8886,"activeCount":119},[],{"trials":8888,"activeCount":119},[],{"intervention":8890,"totalTrials":116,"cells":8891},"ACP-104",{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8902,"PHASE3":8904,"PHASE4":8906,"NA":8908},{"trials":8893,"activeCount":119},[],{"trials":8895,"activeCount":119},[8896],{"nctId":8897,"briefTitle":8898,"status":164,"phases":8899,"primaryCompletion":5231,"completion":3742,"start":4197,"enrollment":1310,"conditions":8900,"interventions":8901},"NCT00628420","Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics",[89],[289],[8890,8890],{"trials":8903,"activeCount":119},[],{"trials":8905,"activeCount":119},[],{"trials":8907,"activeCount":119},[],{"trials":8909,"activeCount":119},[],{"intervention":420,"totalTrials":116,"cells":8911},{"EARLY_PHASE1":8912,"PHASE1":8914,"PHASE2":8920,"PHASE3":8922,"PHASE4":8924,"NA":8926},{"trials":8913,"activeCount":119},[],{"trials":8915,"activeCount":119},[8916],{"nctId":411,"briefTitle":412,"status":385,"phases":8917,"primaryCompletion":414,"completion":415,"start":416,"enrollment":27,"conditions":8918,"interventions":8919},[89],[418],[420,404,421],{"trials":8921,"activeCount":119},[],{"trials":8923,"activeCount":119},[],{"trials":8925,"activeCount":119},[],{"trials":8927,"activeCount":119},[],{"intervention":8791,"totalTrials":116,"cells":8929},{"EARLY_PHASE1":8930,"PHASE1":8932,"PHASE2":8938,"PHASE3":8940,"PHASE4":8942,"NA":8944},{"trials":8931,"activeCount":119},[],{"trials":8933,"activeCount":119},[8934],{"nctId":8785,"briefTitle":8786,"status":951,"phases":8935,"primaryCompletion":8788,"completion":8788,"start":1018,"enrollment":119,"conditions":8936,"interventions":8937},[89],[956],[8791,8792,8778],{"trials":8939,"activeCount":119},[],{"trials":8941,"activeCount":119},[],{"trials":8943,"activeCount":119},[],{"trials":8945,"activeCount":119},[],{"intervention":8792,"totalTrials":116,"cells":8947},{"EARLY_PHASE1":8948,"PHASE1":8950,"PHASE2":8956,"PHASE3":8958,"PHASE4":8960,"NA":8962},{"trials":8949,"activeCount":119},[],{"trials":8951,"activeCount":119},[8952],{"nctId":8785,"briefTitle":8786,"status":951,"phases":8953,"primaryCompletion":8788,"completion":8788,"start":1018,"enrollment":119,"conditions":8954,"interventions":8955},[89],[956],[8791,8792,8778],{"trials":8957,"activeCount":119},[],{"trials":8959,"activeCount":119},[],{"trials":8961,"activeCount":119},[],{"trials":8963,"activeCount":119},[],{"intervention":8965,"totalTrials":116,"cells":8966},"Baclofen 20 mg",{"EARLY_PHASE1":8967,"PHASE1":8969,"PHASE2":8982,"PHASE3":8984,"PHASE4":8986,"NA":8988},{"trials":8968,"activeCount":119},[],{"trials":8970,"activeCount":119},[8971],{"nctId":8972,"briefTitle":8973,"status":164,"phases":8974,"primaryCompletion":8975,"completion":8975,"start":8976,"enrollment":24,"conditions":8977,"interventions":8979},"NCT05257447","Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently",[89],"2022-12-13","2022-04-27",[8978],"Pharmacokinetics",[8965,8980,8981],"Chlorzoxazone 500 mg","Baclofen 20mg tablet and Chlorzoxazone 500 mg",{"trials":8983,"activeCount":119},[],{"trials":8985,"activeCount":119},[],{"trials":8987,"activeCount":119},[],{"trials":8989,"activeCount":119},[],{"intervention":8980,"totalTrials":116,"cells":8991},{"EARLY_PHASE1":8992,"PHASE1":8994,"PHASE2":9000,"PHASE3":9002,"PHASE4":9004,"NA":9006},{"trials":8993,"activeCount":119},[],{"trials":8995,"activeCount":119},[8996],{"nctId":8972,"briefTitle":8973,"status":164,"phases":8997,"primaryCompletion":8975,"completion":8975,"start":8976,"enrollment":24,"conditions":8998,"interventions":8999},[89],[8978],[8965,8980,8981],{"trials":9001,"activeCount":119},[],{"trials":9003,"activeCount":119},[],{"trials":9005,"activeCount":119},[],{"trials":9007,"activeCount":119},[],{"intervention":8981,"totalTrials":116,"cells":9009},{"EARLY_PHASE1":9010,"PHASE1":9012,"PHASE2":9018,"PHASE3":9020,"PHASE4":9022,"NA":9024},{"trials":9011,"activeCount":119},[],{"trials":9013,"activeCount":119},[9014],{"nctId":8972,"briefTitle":8973,"status":164,"phases":9015,"primaryCompletion":8975,"completion":8975,"start":8976,"enrollment":24,"conditions":9016,"interventions":9017},[89],[8978],[8965,8980,8981],{"trials":9019,"activeCount":119},[],{"trials":9021,"activeCount":119},[],{"trials":9023,"activeCount":119},[],{"trials":9025,"activeCount":119},[],{"intervention":9027,"totalTrials":116,"cells":9028},"Erlotinib plus Romidepsin",{"EARLY_PHASE1":9029,"PHASE1":9031,"PHASE2":9042,"PHASE3":9044,"PHASE4":9046,"NA":9048},{"trials":9030,"activeCount":119},[],{"trials":9032,"activeCount":119},[9033],{"nctId":9034,"briefTitle":9035,"status":164,"phases":9036,"primaryCompletion":5715,"completion":5715,"start":5133,"enrollment":27,"conditions":9037,"interventions":9039},"NCT01302808","Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[89],[1031,9038],"Metastatic Cancer",[9027,9027,9040,9041],"Erlotinib plus Romidepsin (10 mg\u002Fm^2) + Antiemetic prophylaxis","(Erlotinib plus Romidepsin (8mg\u002Fm^2)) + Antiemetic prophylaxis",{"trials":9043,"activeCount":119},[],{"trials":9045,"activeCount":119},[],{"trials":9047,"activeCount":119},[],{"trials":9049,"activeCount":119},[],{"intervention":9040,"totalTrials":116,"cells":9051},{"EARLY_PHASE1":9052,"PHASE1":9054,"PHASE2":9060,"PHASE3":9062,"PHASE4":9064,"NA":9066},{"trials":9053,"activeCount":119},[],{"trials":9055,"activeCount":119},[9056],{"nctId":9034,"briefTitle":9035,"status":164,"phases":9057,"primaryCompletion":5715,"completion":5715,"start":5133,"enrollment":27,"conditions":9058,"interventions":9059},[89],[1031,9038],[9027,9027,9040,9041],{"trials":9061,"activeCount":119},[],{"trials":9063,"activeCount":119},[],{"trials":9065,"activeCount":119},[],{"trials":9067,"activeCount":119},[],{"intervention":9041,"totalTrials":116,"cells":9069},{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9078,"PHASE3":9080,"PHASE4":9082,"NA":9084},{"trials":9071,"activeCount":119},[],{"trials":9073,"activeCount":119},[9074],{"nctId":9034,"briefTitle":9035,"status":164,"phases":9075,"primaryCompletion":5715,"completion":5715,"start":5133,"enrollment":27,"conditions":9076,"interventions":9077},[89],[1031,9038],[9027,9027,9040,9041],{"trials":9079,"activeCount":119},[],{"trials":9081,"activeCount":119},[],{"trials":9083,"activeCount":119},[],{"trials":9085,"activeCount":119},[],{"intervention":9087,"totalTrials":116,"cells":9088},"Ad5CMV-p53 gene",{"EARLY_PHASE1":9089,"PHASE1":9091,"PHASE2":9102,"PHASE3":9104,"PHASE4":9106,"NA":9108},{"trials":9090,"activeCount":119},[],{"trials":9092,"activeCount":119},[9093],{"nctId":9094,"briefTitle":9095,"status":164,"phases":9096,"primaryCompletion":9097,"completion":9097,"start":9098,"conditions":9099,"interventions":9101},"NCT00003450","Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer",[89],"1999-01","1998-09",[6855,9100],"Peritoneal Cavity Cancer",[9087],{"trials":9103,"activeCount":119},[],{"trials":9105,"activeCount":119},[],{"trials":9107,"activeCount":119},[],{"trials":9109,"activeCount":119},[],{"intervention":6608,"totalTrials":116,"cells":9111},{"EARLY_PHASE1":9112,"PHASE1":9114,"PHASE2":9120,"PHASE3":9122,"PHASE4":9124,"NA":9126},{"trials":9113,"activeCount":119},[],{"trials":9115,"activeCount":119},[9116],{"nctId":6601,"briefTitle":6602,"status":164,"phases":9117,"primaryCompletion":6604,"completion":3124,"start":3172,"enrollment":796,"conditions":9118,"interventions":9119},[89],[6606],[6608,6594],{"trials":9121,"activeCount":119},[],{"trials":9123,"activeCount":119},[],{"trials":9125,"activeCount":119},[],{"trials":9127,"activeCount":119},[],{"intervention":9129,"totalTrials":116,"cells":9130},"Docosahexaenoic acid",{"EARLY_PHASE1":9131,"PHASE1":9133,"PHASE2":9144,"PHASE3":9146,"PHASE4":9148,"NA":9150},{"trials":9132,"activeCount":119},[],{"trials":9134,"activeCount":119},[9135],{"nctId":9136,"briefTitle":9137,"status":164,"phases":9138,"primaryCompletion":9139,"completion":9139,"start":3850,"enrollment":353,"conditions":9140,"interventions":9143},"NCT01903525","DHA For The Treatment of Pediatric Concussion Related to Sports Injury",[89],"2017-08",[9141,9142],"Concussion","Mild Traumatic Brain Injury",[9129],{"trials":9145,"activeCount":119},[],{"trials":9147,"activeCount":119},[],{"trials":9149,"activeCount":119},[],{"trials":9151,"activeCount":119},[],{"intervention":9153,"totalTrials":116,"cells":9154},"Antibiotics",{"EARLY_PHASE1":9155,"PHASE1":9157,"PHASE2":9168,"PHASE3":9170,"PHASE4":9172,"NA":9174},{"trials":9156,"activeCount":119},[],{"trials":9158,"activeCount":119},[9159],{"nctId":9160,"briefTitle":9161,"status":951,"phases":9162,"primaryCompletion":9163,"completion":9163,"start":9164,"enrollment":119,"conditions":9165,"interventions":9167},"NCT05724628","Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations",[89],"2023-11","2023-10",[9166],"Acute Appendicitis",[9153],{"trials":9169,"activeCount":119},[],{"trials":9171,"activeCount":119},[],{"trials":9173,"activeCount":119},[],{"trials":9175,"activeCount":119},[],{"intervention":9177,"totalTrials":116,"cells":9178},"gemcitabine hydrochloride",{"EARLY_PHASE1":9179,"PHASE1":9181,"PHASE2":9191,"PHASE3":9193,"PHASE4":9195,"NA":9197},{"trials":9180,"activeCount":119},[],{"trials":9182,"activeCount":119},[9183],{"nctId":9184,"briefTitle":9185,"status":385,"phases":9186,"primaryCompletion":9187,"completion":9187,"start":9188,"enrollment":650,"conditions":9189,"interventions":9190},"NCT01025882","Margin-Intense Combo Therapy in Pts w\u002FPotentially Resectable Pancreatic Cancer",[89],"2011-02-18","2009-10",[418],[9177],{"trials":9192,"activeCount":119},[],{"trials":9194,"activeCount":119},[],{"trials":9196,"activeCount":119},[],{"trials":9198,"activeCount":119},[],{"intervention":9200,"totalTrials":116,"cells":9201},"Pregnenolone 500 mg",{"EARLY_PHASE1":9202,"PHASE1":9204,"PHASE2":9216,"PHASE3":9218,"PHASE4":9220,"NA":9222},{"trials":9203,"activeCount":119},[],{"trials":9205,"activeCount":119},[9206],{"nctId":9207,"briefTitle":9208,"status":164,"phases":9209,"primaryCompletion":9210,"completion":9210,"start":9211,"enrollment":9212,"conditions":9213,"interventions":9214},"NCT03645096","Development of Pregnenolone as a Treatment for Depression",[89],"2022-05-31","2019-09-01",34,[29],[9200,9215],"Pregnenolone 800 mg",{"trials":9217,"activeCount":119},[],{"trials":9219,"activeCount":119},[],{"trials":9221,"activeCount":119},[],{"trials":9223,"activeCount":119},[],{"intervention":9215,"totalTrials":116,"cells":9225},{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9234,"PHASE3":9236,"PHASE4":9238,"NA":9240},{"trials":9227,"activeCount":119},[],{"trials":9229,"activeCount":119},[9230],{"nctId":9207,"briefTitle":9208,"status":164,"phases":9231,"primaryCompletion":9210,"completion":9210,"start":9211,"enrollment":9212,"conditions":9232,"interventions":9233},[89],[29],[9200,9215],{"trials":9235,"activeCount":119},[],{"trials":9237,"activeCount":119},[],{"trials":9239,"activeCount":119},[],{"trials":9241,"activeCount":119},[],{"intervention":9243,"totalTrials":116,"cells":9244},"RiVax",{"EARLY_PHASE1":9245,"PHASE1":9247,"PHASE2":9255,"PHASE3":9257,"PHASE4":9259,"NA":9261},{"trials":9246,"activeCount":119},[],{"trials":9248,"activeCount":119},[9249],{"nctId":9250,"briefTitle":9251,"status":164,"phases":9252,"primaryCompletion":3916,"completion":3827,"start":910,"enrollment":617,"conditions":9253,"interventions":9254},"NCT00812071","Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin",[89],[718],[9243],{"trials":9256,"activeCount":119},[],{"trials":9258,"activeCount":119},[],{"trials":9260,"activeCount":119},[],{"trials":9262,"activeCount":119},[],{"intervention":9264,"totalTrials":116,"cells":9265},"ARQ761, Olaparib",{"EARLY_PHASE1":9266,"PHASE1":9268,"PHASE2":9278,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9267,"activeCount":119},[],{"trials":9269,"activeCount":119},[9270],{"nctId":9271,"briefTitle":9272,"status":951,"phases":9273,"primaryCompletion":9274,"completion":9274,"start":9275,"enrollment":119,"conditions":9276,"interventions":9277},"NCT03575078","ARQ761 + PARP Inhibitor in Refractory Solid Tumors",[89],"2019-05-15","2018-06-25",[2177],[9264],{"trials":9279,"activeCount":119},[],{"trials":9281,"activeCount":119},[],{"trials":9283,"activeCount":119},[],{"trials":9285,"activeCount":119},[],{"intervention":9287,"totalTrials":116,"cells":9288},"PD-0332991 and T-DM1",{"EARLY_PHASE1":9289,"PHASE1":9291,"PHASE2":9302,"PHASE3":9304,"PHASE4":9306,"NA":9308},{"trials":9290,"activeCount":119},[],{"trials":9292,"activeCount":119},[9293],{"nctId":9294,"briefTitle":9295,"status":164,"phases":9296,"primaryCompletion":9297,"completion":9297,"start":9298,"enrollment":888,"conditions":9299,"interventions":9301},"NCT01976169","Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)",[89],"2021-05-19","2014-01-24",[9300],"Advanced Breast Cancer",[9287],{"trials":9303,"activeCount":119},[],{"trials":9305,"activeCount":119},[],{"trials":9307,"activeCount":119},[],{"trials":9309,"activeCount":119},[],{"intervention":9311,"totalTrials":116,"cells":9312},"Pregnenolone 250 mg",{"EARLY_PHASE1":9313,"PHASE1":9315,"PHASE2":9326,"PHASE3":9328,"PHASE4":9330,"NA":9332},{"trials":9314,"activeCount":119},[],{"trials":9316,"activeCount":119},[9317],{"nctId":9318,"briefTitle":9319,"status":951,"phases":9320,"primaryCompletion":9321,"completion":9321,"start":9321,"enrollment":119,"conditions":9322,"interventions":9324},"NCT04464148","Feasibility Trial of Pregnenolone for Posttraumatic Stress Disorder and Alcohol Use Disorder",[89],"2021-12",[9323,4383],"Post Traumatic Stress Disorder",[9311,9325],"Pregnenolone 400 mg",{"trials":9327,"activeCount":119},[],{"trials":9329,"activeCount":119},[],{"trials":9331,"activeCount":119},[],{"trials":9333,"activeCount":119},[],{"intervention":9325,"totalTrials":116,"cells":9335},{"EARLY_PHASE1":9336,"PHASE1":9338,"PHASE2":9344,"PHASE3":9346,"PHASE4":9348,"NA":9350},{"trials":9337,"activeCount":119},[],{"trials":9339,"activeCount":119},[9340],{"nctId":9318,"briefTitle":9319,"status":951,"phases":9341,"primaryCompletion":9321,"completion":9321,"start":9321,"enrollment":119,"conditions":9342,"interventions":9343},[89],[9323,4383],[9311,9325],{"trials":9345,"activeCount":119},[],{"trials":9347,"activeCount":119},[],{"trials":9349,"activeCount":119},[],{"trials":9351,"activeCount":119},[],{"intervention":9353,"totalTrials":116,"cells":9354},"Rilonacept",{"EARLY_PHASE1":9355,"PHASE1":9357,"PHASE2":9365,"PHASE3":9367,"PHASE4":9369,"NA":9371},{"trials":9356,"activeCount":119},[],{"trials":9358,"activeCount":119},[9359],{"nctId":9360,"briefTitle":9361,"status":164,"phases":9362,"primaryCompletion":4337,"completion":3386,"start":4171,"enrollment":33,"conditions":9363,"interventions":9364},"NCT00962026","Rilonacept in Diabetes Mellitus Type 1: Safety Study",[89],[6990],[9353],{"trials":9366,"activeCount":119},[],{"trials":9368,"activeCount":119},[],{"trials":9370,"activeCount":119},[],{"trials":9372,"activeCount":119},[],{"intervention":9374,"totalTrials":116,"cells":9375},"ARQ 761",{"EARLY_PHASE1":9376,"PHASE1":9378,"PHASE2":9394,"PHASE3":9396,"PHASE4":9398,"NA":9400},{"trials":9377,"activeCount":119},[],{"trials":9379,"activeCount":119},[9380],{"nctId":9381,"briefTitle":9382,"status":164,"phases":9383,"primaryCompletion":9384,"completion":9385,"start":9386,"enrollment":9387,"conditions":9388,"interventions":9390},"NCT01502800","Clinical Trial of ARQ 761 in Advanced Solid Tumors",[89],"2017-02","2019-03","2011-12-29",91,[9389],"Solid Tumors",[9374,9391,9392,9393],"ARQ 761 Weekly Administration","Bi-Weekly Administration of ARQ 761","Two Consecutive Weeks Administration of ARQ 761 with one week of rest",{"trials":9395,"activeCount":119},[],{"trials":9397,"activeCount":119},[],{"trials":9399,"activeCount":119},[],{"trials":9401,"activeCount":119},[],{"intervention":9391,"totalTrials":116,"cells":9403},{"EARLY_PHASE1":9404,"PHASE1":9406,"PHASE2":9412,"PHASE3":9414,"PHASE4":9416,"NA":9418},{"trials":9405,"activeCount":119},[],{"trials":9407,"activeCount":119},[9408],{"nctId":9381,"briefTitle":9382,"status":164,"phases":9409,"primaryCompletion":9384,"completion":9385,"start":9386,"enrollment":9387,"conditions":9410,"interventions":9411},[89],[9389],[9374,9391,9392,9393],{"trials":9413,"activeCount":119},[],{"trials":9415,"activeCount":119},[],{"trials":9417,"activeCount":119},[],{"trials":9419,"activeCount":119},[],{"intervention":9392,"totalTrials":116,"cells":9421},{"EARLY_PHASE1":9422,"PHASE1":9424,"PHASE2":9430,"PHASE3":9432,"PHASE4":9434,"NA":9436},{"trials":9423,"activeCount":119},[],{"trials":9425,"activeCount":119},[9426],{"nctId":9381,"briefTitle":9382,"status":164,"phases":9427,"primaryCompletion":9384,"completion":9385,"start":9386,"enrollment":9387,"conditions":9428,"interventions":9429},[89],[9389],[9374,9391,9392,9393],{"trials":9431,"activeCount":119},[],{"trials":9433,"activeCount":119},[],{"trials":9435,"activeCount":119},[],{"trials":9437,"activeCount":119},[],{"intervention":9393,"totalTrials":116,"cells":9439},{"EARLY_PHASE1":9440,"PHASE1":9442,"PHASE2":9448,"PHASE3":9450,"PHASE4":9452,"NA":9454},{"trials":9441,"activeCount":119},[],{"trials":9443,"activeCount":119},[9444],{"nctId":9381,"briefTitle":9382,"status":164,"phases":9445,"primaryCompletion":9384,"completion":9385,"start":9386,"enrollment":9387,"conditions":9446,"interventions":9447},[89],[9389],[9374,9391,9392,9393],{"trials":9449,"activeCount":119},[],{"trials":9451,"activeCount":119},[],{"trials":9453,"activeCount":119},[],{"trials":9455,"activeCount":119},[],{"intervention":9457,"totalTrials":116,"cells":9458},"mecasermin",{"EARLY_PHASE1":9459,"PHASE1":9461,"PHASE2":9470,"PHASE3":9472,"PHASE4":9474,"NA":9476},{"trials":9460,"activeCount":119},[],{"trials":9462,"activeCount":119},[9463],{"nctId":9464,"briefTitle":9465,"status":385,"phases":9466,"primaryCompletion":3386,"completion":3386,"start":3136,"enrollment":30,"conditions":9467,"interventions":9469},"NCT01329744","Effects of IGF-I in HIV Metabolic Disease",[89],[9468],"HIV Lipodystrophy",[9457],{"trials":9471,"activeCount":119},[],{"trials":9473,"activeCount":119},[],{"trials":9475,"activeCount":119},[],{"trials":9477,"activeCount":119},[],{"intervention":9479,"totalTrials":116,"cells":9480},"Nitroglycerin 0.2 MG\u002FHR",{"EARLY_PHASE1":9481,"PHASE1":9483,"PHASE2":9494,"PHASE3":9496,"PHASE4":9498,"NA":9500},{"trials":9482,"activeCount":119},[],{"trials":9484,"activeCount":119},[9485],{"nctId":9486,"briefTitle":9487,"status":164,"phases":9488,"primaryCompletion":3915,"completion":1018,"start":3137,"enrollment":33,"conditions":9489,"interventions":9491},"NCT01407107","Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer",[89],[9490],"Rectal Cancer",[9479,9492,9493],"Nitroglycerin 0.4 MG\u002FHR","Nitroglycerin 0.6 MG\u002FHR",{"trials":9495,"activeCount":119},[],{"trials":9497,"activeCount":119},[],{"trials":9499,"activeCount":119},[],{"trials":9501,"activeCount":119},[],{"intervention":9492,"totalTrials":116,"cells":9503},{"EARLY_PHASE1":9504,"PHASE1":9506,"PHASE2":9512,"PHASE3":9514,"PHASE4":9516,"NA":9518},{"trials":9505,"activeCount":119},[],{"trials":9507,"activeCount":119},[9508],{"nctId":9486,"briefTitle":9487,"status":164,"phases":9509,"primaryCompletion":3915,"completion":1018,"start":3137,"enrollment":33,"conditions":9510,"interventions":9511},[89],[9490],[9479,9492,9493],{"trials":9513,"activeCount":119},[],{"trials":9515,"activeCount":119},[],{"trials":9517,"activeCount":119},[],{"trials":9519,"activeCount":119},[],{"intervention":9493,"totalTrials":116,"cells":9521},{"EARLY_PHASE1":9522,"PHASE1":9524,"PHASE2":9530,"PHASE3":9532,"PHASE4":9534,"NA":9536},{"trials":9523,"activeCount":119},[],{"trials":9525,"activeCount":119},[9526],{"nctId":9486,"briefTitle":9487,"status":164,"phases":9527,"primaryCompletion":3915,"completion":1018,"start":3137,"enrollment":33,"conditions":9528,"interventions":9529},[89],[9490],[9479,9492,9493],{"trials":9531,"activeCount":119},[],{"trials":9533,"activeCount":119},[],{"trials":9535,"activeCount":119},[],{"trials":9537,"activeCount":119},[],{"intervention":9539,"totalTrials":116,"cells":9540},"Cocaine hydrochloride",{"EARLY_PHASE1":9541,"PHASE1":9543,"PHASE2":9553,"PHASE3":9555,"PHASE4":9557,"NA":9559},{"trials":9542,"activeCount":119},[],{"trials":9544,"activeCount":119},[9545],{"nctId":9546,"briefTitle":9547,"status":951,"phases":9548,"enrollment":119,"conditions":9549,"interventions":9551},"NCT00338546","Study to Improve Scientific Understanding of the Cardiovascular Actions of Cocaine",[89],[9550],"Cocaine Induced Sympathoexciation and Vasoconstriction",[9539,9552],"Dexmedetomidine",{"trials":9554,"activeCount":119},[],{"trials":9556,"activeCount":119},[],{"trials":9558,"activeCount":119},[],{"trials":9560,"activeCount":119},[],{"intervention":9562,"totalTrials":116,"cells":9563},"Substance P-Saporin",{"EARLY_PHASE1":9564,"PHASE1":9566,"PHASE2":9578,"PHASE3":9580,"PHASE4":9582,"NA":9584},{"trials":9565,"activeCount":119},[],{"trials":9567,"activeCount":119},[9568],{"nctId":9569,"briefTitle":9570,"status":164,"phases":9571,"primaryCompletion":9572,"completion":9572,"start":3208,"enrollment":796,"conditions":9573,"interventions":9577},"NCT02036281","A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain",[89],"2016-09-28",[9574,9575,9576],"Terminally Ill","Histologically-confirmed Advanced Cancer","Pain, Intractable",[9562],{"trials":9579,"activeCount":119},[],{"trials":9581,"activeCount":119},[],{"trials":9583,"activeCount":119},[],{"trials":9585,"activeCount":119},[],{"intervention":9587,"totalTrials":116,"cells":9588},"Vasopressin",{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9603,"PHASE3":9605,"PHASE4":9607,"NA":9609},{"trials":9590,"activeCount":119},[],{"trials":9592,"activeCount":119},[9593],{"nctId":9594,"briefTitle":9595,"status":164,"phases":9596,"primaryCompletion":9597,"completion":9597,"start":9598,"enrollment":8432,"conditions":9599,"interventions":9601},"NCT00628550","Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation",[89],"2010-10","2008-04",[2861,9600],"Cardiac Arrest",[9587,9602],"Epinephrine",{"trials":9604,"activeCount":119},[],{"trials":9606,"activeCount":119},[],{"trials":9608,"activeCount":119},[],{"trials":9610,"activeCount":119},[],{"intervention":9612,"totalTrials":116,"cells":9613},"TSEBT and pembrolizumab",{"EARLY_PHASE1":9614,"PHASE1":9616,"PHASE2":9628,"PHASE3":9630,"PHASE4":9632,"NA":9634},{"trials":9615,"activeCount":119},[],{"trials":9617,"activeCount":119},[9618],{"nctId":9619,"briefTitle":9620,"status":951,"phases":9621,"primaryCompletion":9622,"completion":9623,"start":9624,"enrollment":119,"conditions":9625,"interventions":9627},"NCT03617224","Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome",[89],"2022-07-24","2024-07-24","2018-07-24",[9626],"Cutaneous T-Cell Lymphomas",[9612],{"trials":9629,"activeCount":119},[],{"trials":9631,"activeCount":119},[],{"trials":9633,"activeCount":119},[],{"trials":9635,"activeCount":119},[],{"intervention":9637,"totalTrials":97,"cells":9638},"Phenylephrine",{"EARLY_PHASE1":9639,"PHASE1":9662,"PHASE2":9664,"PHASE3":9666,"PHASE4":9668,"NA":9670},{"trials":9640,"activeCount":119},[9641,9651],{"nctId":9642,"briefTitle":9643,"status":164,"phases":9644,"primaryCompletion":9645,"completion":9645,"start":9646,"enrollment":5257,"conditions":9647,"interventions":9649},"NCT05011357","Phenylephrine and Pulse Pressure Variability",[88],"2024-08-20","2021-09-10",[9648],"Intraoperative Hypotension",[9637,9650],"Saline Control",{"nctId":9652,"briefTitle":9653,"status":164,"phases":9654,"primaryCompletion":9655,"completion":9655,"start":9656,"enrollment":9657,"conditions":9658,"interventions":9660},"NCT06053398","Vasopressor Outcomes in Spine Surgery",[88],"2024-12-30","2023-11-21",101,[9659],"Hypotension",[9637,9661],"Norepinephrine",{"trials":9663,"activeCount":119},[],{"trials":9665,"activeCount":119},[],{"trials":9667,"activeCount":119},[],{"trials":9669,"activeCount":119},[],{"trials":9671,"activeCount":119},[],{"intervention":9673,"totalTrials":116,"cells":9674},"NICOTINE 2MG GUM",{"EARLY_PHASE1":9675,"PHASE1":9688,"PHASE2":9690,"PHASE3":9692,"PHASE4":9694,"NA":9696},{"trials":9676,"activeCount":119},[9677],{"nctId":9678,"briefTitle":9679,"status":951,"phases":9680,"primaryCompletion":9681,"completion":9682,"start":9683,"enrollment":119,"conditions":9684,"interventions":9686},"NCT05758298","Assessing the Use of Nicotine Gum to Decrease Betel Nut Chewing in Saipan",[88],"2024-12","2024-12-01","2023-10-01",[9685],"Betel Nut Cessation",[9673,9687],"NICOTINE 4MG GUM",{"trials":9689,"activeCount":119},[],{"trials":9691,"activeCount":119},[],{"trials":9693,"activeCount":119},[],{"trials":9695,"activeCount":119},[],{"trials":9697,"activeCount":119},[],{"intervention":9687,"totalTrials":116,"cells":9699},{"EARLY_PHASE1":9700,"PHASE1":9706,"PHASE2":9708,"PHASE3":9710,"PHASE4":9712,"NA":9714},{"trials":9701,"activeCount":119},[9702],{"nctId":9678,"briefTitle":9679,"status":951,"phases":9703,"primaryCompletion":9681,"completion":9682,"start":9683,"enrollment":119,"conditions":9704,"interventions":9705},[88],[9685],[9673,9687],{"trials":9707,"activeCount":119},[],{"trials":9709,"activeCount":119},[],{"trials":9711,"activeCount":119},[],{"trials":9713,"activeCount":119},[],{"trials":9715,"activeCount":119},[],{"intervention":9717,"totalTrials":116,"cells":9718},"MiraLAX",{"EARLY_PHASE1":9719,"PHASE1":9732,"PHASE2":9734,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9720,"activeCount":119},[9721],{"nctId":9722,"briefTitle":9723,"status":164,"phases":9724,"primaryCompletion":9725,"completion":9726,"start":9727,"enrollment":627,"conditions":9728,"interventions":9730},"NCT00765557","Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome",[88],"2014-06-17","2014-07-22","2007-12-10",[9729],"Constipation",[9717,9731],"Placebos",{"trials":9733,"activeCount":119},[],{"trials":9735,"activeCount":119},[],{"trials":9737,"activeCount":119},[],{"trials":9739,"activeCount":119},[],{"trials":9741,"activeCount":119},[],{"intervention":9731,"totalTrials":116,"cells":9743},{"EARLY_PHASE1":9744,"PHASE1":9750,"PHASE2":9752,"PHASE3":9754,"PHASE4":9756,"NA":9758},{"trials":9745,"activeCount":119},[9746],{"nctId":9722,"briefTitle":9723,"status":164,"phases":9747,"primaryCompletion":9725,"completion":9726,"start":9727,"enrollment":627,"conditions":9748,"interventions":9749},[88],[9729],[9717,9731],{"trials":9751,"activeCount":119},[],{"trials":9753,"activeCount":119},[],{"trials":9755,"activeCount":119},[],{"trials":9757,"activeCount":119},[],{"trials":9759,"activeCount":119},[],{"intervention":9761,"totalTrials":116,"cells":9762},"Doravirine 100 Mg",{"EARLY_PHASE1":9763,"PHASE1":9775,"PHASE2":9777,"PHASE3":9779,"PHASE4":9781,"NA":9783},{"trials":9764,"activeCount":119},[9765],{"nctId":9766,"briefTitle":9767,"status":164,"phases":9768,"primaryCompletion":8076,"completion":9769,"start":1388,"enrollment":911,"conditions":9770,"interventions":9774},"NCT04820933","Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV",[88],"2025-12-01",[9771,9772,9773],"HIV I Infection","Cardiovascular Risk Factor","Lipid Metabolism Disorders",[9761],{"trials":9776,"activeCount":119},[],{"trials":9778,"activeCount":119},[],{"trials":9780,"activeCount":119},[],{"trials":9782,"activeCount":119},[],{"trials":9784,"activeCount":119},[],{"intervention":9786,"totalTrials":116,"cells":9787},"Itraconazole",{"EARLY_PHASE1":9788,"PHASE1":9797,"PHASE2":9799,"PHASE3":9801,"PHASE4":9803,"NA":9805},{"trials":9789,"activeCount":119},[9790],{"nctId":9791,"briefTitle":9792,"status":164,"phases":9793,"primaryCompletion":9794,"completion":9794,"start":2820,"enrollment":33,"conditions":9795,"interventions":9796},"NCT02357836","Neoadjuvant Itraconazole in Non-small Cell Lung Cancer",[88],"2018-07",[6619],[9786],{"trials":9798,"activeCount":119},[],{"trials":9800,"activeCount":119},[],{"trials":9802,"activeCount":119},[],{"trials":9804,"activeCount":119},[],{"trials":9806,"activeCount":119},[],{"intervention":9808,"totalTrials":116,"cells":9809},"Formal study using hyperpolarized 13C-pyruvate",{"EARLY_PHASE1":9810,"PHASE1":9823,"PHASE2":9825,"PHASE3":9827,"PHASE4":9829,"NA":9831},{"trials":9811,"activeCount":119},[9812],{"nctId":9813,"briefTitle":9814,"status":164,"phases":9815,"primaryCompletion":9816,"completion":9816,"start":9817,"enrollment":9818,"conditions":9819,"interventions":9821},"NCT03685175","Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity",[88],"2025-02-28","2018-07-03",79,[9820],"Breast Neoplasms",[9808,9822],"Feasible study using hyperpolarized 13C-pyruvate",{"trials":9824,"activeCount":119},[],{"trials":9826,"activeCount":119},[],{"trials":9828,"activeCount":119},[],{"trials":9830,"activeCount":119},[],{"trials":9832,"activeCount":119},[],{"intervention":9822,"totalTrials":116,"cells":9834},{"EARLY_PHASE1":9835,"PHASE1":9841,"PHASE2":9843,"PHASE3":9845,"PHASE4":9847,"NA":9849},{"trials":9836,"activeCount":119},[9837],{"nctId":9813,"briefTitle":9814,"status":164,"phases":9838,"primaryCompletion":9816,"completion":9816,"start":9817,"enrollment":9818,"conditions":9839,"interventions":9840},[88],[9820],[9808,9822],{"trials":9842,"activeCount":119},[],{"trials":9844,"activeCount":119},[],{"trials":9846,"activeCount":119},[],{"trials":9848,"activeCount":119},[],{"trials":9850,"activeCount":119},[],{"intervention":9852,"totalTrials":116,"cells":9853},"Loestrin",{"EARLY_PHASE1":9854,"PHASE1":9864,"PHASE2":9866,"PHASE3":9868,"PHASE4":9870,"NA":9872},{"trials":9855,"activeCount":119},[9856],{"nctId":9857,"briefTitle":9858,"status":164,"phases":9859,"primaryCompletion":9860,"completion":9860,"start":4380,"enrollment":3162,"conditions":9861,"interventions":9863},"NCT02036879","Gender Disparity and Hormones in Cystic Fibrosis",[88],"2018-08",[9862],"Cystic Fibrosis (CF)",[9852],{"trials":9865,"activeCount":119},[],{"trials":9867,"activeCount":119},[],{"trials":9869,"activeCount":119},[],{"trials":9871,"activeCount":119},[],{"trials":9873,"activeCount":119},[],{"intervention":9875,"totalTrials":116,"cells":9876},"BAY 2402234",{"EARLY_PHASE1":9877,"PHASE1":9888,"PHASE2":9890,"PHASE3":9892,"PHASE4":9894,"NA":9896},{"trials":9878,"activeCount":119},[9879],{"nctId":9880,"briefTitle":9881,"status":951,"phases":9882,"primaryCompletion":9883,"completion":8685,"start":9884,"enrollment":119,"conditions":9885,"interventions":9887},"NCT05061251","Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma",[88],"2022-12-01","2021-12-01",[7102,9886],"IDH Mutation",[9875],{"trials":9889,"activeCount":119},[],{"trials":9891,"activeCount":119},[],{"trials":9893,"activeCount":119},[],{"trials":9895,"activeCount":119},[],{"trials":9897,"activeCount":119},[],{"intervention":9899,"totalTrials":116,"cells":9900},"Lynparza",{"EARLY_PHASE1":9901,"PHASE1":9909,"PHASE2":9911,"PHASE3":9913,"PHASE4":9915,"NA":9917},{"trials":9902,"activeCount":119},[9903],{"nctId":9904,"briefTitle":9905,"status":164,"phases":9906,"primaryCompletion":8600,"completion":8600,"start":900,"enrollment":3598,"conditions":9907,"interventions":9908},"NCT04041128","PARP Inhibition During Pre-surgical Window in Breast\u002FOvary Cancer",[88],[6855,20],[9899],{"trials":9910,"activeCount":119},[],{"trials":9912,"activeCount":119},[],{"trials":9914,"activeCount":119},[],{"trials":9916,"activeCount":119},[],{"trials":9918,"activeCount":119},[],{"intervention":9920,"totalTrials":116,"cells":9921},"Renal Denervation",{"EARLY_PHASE1":9922,"PHASE1":9931,"PHASE2":9933,"PHASE3":9935,"PHASE4":9937,"NA":9939},{"trials":9923,"activeCount":119},[9924],{"nctId":9925,"briefTitle":9926,"status":164,"phases":9927,"primaryCompletion":9928,"completion":636,"start":954,"enrollment":650,"conditions":9929,"interventions":9930},"NCT03465917","Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation",[88],"2019-03-06",[18],[9920],{"trials":9932,"activeCount":119},[],{"trials":9934,"activeCount":119},[],{"trials":9936,"activeCount":119},[],{"trials":9938,"activeCount":119},[],{"trials":9940,"activeCount":119},[],{"intervention":9942,"totalTrials":116,"cells":9943},"Bupivacaine 0.25% Injectable Solution",{"EARLY_PHASE1":9944,"PHASE1":9954,"PHASE2":9956,"PHASE3":9958,"PHASE4":9960,"NA":9962},{"trials":9945,"activeCount":119},[9946],{"nctId":9947,"briefTitle":9948,"status":164,"phases":9949,"primaryCompletion":9645,"completion":9645,"start":9950,"enrollment":97,"conditions":9951,"interventions":9953},"NCT05925478","Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage",[88],"2023-11-06",[9952],"Subarachnoid Hemorrhage, Aneurysmal",[9942],{"trials":9955,"activeCount":119},[],{"trials":9957,"activeCount":119},[],{"trials":9959,"activeCount":119},[],{"trials":9961,"activeCount":119},[],{"trials":9963,"activeCount":119},[],{"intervention":9965,"totalTrials":116,"cells":9966},"pioglitazone hydrochloride",{"EARLY_PHASE1":9967,"PHASE1":9977,"PHASE2":9979,"PHASE3":9981,"PHASE4":9983,"NA":9985},{"trials":9968,"activeCount":119},[9969],{"nctId":9970,"briefTitle":9971,"status":385,"phases":9972,"primaryCompletion":9973,"completion":9973,"start":9974,"enrollment":2832,"conditions":9975,"interventions":9976},"NCT00867126","Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine",[88],"2012-02","2009-03-02",[418],[9965],{"trials":9978,"activeCount":119},[],{"trials":9980,"activeCount":119},[],{"trials":9982,"activeCount":119},[],{"trials":9984,"activeCount":119},[],{"trials":9986,"activeCount":119},[],{"intervention":9650,"totalTrials":116,"cells":9988},{"EARLY_PHASE1":9989,"PHASE1":9995,"PHASE2":9997,"PHASE3":9999,"PHASE4":10001,"NA":10003},{"trials":9990,"activeCount":119},[9991],{"nctId":9642,"briefTitle":9643,"status":164,"phases":9992,"primaryCompletion":9645,"completion":9645,"start":9646,"enrollment":5257,"conditions":9993,"interventions":9994},[88],[9648],[9637,9650],{"trials":9996,"activeCount":119},[],{"trials":9998,"activeCount":119},[],{"trials":10000,"activeCount":119},[],{"trials":10002,"activeCount":119},[],{"trials":10004,"activeCount":119},[],{"intervention":10006,"totalTrials":116,"cells":10007},"[18F]FLT-PET\u002FCT",{"EARLY_PHASE1":10008,"PHASE1":10017,"PHASE2":10019,"PHASE3":10021,"PHASE4":10023,"NA":10025},{"trials":10009,"activeCount":119},[10010],{"nctId":10011,"briefTitle":10012,"status":951,"phases":10013,"primaryCompletion":9681,"completion":9681,"start":10014,"enrollment":119,"conditions":10015,"interventions":10016},"NCT03905538","Evaluation of [18F]FLT PET\u002FCT as an Early Predictor of Outcome in Pediatric Solid Tumors",[88],"2019-08-13",[798],[10006],{"trials":10018,"activeCount":119},[],{"trials":10020,"activeCount":119},[],{"trials":10022,"activeCount":119},[],{"trials":10024,"activeCount":119},[],{"trials":10026,"activeCount":119},[],{"intervention":10028,"totalTrials":116,"cells":10029},"Warfarin",{"EARLY_PHASE1":10030,"PHASE1":10040,"PHASE2":10042,"PHASE3":10044,"PHASE4":10046,"NA":10048},{"trials":10031,"activeCount":119},[10032],{"nctId":10033,"briefTitle":10034,"status":951,"phases":10035,"primaryCompletion":10036,"completion":10037,"start":9274,"enrollment":119,"conditions":10038,"interventions":10039},"NCT03536208","Biological Effect of Warfarin on Pancreatic Cancer",[88],"2021-06","2022-06",[418],[10028],{"trials":10041,"activeCount":119},[],{"trials":10043,"activeCount":119},[],{"trials":10045,"activeCount":119},[],{"trials":10047,"activeCount":119},[],{"trials":10049,"activeCount":119},[],{"intervention":9661,"totalTrials":116,"cells":10051},{"EARLY_PHASE1":10052,"PHASE1":10058,"PHASE2":10060,"PHASE3":10062,"PHASE4":10064,"NA":10066},{"trials":10053,"activeCount":119},[10054],{"nctId":9652,"briefTitle":9653,"status":164,"phases":10055,"primaryCompletion":9655,"completion":9655,"start":9656,"enrollment":9657,"conditions":10056,"interventions":10057},[88],[9659],[9637,9661],{"trials":10059,"activeCount":119},[],{"trials":10061,"activeCount":119},[],{"trials":10063,"activeCount":119},[],{"trials":10065,"activeCount":119},[],{"trials":10067,"activeCount":119},[],{"intervention":10069,"totalTrials":116,"cells":10070},"Botulinum toxin",{"EARLY_PHASE1":10071,"PHASE1":10082,"PHASE2":10084,"PHASE3":10086,"PHASE4":10088,"NA":10090},{"trials":10072,"activeCount":119},[10073],{"nctId":10074,"briefTitle":10075,"status":164,"phases":10076,"primaryCompletion":10077,"completion":10077,"start":10078,"enrollment":27,"conditions":10079,"interventions":10081},"NCT04523506","The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma",[88],"2021-04-22","2020-05-08",[10080],"Scleroderma",[10069],{"trials":10083,"activeCount":119},[],{"trials":10085,"activeCount":119},[],{"trials":10087,"activeCount":119},[],{"trials":10089,"activeCount":119},[],{"trials":10091,"activeCount":119},[],{"intervention":10093,"totalTrials":116,"cells":10094},"Normal Saline Group",{"EARLY_PHASE1":10095,"PHASE1":10108,"PHASE2":10110,"PHASE3":10112,"PHASE4":10114,"NA":10116},{"trials":10096,"activeCount":119},[10097],{"nctId":10098,"briefTitle":10099,"status":164,"phases":10100,"primaryCompletion":10101,"completion":10101,"start":10102,"enrollment":10103,"conditions":10104,"interventions":10106},"NCT05029596","Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines",[88],"2023-03-30","2020-02-12",142,[10105],"Cancer",[10093,10107],"Heparin Group",{"trials":10109,"activeCount":119},[],{"trials":10111,"activeCount":119},[],{"trials":10113,"activeCount":119},[],{"trials":10115,"activeCount":119},[],{"trials":10117,"activeCount":119},[],{"intervention":10107,"totalTrials":116,"cells":10119},{"EARLY_PHASE1":10120,"PHASE1":10126,"PHASE2":10128,"PHASE3":10130,"PHASE4":10132,"NA":10134},{"trials":10121,"activeCount":119},[10122],{"nctId":10098,"briefTitle":10099,"status":164,"phases":10123,"primaryCompletion":10101,"completion":10101,"start":10102,"enrollment":10103,"conditions":10124,"interventions":10125},[88],[10105],[10093,10107],{"trials":10127,"activeCount":119},[],{"trials":10129,"activeCount":119},[],{"trials":10131,"activeCount":119},[],{"trials":10133,"activeCount":119},[],{"trials":10135,"activeCount":119},[],{"intervention":3366,"totalTrials":650,"cells":10137},{"EARLY_PHASE1":10138,"PHASE1":10140,"PHASE2":10142,"PHASE3":10144,"PHASE4":10155,"NA":10174},{"trials":10139,"activeCount":119},[],{"trials":10141,"activeCount":119},[],{"trials":10143,"activeCount":119},[],{"trials":10145,"activeCount":119},[10146],{"nctId":10147,"briefTitle":10148,"status":164,"phases":10149,"primaryCompletion":3827,"completion":3827,"start":4044,"enrollment":7953,"conditions":10150,"interventions":10154},"NCT00223236","Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse\u002FDependence",[91],[10151,10152,10153,2942],"Mania","Hypomania","Cocaine Abuse",[3366],{"trials":10156,"activeCount":119},[10157,10164,10168],{"nctId":10158,"briefTitle":10159,"status":164,"phases":10160,"primaryCompletion":10161,"completion":10161,"start":9598,"enrollment":8432,"conditions":10162,"interventions":10163},"NCT00619723","Citicoline for Bipolar 1 Disorder and Cocaine Dependence",[92],"2012-04",[26,2942],[3366],{"nctId":3358,"briefTitle":3359,"status":951,"phases":10165,"primaryCompletion":3361,"completion":3361,"start":3362,"enrollment":119,"conditions":10166,"interventions":10167},[92],[3364],[892,3366],{"nctId":10169,"briefTitle":10170,"status":164,"phases":10171,"primaryCompletion":1018,"completion":3172,"start":2891,"enrollment":389,"conditions":10172,"interventions":10173},"NCT02074735","Citicoline for Alcohol Dependence",[92],[2961],[3366],{"trials":10175,"activeCount":119},[10176],{"nctId":10177,"briefTitle":10178,"status":164,"phases":10179,"primaryCompletion":3558,"completion":3558,"start":10180,"enrollment":833,"conditions":10181,"interventions":10184},"NCT00377299","A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence",[93],"2006-10",[10182,10183,26,29],"Amphetamine Abuse","Amphetamine Dependence",[3366],{"intervention":10186,"totalTrials":650,"cells":10187},"Pioglitazone",{"EARLY_PHASE1":10188,"PHASE1":10190,"PHASE2":10192,"PHASE3":10201,"PHASE4":10203,"NA":10205},{"trials":10189,"activeCount":119},[],{"trials":10191,"activeCount":119},[],{"trials":10193,"activeCount":119},[10194],{"nctId":10195,"briefTitle":10196,"status":164,"phases":10197,"primaryCompletion":2845,"completion":2845,"start":7863,"enrollment":3598,"conditions":10198,"interventions":10200},"NCT01838317","A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas",[90],[10199],"Cancer of the Pancreas",[10186],{"trials":10202,"activeCount":119},[],{"trials":10204,"activeCount":119},[],{"trials":10206,"activeCount":119},[10207,10218,10227,10236],{"nctId":10208,"briefTitle":10209,"status":164,"phases":10210,"primaryCompletion":6791,"completion":6791,"start":10211,"enrollment":1267,"conditions":10212,"interventions":10214},"NCT00232583","Preservation of Beta-cell Function in Type 2 Diabetes Mellitus",[93],"2003-11",[10213],"Type 2 Diabetes Mellitus",[3336,10215,10216,10186,10217],"Insulin","Metfomin","glyburide",{"nctId":10219,"briefTitle":10220,"status":164,"phases":10221,"primaryCompletion":7170,"completion":7170,"start":10222,"enrollment":10223,"conditions":10224,"interventions":10225},"NCT00855010","Pioglitazone on Pancreatic Steatosis and Bone Health",[93],"2009-02",42,[23,239],[10226],"pioglitazone",{"nctId":10228,"briefTitle":10229,"status":164,"phases":10230,"primaryCompletion":10231,"completion":10231,"start":10232,"enrollment":3025,"conditions":10233,"interventions":10235},"NCT00904046","Pathophysiology of Uric Acid Nephrolithiasis",[93],"2017-11-16","2010-01-15",[10234],"Uric Acid Kidney Stone Disease",[10186],{"nctId":10237,"briefTitle":10238,"status":164,"phases":10239,"primaryCompletion":10240,"completion":10240,"start":9188,"enrollment":724,"conditions":10241,"interventions":10242},"NCT01023620","HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)",[93],"2010-05-31",[3746],[10186],{"intervention":10244,"totalTrials":724,"cells":10245},"Fluoxetine",{"EARLY_PHASE1":10246,"PHASE1":10248,"PHASE2":10250,"PHASE3":10267,"PHASE4":10269,"NA":10271},{"trials":10247,"activeCount":119},[],{"trials":10249,"activeCount":119},[],{"trials":10251,"activeCount":119},[10252,10261],{"nctId":10253,"briefTitle":10254,"status":164,"phases":10255,"primaryCompletion":10256,"completion":10257,"start":10258,"enrollment":5257,"conditions":10259,"interventions":10260},"NCT03638908","Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial",[90],"2017-05","2018-12","2013-11",[2621],[10244],{"nctId":10262,"briefTitle":10263,"status":164,"phases":10264,"primaryCompletion":3136,"completion":3440,"start":5133,"enrollment":2832,"conditions":10265,"interventions":10266},"NCT00942708","Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension",[90],[2621],[10244],{"trials":10268,"activeCount":119},[],{"trials":10270,"activeCount":119},[],{"trials":10272,"activeCount":119},[10273,10280],{"nctId":10274,"briefTitle":10275,"status":164,"phases":10276,"completion":3264,"start":10277,"enrollment":523,"conditions":10278,"interventions":10279},"NCT00332787","Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents",[93],"2000-06",[15],[10244],{"nctId":10281,"briefTitle":10282,"status":164,"phases":10283,"primaryCompletion":4406,"completion":3208,"start":3484,"enrollment":10284,"conditions":10285,"interventions":10286},"NCT00612313","Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse",[93],144,[15],[10244],{"intervention":10288,"totalTrials":360,"cells":10289},"Ropivacaine",{"EARLY_PHASE1":10290,"PHASE1":10292,"PHASE2":10294,"PHASE3":10296,"PHASE4":10298,"NA":10308},{"trials":10291,"activeCount":119},[],{"trials":10293,"activeCount":119},[],{"trials":10295,"activeCount":119},[],{"trials":10297,"activeCount":119},[],{"trials":10299,"activeCount":119},[10300],{"nctId":10301,"briefTitle":10302,"status":385,"phases":10303,"primaryCompletion":10304,"completion":10304,"start":10305,"enrollment":7148,"conditions":10306,"interventions":10307},"NCT02788019","Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?",[92],"2020-03-23","2016-05-26",[3210],[10288],{"trials":10309,"activeCount":119},[10310,10323],{"nctId":10311,"briefTitle":10312,"status":164,"phases":10313,"primaryCompletion":6125,"completion":10314,"start":10315,"enrollment":10316,"conditions":10317,"interventions":10319},"NCT02151487","A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block",[],"2016-08-20","2014-03",97,[10318],"Upper Extremity Surgery",[10288,10320,10321,10322],"Ropivacaine and dexamethasone","Ropivacaine and clonidine","Ropivacaine, dexamethasone and clonidine",{"nctId":10324,"briefTitle":10325,"status":164,"phases":10326,"primaryCompletion":10327,"completion":10328,"start":10329,"enrollment":833,"conditions":10330,"interventions":10331},"NCT02658240","Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration",[93],"2017-11-13","2017-12-16","2016-04-05",[3210],[10288,9602],{"intervention":9552,"totalTrials":360,"cells":10333},{"EARLY_PHASE1":10334,"PHASE1":10336,"PHASE2":10342,"PHASE3":10344,"PHASE4":10346,"NA":10356},{"trials":10335,"activeCount":119},[],{"trials":10337,"activeCount":119},[10338],{"nctId":9546,"briefTitle":9547,"status":951,"phases":10339,"enrollment":119,"conditions":10340,"interventions":10341},[89],[9550],[9539,9552],{"trials":10343,"activeCount":119},[],{"trials":10345,"activeCount":119},[],{"trials":10347,"activeCount":119},[10348],{"nctId":10349,"briefTitle":10350,"status":951,"phases":10351,"primaryCompletion":10352,"completion":10352,"start":10352,"enrollment":119,"conditions":10353,"interventions":10355},"NCT00363935","Bariatric Dose-ranging Study With Dexmedetomidine",[92],"2007-01-01",[10354],"Abdominal Surgery Patients",[9552],{"trials":10357,"activeCount":119},[10358],{"nctId":10359,"briefTitle":10360,"status":164,"phases":10361,"primaryCompletion":10362,"completion":10362,"start":2820,"enrollment":353,"conditions":10363,"interventions":10364},"NCT02524145","Chronotropic Incompetence in Patients With HFpEF",[93],"2017-11-15",[35],[9552,10365,10366],"Glycopyrrolate","Isoproterenol",{"intervention":10368,"totalTrials":97,"cells":10369},"Propofol",{"EARLY_PHASE1":10370,"PHASE1":10372,"PHASE2":10374,"PHASE3":10376,"PHASE4":10378,"NA":10380},{"trials":10371,"activeCount":119},[],{"trials":10373,"activeCount":119},[],{"trials":10375,"activeCount":119},[],{"trials":10377,"activeCount":119},[],{"trials":10379,"activeCount":119},[],{"trials":10381,"activeCount":119},[10382,10390],{"nctId":10383,"briefTitle":10384,"status":164,"phases":10385,"primaryCompletion":1852,"completion":1852,"start":10386,"enrollment":5369,"conditions":10387,"interventions":10389},"NCT04502550","Brain Networks and Consciousness",[],"2020-10-15",[10388,2714,2715,525],"Loss of Consciousness",[10368],{"nctId":10391,"briefTitle":10392,"status":164,"phases":10393,"primaryCompletion":10394,"completion":10394,"start":2820,"enrollment":353,"conditions":10395,"interventions":10397},"NCT02485418","Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients",[93],"2023-01-24",[10396],"Migraine Headache",[10368],{"intervention":10215,"totalTrials":97,"cells":10399},{"EARLY_PHASE1":10400,"PHASE1":10402,"PHASE2":10404,"PHASE3":10406,"PHASE4":10408,"NA":10410},{"trials":10401,"activeCount":119},[],{"trials":10403,"activeCount":119},[],{"trials":10405,"activeCount":119},[],{"trials":10407,"activeCount":119},[],{"trials":10409,"activeCount":119},[],{"trials":10411,"activeCount":119},[10412,10420],{"nctId":10413,"briefTitle":10414,"status":951,"phases":10415,"primaryCompletion":10416,"completion":10416,"start":10416,"enrollment":119,"conditions":10417,"interventions":10419},"NCT00287456","Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.",[93],"2006-02-02",[10418],"Cystic Fibrosis Related Diabetes",[10215],{"nctId":10208,"briefTitle":10209,"status":164,"phases":10421,"primaryCompletion":6791,"completion":6791,"start":10211,"enrollment":1267,"conditions":10422,"interventions":10423},[93],[10213],[3336,10215,10216,10186,10217],{"intervention":3336,"totalTrials":97,"cells":10425},{"EARLY_PHASE1":10426,"PHASE1":10428,"PHASE2":10430,"PHASE3":10432,"PHASE4":10434,"NA":10440},{"trials":10427,"activeCount":119},[],{"trials":10429,"activeCount":119},[],{"trials":10431,"activeCount":119},[],{"trials":10433,"activeCount":119},[],{"trials":10435,"activeCount":119},[10436],{"nctId":3326,"briefTitle":3327,"status":164,"phases":10437,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":10438,"interventions":10439},[92],[3333,3334],[3336,3337,3302,3338],{"trials":10441,"activeCount":119},[10442],{"nctId":10208,"briefTitle":10209,"status":164,"phases":10443,"primaryCompletion":6791,"completion":6791,"start":10211,"enrollment":1267,"conditions":10444,"interventions":10445},[93],[10213],[3336,10215,10216,10186,10217],{"intervention":10217,"totalTrials":97,"cells":10447},{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10452,"PHASE3":10454,"PHASE4":10456,"NA":10468},{"trials":10449,"activeCount":119},[],{"trials":10451,"activeCount":119},[],{"trials":10453,"activeCount":119},[],{"trials":10455,"activeCount":119},[],{"trials":10457,"activeCount":119},[10458],{"nctId":10459,"briefTitle":10460,"status":164,"phases":10461,"primaryCompletion":4196,"completion":5918,"start":10462,"enrollment":10463,"conditions":10464,"interventions":10466},"NCT00744965","Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo",[92],"2008-09-16",395,[10465],"Mild Gestational Diabetes",[10467],"Glyburide",{"trials":10469,"activeCount":119},[10470],{"nctId":10208,"briefTitle":10209,"status":164,"phases":10471,"primaryCompletion":6791,"completion":6791,"start":10211,"enrollment":1267,"conditions":10472,"interventions":10473},[93],[10213],[3336,10215,10216,10186,10217],{"intervention":10475,"totalTrials":97,"cells":10476},"Potassium Magnesium Citrate",{"EARLY_PHASE1":10477,"PHASE1":10479,"PHASE2":10481,"PHASE3":10483,"PHASE4":10485,"NA":10491},{"trials":10478,"activeCount":119},[],{"trials":10480,"activeCount":119},[],{"trials":10482,"activeCount":119},[],{"trials":10484,"activeCount":119},[],{"trials":10486,"activeCount":119},[10487],{"nctId":3515,"briefTitle":3502,"status":164,"phases":10488,"primaryCompletion":3517,"completion":3517,"start":3518,"enrollment":617,"conditions":10489,"interventions":10490},[92],[18],[3492,3521,3508],{"trials":10492,"activeCount":119},[10493],{"nctId":10494,"briefTitle":10495,"status":164,"phases":10496,"primaryCompletion":6545,"completion":6545,"start":3517,"enrollment":1152,"conditions":10497,"interventions":10498},"NCT02665117","Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate",[93],[18],[10475,7842,10499],"Chlorthalidone",{"intervention":7842,"totalTrials":97,"cells":10501},{"EARLY_PHASE1":10502,"PHASE1":10504,"PHASE2":10506,"PHASE3":10512,"PHASE4":10514,"NA":10516},{"trials":10503,"activeCount":119},[],{"trials":10505,"activeCount":119},[],{"trials":10507,"activeCount":119},[10508],{"nctId":7836,"briefTitle":7837,"status":951,"phases":10509,"primaryCompletion":3518,"completion":2892,"start":5133,"enrollment":119,"conditions":10510,"interventions":10511},[89,90],[7840,18],[7827,7842],{"trials":10513,"activeCount":119},[],{"trials":10515,"activeCount":119},[],{"trials":10517,"activeCount":119},[10518],{"nctId":10494,"briefTitle":10495,"status":164,"phases":10519,"primaryCompletion":6545,"completion":6545,"start":3517,"enrollment":1152,"conditions":10520,"interventions":10521},[93],[18],[10475,7842,10499],{"intervention":10499,"totalTrials":97,"cells":10523},{"EARLY_PHASE1":10524,"PHASE1":10537,"PHASE2":10539,"PHASE3":10541,"PHASE4":10543,"NA":10545},{"trials":10525,"activeCount":119},[10526],{"nctId":10527,"briefTitle":10528,"status":164,"phases":10529,"primaryCompletion":10530,"completion":10530,"start":10531,"enrollment":5773,"conditions":10532,"interventions":10535},"NCT06287580","Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.",[88],"2026-02-20","2024-08-15",[10533,10534],"Essential Hypertension","Older Adults",[10536],"chlorthalidone",{"trials":10538,"activeCount":119},[],{"trials":10540,"activeCount":119},[],{"trials":10542,"activeCount":119},[],{"trials":10544,"activeCount":119},[],{"trials":10546,"activeCount":119},[10547],{"nctId":10494,"briefTitle":10495,"status":164,"phases":10548,"primaryCompletion":6545,"completion":6545,"start":3517,"enrollment":1152,"conditions":10549,"interventions":10550},[93],[18],[10475,7842,10499],{"intervention":3454,"totalTrials":97,"cells":10552},{"EARLY_PHASE1":10553,"PHASE1":10555,"PHASE2":10557,"PHASE3":10559,"PHASE4":10561,"NA":10567},{"trials":10554,"activeCount":119},[],{"trials":10556,"activeCount":119},[],{"trials":10558,"activeCount":119},[],{"trials":10560,"activeCount":119},[],{"trials":10562,"activeCount":119},[10563],{"nctId":3447,"briefTitle":3448,"status":951,"phases":10564,"primaryCompletion":3450,"completion":3450,"start":1029,"enrollment":119,"conditions":10565,"interventions":10566},[92],[3452],[3424,3454,3455,3456],{"trials":10568,"activeCount":119},[10569],{"nctId":10570,"briefTitle":10571,"status":385,"phases":10572,"primaryCompletion":10222,"completion":7052,"start":10573,"enrollment":3442,"conditions":10574,"interventions":10575},"NCT00564018","Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH",[93],"2006-09",[3452],[10576,3454,10577],"Insulin detemir","NPH",{"intervention":10579,"totalTrials":97,"cells":10580},"Growth Hormone",{"EARLY_PHASE1":10581,"PHASE1":10583,"PHASE2":10585,"PHASE3":10587,"PHASE4":10589,"NA":10591},{"trials":10582,"activeCount":119},[],{"trials":10584,"activeCount":119},[],{"trials":10586,"activeCount":119},[],{"trials":10588,"activeCount":119},[],{"trials":10590,"activeCount":119},[],{"trials":10592,"activeCount":119},[10593,10604],{"nctId":10594,"briefTitle":10595,"status":951,"phases":10596,"primaryCompletion":10597,"completion":10597,"start":10597,"enrollment":119,"conditions":10598,"interventions":10603},"NCT00286689","Effects of Growth Hormone in Chronically Ill Children",[93],"2006-02-03",[10599,10600,10601,10602,3746],"Hurler Syndrome","Cerebral Palsy","Juvenile Rheumatoid Arthritis","Crohn Disease",[10579],{"nctId":10605,"briefTitle":10606,"status":951,"phases":10607,"primaryCompletion":10608,"completion":10608,"start":10608,"enrollment":119,"conditions":10609,"interventions":10610},"NCT00287430","Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis",[93],"2006-01",[264],[10579],{"intervention":9602,"totalTrials":97,"cells":10612},{"EARLY_PHASE1":10613,"PHASE1":10615,"PHASE2":10621,"PHASE3":10623,"PHASE4":10625,"NA":10627},{"trials":10614,"activeCount":119},[],{"trials":10616,"activeCount":119},[10617],{"nctId":9594,"briefTitle":9595,"status":164,"phases":10618,"primaryCompletion":9597,"completion":9597,"start":9598,"enrollment":8432,"conditions":10619,"interventions":10620},[89],[2861,9600],[9587,9602],{"trials":10622,"activeCount":119},[],{"trials":10624,"activeCount":119},[],{"trials":10626,"activeCount":119},[],{"trials":10628,"activeCount":119},[10629],{"nctId":10324,"briefTitle":10325,"status":164,"phases":10630,"primaryCompletion":10327,"completion":10328,"start":10329,"enrollment":833,"conditions":10631,"interventions":10632},[93],[3210],[10288,9602],{"intervention":10320,"totalTrials":116,"cells":10634},{"EARLY_PHASE1":10635,"PHASE1":10637,"PHASE2":10639,"PHASE3":10641,"PHASE4":10643,"NA":10645},{"trials":10636,"activeCount":119},[],{"trials":10638,"activeCount":119},[],{"trials":10640,"activeCount":119},[],{"trials":10642,"activeCount":119},[],{"trials":10644,"activeCount":119},[],{"trials":10646,"activeCount":119},[10647],{"nctId":10311,"briefTitle":10312,"status":164,"phases":10648,"primaryCompletion":6125,"completion":10314,"start":10315,"enrollment":10316,"conditions":10649,"interventions":10650},[],[10318],[10288,10320,10321,10322],{"intervention":10321,"totalTrials":116,"cells":10652},{"EARLY_PHASE1":10653,"PHASE1":10655,"PHASE2":10657,"PHASE3":10659,"PHASE4":10661,"NA":10663},{"trials":10654,"activeCount":119},[],{"trials":10656,"activeCount":119},[],{"trials":10658,"activeCount":119},[],{"trials":10660,"activeCount":119},[],{"trials":10662,"activeCount":119},[],{"trials":10664,"activeCount":119},[10665],{"nctId":10311,"briefTitle":10312,"status":164,"phases":10666,"primaryCompletion":6125,"completion":10314,"start":10315,"enrollment":10316,"conditions":10667,"interventions":10668},[],[10318],[10288,10320,10321,10322],{"intervention":10322,"totalTrials":116,"cells":10670},{"EARLY_PHASE1":10671,"PHASE1":10673,"PHASE2":10675,"PHASE3":10677,"PHASE4":10679,"NA":10681},{"trials":10672,"activeCount":119},[],{"trials":10674,"activeCount":119},[],{"trials":10676,"activeCount":119},[],{"trials":10678,"activeCount":119},[],{"trials":10680,"activeCount":119},[],{"trials":10682,"activeCount":119},[10683],{"nctId":10311,"briefTitle":10312,"status":164,"phases":10684,"primaryCompletion":6125,"completion":10314,"start":10315,"enrollment":10316,"conditions":10685,"interventions":10686},[],[10318],[10288,10320,10321,10322],{"intervention":10688,"totalTrials":116,"cells":10689},"Carvedilol vs. Prazosin",{"EARLY_PHASE1":10690,"PHASE1":10692,"PHASE2":10694,"PHASE3":10696,"PHASE4":10698,"NA":10700},{"trials":10691,"activeCount":119},[],{"trials":10693,"activeCount":119},[],{"trials":10695,"activeCount":119},[],{"trials":10697,"activeCount":119},[],{"trials":10699,"activeCount":119},[],{"trials":10701,"activeCount":119},[10702],{"nctId":10703,"briefTitle":10704,"status":164,"phases":10705,"primaryCompletion":8454,"completion":8454,"start":4196,"enrollment":6273,"conditions":10706,"interventions":10707},"NCT01862497","Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension",[],[3164],[10688],{"intervention":10709,"totalTrials":116,"cells":10710},"3% Hypertonic Saline",{"EARLY_PHASE1":10711,"PHASE1":10713,"PHASE2":10715,"PHASE3":10717,"PHASE4":10719,"NA":10721},{"trials":10712,"activeCount":119},[],{"trials":10714,"activeCount":119},[],{"trials":10716,"activeCount":119},[],{"trials":10718,"activeCount":119},[],{"trials":10720,"activeCount":119},[],{"trials":10722,"activeCount":119},[10723],{"nctId":10724,"briefTitle":10725,"status":164,"phases":10726,"primaryCompletion":5715,"completion":5715,"start":7170,"enrollment":7148,"conditions":10727,"interventions":10729},"NCT02029040","Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis",[93],[10728],"Acute Bronchiolitis",[10709,10730],"0.9 % normal saline",{"intervention":10730,"totalTrials":116,"cells":10732},{"EARLY_PHASE1":10733,"PHASE1":10735,"PHASE2":10737,"PHASE3":10739,"PHASE4":10741,"NA":10743},{"trials":10734,"activeCount":119},[],{"trials":10736,"activeCount":119},[],{"trials":10738,"activeCount":119},[],{"trials":10740,"activeCount":119},[],{"trials":10742,"activeCount":119},[],{"trials":10744,"activeCount":119},[10745],{"nctId":10724,"briefTitle":10725,"status":164,"phases":10746,"primaryCompletion":5715,"completion":5715,"start":7170,"enrollment":7148,"conditions":10747,"interventions":10748},[93],[10728],[10709,10730],{"intervention":10750,"totalTrials":116,"cells":10751},"Polyethylene glycol 3350-electrolyte solution",{"EARLY_PHASE1":10752,"PHASE1":10754,"PHASE2":10756,"PHASE3":10758,"PHASE4":10760,"NA":10762},{"trials":10753,"activeCount":119},[],{"trials":10755,"activeCount":119},[],{"trials":10757,"activeCount":119},[],{"trials":10759,"activeCount":119},[],{"trials":10761,"activeCount":119},[],{"trials":10763,"activeCount":119},[10764],{"nctId":10765,"briefTitle":10766,"status":164,"phases":10767,"primaryCompletion":3828,"completion":3828,"start":3137,"enrollment":702,"conditions":10768,"interventions":10773},"NCT01283152","Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.",[93],[10769,10770,10771,10772],"Hepatic Encephalopathy","Cirrhosis","Portosystemic Encephalopathy","PSE",[10750,10774],"Lactulose",{"intervention":10774,"totalTrials":116,"cells":10776},{"EARLY_PHASE1":10777,"PHASE1":10779,"PHASE2":10781,"PHASE3":10783,"PHASE4":10785,"NA":10787},{"trials":10778,"activeCount":119},[],{"trials":10780,"activeCount":119},[],{"trials":10782,"activeCount":119},[],{"trials":10784,"activeCount":119},[],{"trials":10786,"activeCount":119},[],{"trials":10788,"activeCount":119},[10789],{"nctId":10765,"briefTitle":10766,"status":164,"phases":10790,"primaryCompletion":3828,"completion":3828,"start":3137,"enrollment":702,"conditions":10791,"interventions":10792},[93],[10769,10770,10771,10772],[10750,10774],{"intervention":10794,"totalTrials":116,"cells":10795},"quetiapine, risperidone",{"EARLY_PHASE1":10796,"PHASE1":10798,"PHASE2":10800,"PHASE3":10802,"PHASE4":10804,"NA":10806},{"trials":10797,"activeCount":119},[],{"trials":10799,"activeCount":119},[],{"trials":10801,"activeCount":119},[],{"trials":10803,"activeCount":119},[],{"trials":10805,"activeCount":119},[],{"trials":10807,"activeCount":119},[10808],{"nctId":10809,"briefTitle":10810,"status":164,"phases":10811,"completion":5231,"start":10812,"enrollment":10813,"conditions":10814,"interventions":10816},"NCT00227123","A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence",[93],"2002-10",96,[26,2942,10815],"Methamphetamine Dependence",[10794],{"intervention":10818,"totalTrials":116,"cells":10819},"15% Trichloroacetic acid peel",{"EARLY_PHASE1":10820,"PHASE1":10822,"PHASE2":10824,"PHASE3":10826,"PHASE4":10828,"NA":10830},{"trials":10821,"activeCount":119},[],{"trials":10823,"activeCount":119},[],{"trials":10825,"activeCount":119},[],{"trials":10827,"activeCount":119},[],{"trials":10829,"activeCount":119},[],{"trials":10831,"activeCount":119},[10832],{"nctId":10833,"briefTitle":10834,"status":951,"phases":10835,"primaryCompletion":10836,"completion":10837,"start":10838,"enrollment":119,"conditions":10839,"interventions":10841},"NCT04889703","A Pilot Study Testing the Effects of Chemical Peels in Patients With Rosacea",[93],"2023-12","2024-05","2022-12",[10840],"Rosacea",[10818,10842],"30% Salicylic acid peel",{"intervention":10842,"totalTrials":116,"cells":10844},{"EARLY_PHASE1":10845,"PHASE1":10847,"PHASE2":10849,"PHASE3":10851,"PHASE4":10853,"NA":10855},{"trials":10846,"activeCount":119},[],{"trials":10848,"activeCount":119},[],{"trials":10850,"activeCount":119},[],{"trials":10852,"activeCount":119},[],{"trials":10854,"activeCount":119},[],{"trials":10856,"activeCount":119},[10857],{"nctId":10833,"briefTitle":10834,"status":951,"phases":10858,"primaryCompletion":10836,"completion":10837,"start":10838,"enrollment":119,"conditions":10859,"interventions":10860},[93],[10840],[10818,10842],{"intervention":10216,"totalTrials":116,"cells":10862},{"EARLY_PHASE1":10863,"PHASE1":10865,"PHASE2":10867,"PHASE3":10869,"PHASE4":10871,"NA":10873},{"trials":10864,"activeCount":119},[],{"trials":10866,"activeCount":119},[],{"trials":10868,"activeCount":119},[],{"trials":10870,"activeCount":119},[],{"trials":10872,"activeCount":119},[],{"trials":10874,"activeCount":119},[10875],{"nctId":10208,"briefTitle":10209,"status":164,"phases":10876,"primaryCompletion":6791,"completion":6791,"start":10211,"enrollment":1267,"conditions":10877,"interventions":10878},[93],[10213],[3336,10215,10216,10186,10217],{"intervention":10880,"totalTrials":116,"cells":10881},"1st visit Optive, then 2nd visit Systane",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10888,"PHASE4":10890,"NA":10892},{"trials":10883,"activeCount":119},[],{"trials":10885,"activeCount":119},[],{"trials":10887,"activeCount":119},[],{"trials":10889,"activeCount":119},[],{"trials":10891,"activeCount":119},[],{"trials":10893,"activeCount":119},[10894],{"nctId":10895,"briefTitle":10896,"status":164,"phases":10897,"primaryCompletion":6852,"completion":6852,"start":3441,"enrollment":1020,"conditions":10898,"interventions":10900},"NCT00610480","Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops",[93],[10899],"Dry Eye Disease",[10880,10901],"1st visit Systane, then 2nd visit Optive",{"intervention":10901,"totalTrials":116,"cells":10903},{"EARLY_PHASE1":10904,"PHASE1":10906,"PHASE2":10908,"PHASE3":10910,"PHASE4":10912,"NA":10914},{"trials":10905,"activeCount":119},[],{"trials":10907,"activeCount":119},[],{"trials":10909,"activeCount":119},[],{"trials":10911,"activeCount":119},[],{"trials":10913,"activeCount":119},[],{"trials":10915,"activeCount":119},[10916],{"nctId":10895,"briefTitle":10896,"status":164,"phases":10917,"primaryCompletion":6852,"completion":6852,"start":3441,"enrollment":1020,"conditions":10918,"interventions":10919},[93],[10899],[10880,10901],{"intervention":10921,"totalTrials":116,"cells":10922},"Drug therapy",{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10927,"PHASE3":10929,"PHASE4":10931,"NA":10933},{"trials":10924,"activeCount":119},[],{"trials":10926,"activeCount":119},[],{"trials":10928,"activeCount":119},[],{"trials":10930,"activeCount":119},[],{"trials":10932,"activeCount":119},[],{"trials":10934,"activeCount":119},[10935],{"nctId":10936,"briefTitle":10937,"status":164,"phases":10938,"primaryCompletion":3441,"completion":3484,"start":6379,"enrollment":7370,"conditions":10939,"interventions":10940},"NCT00158301","Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents",[93],[15],[10921],{"intervention":10942,"totalTrials":116,"cells":10943},"Systane Ocular Drops",{"EARLY_PHASE1":10944,"PHASE1":10946,"PHASE2":10948,"PHASE3":10950,"PHASE4":10952,"NA":10954},{"trials":10945,"activeCount":119},[],{"trials":10947,"activeCount":119},[],{"trials":10949,"activeCount":119},[],{"trials":10951,"activeCount":119},[],{"trials":10953,"activeCount":119},[],{"trials":10955,"activeCount":119},[10956],{"nctId":10957,"briefTitle":10958,"status":164,"phases":10959,"primaryCompletion":6248,"completion":6248,"start":10608,"enrollment":1577,"conditions":10960,"interventions":10962},"NCT00345241","Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points",[93],[10961],"Keratoconjunctivitis Sicca",[10942],{"intervention":10964,"totalTrials":116,"cells":10965},"trimethoprim-sulfamethoxazole or doxycycline",{"EARLY_PHASE1":10966,"PHASE1":10968,"PHASE2":10970,"PHASE3":10972,"PHASE4":10974,"NA":10976},{"trials":10967,"activeCount":119},[],{"trials":10969,"activeCount":119},[],{"trials":10971,"activeCount":119},[],{"trials":10973,"activeCount":119},[],{"trials":10975,"activeCount":119},[],{"trials":10977,"activeCount":119},[10978],{"nctId":10979,"briefTitle":10980,"status":164,"phases":10981,"completion":10982,"start":10983,"enrollment":2778,"conditions":10984,"interventions":10986},"NCT00428818","Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections",[93],"2006-07","2005-08",[10985],"Infection",[10964],{"intervention":10988,"totalTrials":116,"cells":10989},"ondansetron, lidocaine",{"EARLY_PHASE1":10990,"PHASE1":10992,"PHASE2":10994,"PHASE3":10996,"PHASE4":10998,"NA":11000},{"trials":10991,"activeCount":119},[],{"trials":10993,"activeCount":119},[],{"trials":10995,"activeCount":119},[],{"trials":10997,"activeCount":119},[],{"trials":10999,"activeCount":119},[],{"trials":11001,"activeCount":119},[11002],{"nctId":11003,"briefTitle":11004,"status":164,"phases":11005,"primaryCompletion":11006,"completion":11006,"start":11007,"enrollment":1577,"conditions":11008,"interventions":11009},"NCT01652378","Pharmacologic MRI in Cocaine Addiction",[],"2016-08","2012-08",[2942],[10988],{"intervention":11011,"totalTrials":116,"cells":11012},"HylaCare",{"EARLY_PHASE1":11013,"PHASE1":11015,"PHASE2":11017,"PHASE3":11019,"PHASE4":11021,"NA":11023},{"trials":11014,"activeCount":119},[],{"trials":11016,"activeCount":119},[],{"trials":11018,"activeCount":119},[],{"trials":11020,"activeCount":119},[],{"trials":11022,"activeCount":119},[],{"trials":11024,"activeCount":119},[11025],{"nctId":11026,"briefTitle":11027,"status":164,"phases":11028,"primaryCompletion":1109,"completion":1121,"start":11007,"enrollment":1100,"conditions":11029,"interventions":11030},"NCT02165605","HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer",[93],[20],[11011],{"intervention":11032,"totalTrials":116,"cells":11033},"Simvastatin",{"EARLY_PHASE1":11034,"PHASE1":11036,"PHASE2":11038,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11035,"activeCount":119},[],{"trials":11037,"activeCount":119},[],{"trials":11039,"activeCount":119},[],{"trials":11041,"activeCount":119},[],{"trials":11043,"activeCount":119},[],{"trials":11045,"activeCount":119},[11046],{"nctId":11047,"briefTitle":11048,"status":164,"phases":11049,"primaryCompletion":11050,"completion":11051,"start":11052,"enrollment":5257,"conditions":11053,"interventions":11058},"NCT04575090","7 Tesla MRI Study in Patients With Statin Related Muscle Complaints",[93],"2017-02-20","2021-06-23","2016-03-05",[11054,11055,11056,3673,11057],"Statin-related Muscle Pain","Muscle Aches","Muscle Weakness","Muscle Stiffness",[11032],{"intervention":11060,"totalTrials":116,"cells":11061},"Lipiodol",{"EARLY_PHASE1":11062,"PHASE1":11064,"PHASE2":11066,"PHASE3":11068,"PHASE4":11070,"NA":11072},{"trials":11063,"activeCount":119},[],{"trials":11065,"activeCount":119},[],{"trials":11067,"activeCount":119},[],{"trials":11069,"activeCount":119},[],{"trials":11071,"activeCount":119},[],{"trials":11073,"activeCount":119},[11074],{"nctId":11075,"briefTitle":11076,"status":164,"phases":11077,"primaryCompletion":11078,"completion":11078,"start":6545,"enrollment":27,"conditions":11079,"interventions":11080},"NCT04459468","Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC",[],"2025-09-23",[1272],[11060],{"intervention":11082,"totalTrials":116,"cells":11083},"131 I-Metaiodobenzylguanidine",{"EARLY_PHASE1":11084,"PHASE1":11086,"PHASE2":11088,"PHASE3":11090,"PHASE4":11092,"NA":11094},{"trials":11085,"activeCount":119},[],{"trials":11087,"activeCount":119},[],{"trials":11089,"activeCount":119},[],{"trials":11091,"activeCount":119},[],{"trials":11093,"activeCount":119},[],{"trials":11095,"activeCount":119},[11096],{"nctId":11097,"briefTitle":11098,"status":11099,"phases":11100,"conditions":11101,"interventions":11104},"NCT03649438","131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed\u002FRefractory Neuroblastoma","NO_LONGER_AVAILABLE",[],[11102,11103],"Relapsed Neuroblastoma","Metastatic Pheochromocytoma",[11082,11105,11106],"Potassium Iodide","G-csf",{"intervention":11105,"totalTrials":116,"cells":11108},{"EARLY_PHASE1":11109,"PHASE1":11111,"PHASE2":11113,"PHASE3":11115,"PHASE4":11117,"NA":11119},{"trials":11110,"activeCount":119},[],{"trials":11112,"activeCount":119},[],{"trials":11114,"activeCount":119},[],{"trials":11116,"activeCount":119},[],{"trials":11118,"activeCount":119},[],{"trials":11120,"activeCount":119},[11121],{"nctId":11097,"briefTitle":11098,"status":11099,"phases":11122,"conditions":11123,"interventions":11124},[],[11102,11103],[11082,11105,11106],{"intervention":11106,"totalTrials":116,"cells":11126},{"EARLY_PHASE1":11127,"PHASE1":11129,"PHASE2":11131,"PHASE3":11133,"PHASE4":11135,"NA":11137},{"trials":11128,"activeCount":119},[],{"trials":11130,"activeCount":119},[],{"trials":11132,"activeCount":119},[],{"trials":11134,"activeCount":119},[],{"trials":11136,"activeCount":119},[],{"trials":11138,"activeCount":119},[11139],{"nctId":11097,"briefTitle":11098,"status":11099,"phases":11140,"conditions":11141,"interventions":11142},[],[11102,11103],[11082,11105,11106],{"intervention":11144,"totalTrials":116,"cells":11145},"Rapamycin",{"EARLY_PHASE1":11146,"PHASE1":11148,"PHASE2":11150,"PHASE3":11152,"PHASE4":11154,"NA":11156},{"trials":11147,"activeCount":119},[],{"trials":11149,"activeCount":119},[],{"trials":11151,"activeCount":119},[],{"trials":11153,"activeCount":119},[],{"trials":11155,"activeCount":119},[],{"trials":11157,"activeCount":119},[11158],{"nctId":11159,"briefTitle":11160,"status":164,"phases":11161,"primaryCompletion":4044,"completion":4044,"start":11162,"enrollment":2990,"conditions":11163,"interventions":11165},"NCT01449955","Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory",[93],"2008-08",[11164],"Posttraumatic Stress Disorder",[11144],{"intervention":10576,"totalTrials":116,"cells":11167},{"EARLY_PHASE1":11168,"PHASE1":11170,"PHASE2":11172,"PHASE3":11174,"PHASE4":11176,"NA":11178},{"trials":11169,"activeCount":119},[],{"trials":11171,"activeCount":119},[],{"trials":11173,"activeCount":119},[],{"trials":11175,"activeCount":119},[],{"trials":11177,"activeCount":119},[],{"trials":11179,"activeCount":119},[11180],{"nctId":10570,"briefTitle":10571,"status":385,"phases":11181,"primaryCompletion":10222,"completion":7052,"start":10573,"enrollment":3442,"conditions":11182,"interventions":11183},[93],[3452],[10576,3454,10577],{"intervention":10577,"totalTrials":116,"cells":11185},{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11192,"PHASE4":11194,"NA":11196},{"trials":11187,"activeCount":119},[],{"trials":11189,"activeCount":119},[],{"trials":11191,"activeCount":119},[],{"trials":11193,"activeCount":119},[],{"trials":11195,"activeCount":119},[],{"trials":11197,"activeCount":119},[11198],{"nctId":10570,"briefTitle":10571,"status":385,"phases":11199,"primaryCompletion":10222,"completion":7052,"start":10573,"enrollment":3442,"conditions":11200,"interventions":11201},[93],[3452],[10576,3454,10577],{"intervention":11203,"totalTrials":116,"cells":11204},"MRI Tracer",{"EARLY_PHASE1":11205,"PHASE1":11207,"PHASE2":11209,"PHASE3":11211,"PHASE4":11213,"NA":11215},{"trials":11206,"activeCount":119},[],{"trials":11208,"activeCount":119},[],{"trials":11210,"activeCount":119},[],{"trials":11212,"activeCount":119},[],{"trials":11214,"activeCount":119},[],{"trials":11216,"activeCount":119},[11217],{"nctId":11218,"briefTitle":11219,"status":164,"phases":11220,"primaryCompletion":11221,"completion":11221,"start":11222,"enrollment":21,"conditions":11223,"interventions":11225},"NCT03480594","Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway",[],"2023-10-13","2018-10-01",[11224],"Fatty Liver",[11203],{"intervention":11227,"totalTrials":116,"cells":11228},"Tetracycline: Doxycycline analog",{"EARLY_PHASE1":11229,"PHASE1":11231,"PHASE2":11233,"PHASE3":11235,"PHASE4":11237,"NA":11239},{"trials":11230,"activeCount":119},[],{"trials":11232,"activeCount":119},[],{"trials":11234,"activeCount":119},[],{"trials":11236,"activeCount":119},[],{"trials":11238,"activeCount":119},[],{"trials":11240,"activeCount":119},[11241],{"nctId":11242,"briefTitle":11243,"status":951,"phases":11244,"completion":3293,"start":10983,"enrollment":119,"conditions":11245,"interventions":11247},"NCT00355459","A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease",[93],[11246],"Dry Eye Syndrome",[11227],{"intervention":11249,"totalTrials":116,"cells":11250},"Hyperpolarized 13CPyruvate",{"EARLY_PHASE1":11251,"PHASE1":11253,"PHASE2":11255,"PHASE3":11257,"PHASE4":11259,"NA":11261},{"trials":11252,"activeCount":119},[],{"trials":11254,"activeCount":119},[],{"trials":11256,"activeCount":119},[],{"trials":11258,"activeCount":119},[],{"trials":11260,"activeCount":119},[],{"trials":11262,"activeCount":119},[11263],{"nctId":11264,"briefTitle":11265,"status":951,"phases":11266,"primaryCompletion":11267,"completion":11267,"start":388,"enrollment":119,"conditions":11268,"interventions":11270},"NCT03759704","Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)",[],"2021-08-26",[11269],"Sarcoma, Soft Tissue",[11249],{"intervention":11272,"totalTrials":116,"cells":11273},"Acetaminophen",{"EARLY_PHASE1":11274,"PHASE1":11276,"PHASE2":11278,"PHASE3":11280,"PHASE4":11282,"NA":11284},{"trials":11275,"activeCount":119},[],{"trials":11277,"activeCount":119},[],{"trials":11279,"activeCount":119},[],{"trials":11281,"activeCount":119},[],{"trials":11283,"activeCount":119},[],{"trials":11285,"activeCount":119},[11286],{"nctId":11287,"briefTitle":11288,"status":951,"phases":11289,"primaryCompletion":11290,"completion":11290,"start":3387,"enrollment":119,"conditions":11291,"interventions":11292},"NCT00855049","A Randomized Crossover Study to Determine the Pharmacokinetics of Intranasally Administered Acetaminophen in Healthy Adults",[93],"2009-12",[8978],[11272,11272],{"intervention":11294,"totalTrials":116,"cells":11295},"Duloxetine",{"EARLY_PHASE1":11296,"PHASE1":11298,"PHASE2":11300,"PHASE3":11302,"PHASE4":11304,"NA":11306},{"trials":11297,"activeCount":119},[],{"trials":11299,"activeCount":119},[],{"trials":11301,"activeCount":119},[],{"trials":11303,"activeCount":119},[],{"trials":11305,"activeCount":119},[],{"trials":11307,"activeCount":119},[11308],{"nctId":11309,"briefTitle":11310,"status":164,"phases":11311,"primaryCompletion":4124,"completion":4124,"start":3476,"enrollment":617,"conditions":11312,"interventions":11313},"NCT00933439","Assessment of Cognitive Functioning Before and After Treatment With Duloxetine",[93],[29],[11294],{"intervention":11315,"totalTrials":116,"cells":11316},"esomeprazole",{"EARLY_PHASE1":11317,"PHASE1":11319,"PHASE2":11321,"PHASE3":11323,"PHASE4":11325,"NA":11327},{"trials":11318,"activeCount":119},[],{"trials":11320,"activeCount":119},[],{"trials":11322,"activeCount":119},[],{"trials":11324,"activeCount":119},[],{"trials":11326,"activeCount":119},[],{"trials":11328,"activeCount":119},[11329],{"nctId":11330,"briefTitle":11331,"status":164,"phases":11332,"primaryCompletion":910,"completion":910,"start":11333,"enrollment":9,"conditions":11334,"interventions":11336},"NCT00745849","Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial",[93],"2005-06",[11335],"Vasomotor Rhinitis",[11315],{"intervention":11338,"totalTrials":116,"cells":11339},"SGLT2 inhibitor",{"EARLY_PHASE1":11340,"PHASE1":11342,"PHASE2":11344,"PHASE3":11346,"PHASE4":11348,"NA":11350},{"trials":11341,"activeCount":119},[],{"trials":11343,"activeCount":119},[],{"trials":11345,"activeCount":119},[],{"trials":11347,"activeCount":119},[],{"trials":11349,"activeCount":119},[],{"trials":11351,"activeCount":119},[11352],{"nctId":11353,"briefTitle":11354,"status":164,"phases":11355,"primaryCompletion":11356,"completion":11357,"start":11358,"enrollment":3442,"conditions":11359,"interventions":11361},"NCT05033054","Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4",[],"2025-01-02","2025-02-01","2022-01-01",[11360,3334],"Kidney Disease, Chronic",[11338],{"intervention":11363,"totalTrials":116,"cells":11364},"Lexapro",{"EARLY_PHASE1":11365,"PHASE1":11367,"PHASE2":11369,"PHASE3":11371,"PHASE4":11373,"NA":11375},{"trials":11366,"activeCount":119},[],{"trials":11368,"activeCount":119},[],{"trials":11370,"activeCount":119},[],{"trials":11372,"activeCount":119},[],{"trials":11374,"activeCount":119},[],{"trials":11376,"activeCount":119},[11377],{"nctId":11378,"briefTitle":11379,"status":164,"phases":11380,"primaryCompletion":1066,"completion":1066,"start":11381,"enrollment":11382,"conditions":11383,"interventions":11385},"NCT00223288","Impact of Caregiver Depression on Asthma in the Child",[],"2003-03",175,[11384,878],"Depressive Disorder, Major",[11363],{"intervention":11387,"totalTrials":116,"cells":11388},"Trabectedin",{"EARLY_PHASE1":11389,"PHASE1":11391,"PHASE2":11393,"PHASE3":11395,"PHASE4":11397,"NA":11399},{"trials":11390,"activeCount":119},[],{"trials":11392,"activeCount":119},[],{"trials":11394,"activeCount":119},[],{"trials":11396,"activeCount":119},[],{"trials":11398,"activeCount":119},[],{"trials":11400,"activeCount":119},[11401],{"nctId":11402,"briefTitle":11403,"status":11099,"phases":11404,"conditions":11405,"interventions":11407},"NCT01427582","YONDELIS (Trabectedin) Single Patient Compassionate Use \u002F Expanded Access",[],[11406],"Soft Tissue Sarcoma",[11387],{"intervention":11409,"totalTrials":116,"cells":11410},"40 mg Triamcinolone acetonide",{"EARLY_PHASE1":11411,"PHASE1":11413,"PHASE2":11415,"PHASE3":11417,"PHASE4":11419,"NA":11421},{"trials":11412,"activeCount":119},[],{"trials":11414,"activeCount":119},[],{"trials":11416,"activeCount":119},[],{"trials":11418,"activeCount":119},[],{"trials":11420,"activeCount":119},[],{"trials":11422,"activeCount":119},[11423],{"nctId":11424,"briefTitle":11425,"status":164,"phases":11426,"primaryCompletion":748,"completion":748,"start":2831,"enrollment":7864,"conditions":11427,"interventions":11429},"NCT04317404","Knee Steroid Injection and Blood Sugar Signatur",[],[3334,11428],"Knee Osteoarthritis",[11409],{"intervention":11431,"totalTrials":116,"cells":11432},"Axumin PET scan",{"EARLY_PHASE1":11433,"PHASE1":11435,"PHASE2":11437,"PHASE3":11439,"PHASE4":11441,"NA":11443},{"trials":11434,"activeCount":119},[],{"trials":11436,"activeCount":119},[],{"trials":11438,"activeCount":119},[],{"trials":11440,"activeCount":119},[],{"trials":11442,"activeCount":119},[],{"trials":11444,"activeCount":119},[11445],{"nctId":11446,"briefTitle":11447,"status":164,"phases":11448,"primaryCompletion":1266,"completion":1266,"start":954,"enrollment":660,"conditions":11449,"interventions":11463},"NCT03426865","Role of Axumin PET Scan in Germ Cell Tumor",[],[11450,11451,11452,11453,11454,11455,11456,11457,11458,11459,11460,11461,11462],"Testis Cancer","Germ Cell Tumor","Testicular Cancer","Germ Cell Tumor of Testis","Germ Cell Tumor, Testicular, Childhood","Testicular Neoplasms","Testicular Germ Cell Tumor","Testicular Yolk Sac Tumor","Testicular Choriocarcinoma","Testicular Diseases","Germ Cell Cancer Metastatic","Germ Cell Neoplasm of Retroperitoneum","Germ Cell Cancer, Nos",[11431],{"intervention":11465,"totalTrials":116,"cells":11466},"13C-glucose",{"EARLY_PHASE1":11467,"PHASE1":11469,"PHASE2":11471,"PHASE3":11473,"PHASE4":11475,"NA":11477},{"trials":11468,"activeCount":119},[],{"trials":11470,"activeCount":119},[],{"trials":11472,"activeCount":119},[],{"trials":11474,"activeCount":119},[],{"trials":11476,"activeCount":119},[],{"trials":11478,"activeCount":119},[11479],{"nctId":11480,"briefTitle":11481,"status":164,"phases":11482,"primaryCompletion":11483,"completion":1099,"start":11484,"enrollment":11485,"conditions":11486,"interventions":11490},"NCT03686566","Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]",[],"2024-01-02","2018-11-16",84,[11487,11488,11489],"Neuroblastoma","Sarcoma","Pediatric Cancer",[11465],{"intervention":10365,"totalTrials":116,"cells":11492},{"EARLY_PHASE1":11493,"PHASE1":11495,"PHASE2":11497,"PHASE3":11499,"PHASE4":11501,"NA":11503},{"trials":11494,"activeCount":119},[],{"trials":11496,"activeCount":119},[],{"trials":11498,"activeCount":119},[],{"trials":11500,"activeCount":119},[],{"trials":11502,"activeCount":119},[],{"trials":11504,"activeCount":119},[11505],{"nctId":10359,"briefTitle":10360,"status":164,"phases":11506,"primaryCompletion":10362,"completion":10362,"start":2820,"enrollment":353,"conditions":11507,"interventions":11508},[93],[35],[9552,10365,10366],{"intervention":10366,"totalTrials":116,"cells":11510},{"EARLY_PHASE1":11511,"PHASE1":11513,"PHASE2":11515,"PHASE3":11517,"PHASE4":11519,"NA":11521},{"trials":11512,"activeCount":119},[],{"trials":11514,"activeCount":119},[],{"trials":11516,"activeCount":119},[],{"trials":11518,"activeCount":119},[],{"trials":11520,"activeCount":119},[],{"trials":11522,"activeCount":119},[11523],{"nctId":10359,"briefTitle":10360,"status":164,"phases":11524,"primaryCompletion":10362,"completion":10362,"start":2820,"enrollment":353,"conditions":11525,"interventions":11526},[93],[35],[9552,10365,10366],{"intervention":11528,"totalTrials":116,"cells":11529},"Ezetimibe and Simvastatin",{"EARLY_PHASE1":11530,"PHASE1":11532,"PHASE2":11534,"PHASE3":11536,"PHASE4":11538,"NA":11540},{"trials":11531,"activeCount":119},[],{"trials":11533,"activeCount":119},[],{"trials":11535,"activeCount":119},[],{"trials":11537,"activeCount":119},[],{"trials":11539,"activeCount":119},[],{"trials":11541,"activeCount":119},[11542],{"nctId":11543,"briefTitle":11544,"status":164,"phases":11545,"completion":3293,"start":3476,"enrollment":11546,"conditions":11547,"interventions":11549},"NCT00461968","Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both",[93],240,[11548],"Cholesterol, LDL",[11528],{"intervention":11551,"totalTrials":116,"cells":11552},"LNG-IUS",{"EARLY_PHASE1":11553,"PHASE1":11555,"PHASE2":11557,"PHASE3":11559,"PHASE4":11561,"NA":11563},{"trials":11554,"activeCount":119},[],{"trials":11556,"activeCount":119},[],{"trials":11558,"activeCount":119},[],{"trials":11560,"activeCount":119},[],{"trials":11562,"activeCount":119},[],{"trials":11564,"activeCount":119},[11565],{"nctId":11566,"briefTitle":11567,"status":951,"phases":11568,"primaryCompletion":11569,"completion":11569,"start":2857,"enrollment":119,"conditions":11570,"interventions":11573},"NCT03428854","Adenomyosis: Genomic Mechanisms and Biological Response",[],"2022-10-01",[11571,11572],"Adenomyosis","Abnormal Uterine Bleeding",[11551],{"intervention":11575,"totalTrials":116,"cells":11576},"Morphine Sulfate",{"EARLY_PHASE1":11577,"PHASE1":11579,"PHASE2":11581,"PHASE3":11583,"PHASE4":11585,"NA":11587},{"trials":11578,"activeCount":119},[],{"trials":11580,"activeCount":119},[],{"trials":11582,"activeCount":119},[],{"trials":11584,"activeCount":119},[],{"trials":11586,"activeCount":119},[],{"trials":11588,"activeCount":119},[11589],{"nctId":11590,"briefTitle":11591,"status":951,"phases":11592,"primaryCompletion":11290,"completion":3647,"start":3450,"enrollment":119,"conditions":11593,"interventions":11595},"NCT00839787","The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision",[93],[11594],"Abdominal Pain",[11575]]